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 ABSTRACT 
 
De Novo Asymmetric Synthesis of Mannopeptimycin-E, Novobiocin and 
Methymycin Analogues 
 
Sanjeeva Rao Guppi 
 
The carbohydrate portion of the natural products plays a crucial role in biology, 
such as target binding, solubility, tissue targeting, and membrane transportation. The 
O’Doherty group use a de novo methodology to build the desired functionality and 
stereochemistry within each sugar, in contrast to the traditional approach using known 
sugar isomers as starting materials.  Recently, we have developed a practical and 
highly diastereoselective palladium catalyzed glycosylation reaction to control the 
stereochemistry at the anomeric center.  Continuing, our investigations on the utility 
of this strategy, we turned our attention to the syntheses of the bioactive 
carbohydrate-based natural product analogues.  The targets we chose are 
mannopeptimycin-E, novobiocin, methymycin, ribofuranose-adenosine and coumarin 
glycosides.  All of which we felt were amenable to medicinal SAR studies.  
 
Mannopeptimicins are cyclic hexapeptides glycosylated with a disaccharide 
side chain, which possesses potent antibacterial activity against gram-positive bacteria 
with good activity against drug resistant (MDR) bacteria. An enantioselective 
syntheses of the manno-disaccharide fragments of mannopeptimycin-E and its nine 
analogues were been achieved in 7-10 steps and 35-40% overall yield via an iterative 
palladium-glycosylation strategy. Key to the success of this approach was the ease 
with which the C-4 isovalerate group was introduced, and the high diastereoselectivity 
of the palladium-catalyzed glycosylation and bis-dihydroxylation reactions.   
 
Recently novobiocin was shown to inhibit Hsp90 protein, which is a 
promising target for development of cancer chemotherapeutics. We developed a 
practical 7-10 steps diastereoselective route for the syntheses of nine different 
analogues of three aglycones all in good yields.  This route relies on an alternative 
pyranol palladium-catalyzed glycosylation reaction, diastereoselective 
dihydroxylation, regioselective carbamate installation strategy.  Currently, the 
nine-novobiocin analogues are being tested against different cancer cell lines in Prof. 
Blagg’s labs. 
 
Methymycin is a 12-membered macrolactone, an important class of antibiotics 
used to treat infections caused by Gram-positive bacteria. We have developed 
divergent and highly enantioselective route to eight various amino/azido/dideoxy 
methymycin analogues. The key to the success of this method is the iterative use of   
the palladium-catalyzed glycosylation reaction, Luche reduction and Myers’ reductive 
rearrangement.  Currently, a small library of methymycin analogues was under 
testing on glycosyltransferase assays in Prof. Hung-Wen Liu labs. 
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Chapter 1 
Studies towards Palladium-Catalyzed Glycosylation Reaction and 
Syntheses of Biologically Important Glycosides. 
 1.1. Introduction. 
Recently, it has been shown that the carbohydrate portion of the natural products 
play a crucial role in its biological activities, such as target binding, solubility, tissue 
targeting, and membrane transportation.1  For example, the corresponding aglycons of 
natural products are often devoid of activity.  Since the initial discovery of biologically 
active glycosylated natural products, medicinal chemists have desired the ability to 
change the carbohydrate structures of natural products to reveal the role the carbohydrate 
plays.  Although nature uses a diverse array of carbohydrate structures in these natural 
products only a limited number of sugar isomers (glucose, galactose and mannose) are 
provided in accessible quantities for SAR studies, eventually affecting the ability of 
chemists to install rare/unnatural sugar isomers.  Undoubtedly, synthetic alternative 
methods are required to address this medicinal chemistry need. 
An alternative method would be to not use the carbohydrate based starting 
materials and prepare the desired carbohydrate functionality and chirality from simple 
achiral starting materials.2 ,3 ,4  This de novo methodology should allow the medicinal 
chemist to install a much broader range of carbohydrate structures amenable for SAR-
studies. This new approach is in stark contrast to using known sugar isomers as starting 
materials where variability is narrow and extensive the protecting group chemistry is 
required.  The term “de novo” approach is used to illustrate the way we built the desired 
functionality and stereochemistry within each sugar, in contrast to the traditional 
 2
carbohydrate approach, which start with known sugars.  Herein we describe our efforts 
towards the development of this methodology and its ongoing application towards the 
synthesis of various carbohydrate structural motifs. 
1.2. De Novo Syntheses of Various Hexose. 
 Over the past years, significant efforts have been made toward the development of 
new synthetic routes to monosaccharides.3 Of particular interest is the de novo synthesis 
of these sugar isomers (i.e., from simple achiral starting materials using asymmetric 
catalysis). While there are many uses of the term “de novo” in carbohydrate chemistry,5 
herein the term de novo asymmetric syntheses refer to the use of asymmetric catalysis for 
the asymmetric synthesis of carbohydrates from achiral compounds (vide infra). 
 The de novo enantioselective synthesis of the various hexoses stands as a 
challenge to asymmetric catalysis.3 Despite some seminal efforts toward the hexoses, 
notably by Masamune/Sharpless (epoxidation),2 Danishefsky (Diels-Alder), 6 
Johnson/Hudlicky (enzymatic desymmetrization)4 and Wong/Sharpless 
(osmium/enzyme),7 a practical, non-enzymatic route does not exist to all the hexoses.8  
Recently this task has also been taken up by others like MacMillan (iterative aldol 
strategy)9 and White (allylic oxidation)10. 
 For the last ten years O’Doherty group have endeavored to develop practical 
methods for the de novo synthesis of the hexoses.  Our group has resulted in the 
discovery of two orthogonal approaches to pyrano-hexoses with variable C-6 substitution 
as -CH3/-CH2OH.   
Our first generation approach started with furfuraldehyde I-1, which when 
exposed to the Petersen olefination conditions (TMSCH2MgCl/1N HCl) produced 
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vinylfuran I-2 (Scheme 1). We derived the furfuryl alcohol stereochemistry in either 
enantiomeric form I-3 and I-4 by means of the Sharpless asymmetric dihydroxylation 
(AD-mix-α/β) of vinyl furan I-2.11 
Scheme 1. O’Doherty group’s first-generation approach to furfuryl alcohols. 
OO
O
H
TMSCH2MgCl
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 1. AD-mix-α
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O
OH
OTBS
 AD-mix-α : (DHQ)2PHAL
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(R)
(S)
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O
H
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O
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 AD-mix-β : (DHQD)2PHAL
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2. TBSCl, Et3N
90 %
I-1 I-2 I-3
I-4I-2I-2
 
Because the enantioselectivity of dihydroxylation step was too low (~90% ee), we 
looked for a better approach and settled on the Noyori reduction of acylfurans (Scheme 
2).12  This improved approach requires the preparation of the acylketone I-9 in three steps 
from glycolic acid I-5 via a 2-lithiofuran addition to the TBS-protected amide I-7 in 70% 
overall yield. The furyl alcohols I-3/I-4 were enantioselectively prepared from Noyori 
asymmetric reduction of furyl ketone I-9 catalyst I-10a/I-10b in good yields (85-90%) 
and excellent enantioselectivity (>95% ee).13 
Scheme 2. O’Doherty group’s improved approach to furyl alcohols via Noyori reduction. 
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The synthesis of pyrano-hexoses relies on the use of the Achmatowicz 
rearrangement 14  (Scheme 4 for mechanism), which is an oxidative rearrangement of 
furfuryl alcohols I-3/I-4 to hemiacetals I-11/I-12. Thus, treatment of furyl alcohols I-3/I-
4 with NBS in aqueous THF gave hemiacetals I-11/I-12 in very good yields (Scheme 3). 
We have succeeded in developing a short route that is flexible enough for the syntheses 
of four possible diastereomeric hexoses I-13, I-14, I-15 and I-16 by selectively acylation 
with Boc anhydride in high yields (86-88%). Depending on the reaction temperature, the 
acylation step can selectively give the α-Boc pyranones I-13 and I-15 at (–78 oC) or a 1:1 
ratio of α/β-Boc pyranones at room temperature. 
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Scheme 3. Syntheses of pyranones. 
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Scheme 4. Achmatowicz reaction and its mechanism. 
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1.3.  De Novo Synthesis of Coumarin and Flavonol Glycosides. 
A related family of interesting natural products are the coumarin and flavonol 
glycosides, which are used for the treatments of digestive disordered, bronchitis, and 
inflammation in the traditional medicine.15 , 16 ,17   These active coumarin and flavonol 
glycosides attracted our attention towards the synthesis of several manno-glycoside 
analogues of these phenols, flavones and coumarins glycosides using our recently 
developed palladium catalyzed glycosylation reaction.  
 6
Recently, we have developed a practical and highly diastereoselective palladium 
catalyzed glycosylation reaction (coupling of I-15 and ROH to give I-17) to control the 
stereochemistry at the anomeric center (Scheme 4).  We have also demonstrated the 
practical utility of this reaction for the de novo synthesis of oligosaccharides.18 
Scheme 4. Pd-catalyzed reaction and its mechanism. 
O
O
O O
O
RO
ROH
OTBS
O
O OTBS
(1.1 equiv)
1- 5% Pd(0)L2
OO
R Pd LL
X O
O
R Pd LL
X
O
R H
pi-ally-Pd 
intermediate
ROH
I-15 I-17
 
 Herein, we describe our results for the de novo synthesis of α-and β- linked 
coumarin and flavonol glycosides using this palladium catalyzed glycosylation reaction.  
In addition, the coumarin and flavone glycosylation products were transformed into 
manno-glycosides using a simple reduction/oxidation sequence.  
Since our approach is quite mild and equally amenable to the glycosyl transfer of 
either a α-and β-linked glycosides. Initially we subjected several substituted phenols to 
the diastereoselective glycosylation reaction and gave excellent results.19  With these 
primary results at hand, we next explored the glycosylation reaction of the coumarins.  
The palladium-catalyzed glycosylation of coumarin I-18 with α/β-pyranones I-15/I-16 
gave the respective α/β-glycosides I-19α/I-19β as a single diastereomers in good yields.  
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Scheme 5. Syntheses of coumarin glycosides. 
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The glycosylation reaction worked well with good yields for phenols and simple 
alcohols19 but not promising yields for coumarin and flavanol aglycones.  A change in 
solvent from CH2Cl2 to THF for glycosylation of coumarins and flavone  remarkably 
improved the yields.  The yields of various coumarin α/β-glycosides shown in the table 
1.   
Table 1.  Syntheses of various coumarin glycosides and their yields. 
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We next turned our attention towards the preparation of α-and β-flavanol-
glycosides.  Thus, using the same Pd-catalyzed glycosylation conditions (2.5 mol % 
Pd(0)/10%PPh3, THF), the α-/β-pyranones I-15/I-16 were coupled with flavanol  
providing α/β- glycosides I-33α/I-33β respectively. The yields for flavanol glycosides 
were shown in Scheme 6.   
Scheme 6. Syntheses of flavone glycosides. 
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The flavonol and coumarin α-glycoside products were easily converted into L- 
hexo-pyranoses by a two-step reduction/oxidation sequence.  Thus by exposure of the 
glycosylated products to NaBH4 at –78 °C in CH2Cl2 and CH3OH (Scheme 7) gave good 
yields (78-96%) of equatorial alcohols I-41a-d with complete stereocontrol (Table 2). 
Similarly, the resulting allylic alcohols I-41a-d could be diastereoselectively oxidized to 
the manno-triols I-42a-d in excellent yields (84-92%) with complete stereocontrol under 
the Upjohn condition (OsO4/NMO).20  The yields for reduction and dihydroxylation steps 
were all high and are summerized in table 2. 
Scheme 7. Syntheses of various manno-sugars. 
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O
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O
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RO OTBS
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Table 2  Syntheses of various manno-glycosides and their yields 
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1.4.  De Novo Asymmetric Synthesis of Homoadenosine.† 
1.4.a.  Introduction. 
The hexopyranosyl nucleosides make up a large and varied class of natural 
products (e.g., blasticidin, 21  gougerotin, 22  hikizimycin, 23  mildiomycin, 24  the 
bagougeramines,25 SF-2140,26 the pentopyranines,27 and miharamycin28). In addition to 
the intriguing structures, they also possess distinct biological activities.29  Inspired by 
these natural products, chemists have made two hexopyranosyl nucleosides 2-deoxy-β-D-
ribo-hexopyranose adenosine (I-51)30 and 2,3-dideoxy-β-D-ribo-hexopyranose adenosine 
(I-52). 31  These homologous nucleosides of adenosine and deoxyadenosine possess 
obvious structural and configurational similarities to the corresponding ribofuranose 
adenosines I-53 and I-54 (Figure 1). 
                                                 
†
 Reproduced with permission from Org. Lett. 2006, 8, 293-296.  Copyright 2006, with 
permission from American Chemical Society. 
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Figure 1. Adenosines and hexopyranosyl nucleosides. 
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Biological studies of these ring-expanded analogues (I-51 and I-52) have led to 
the discovery of several pyrano-nucleotide analogues with both antitumor and antiviral 
activity.32  
 
1.4.b.  Project Description and Goals. 
While there has been significant synthetic effort toward the synthesis of adenosine 
analogues,29 we were interested in preparing pyrano-analogues of this class of 
compounds from an achiral starting material using enantioselective catalysis to set the 
asymmetry (de novo synthesis). In addition, we were interested in a synthesis that allows 
for the diastereoselective installation of the base at C-1. To test the breadth of this 
methodology, we set out to prepare various analogues of pyranose adenosines (I-51 and 
I-52).  To accomplish this goal, we needed to extend the palladium glycosylation reaction 
to nitrogen nucleophiles  (e.g., benzimidazole and purines).33 Herein, we describe our 
successful efforts to prepare the homoadenosine analogues (ent)- I-51 and (ent)- I-52.34 
Scheme 8. Pd-catalyzed N-glycosylation. 
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To test the strategy, we carried out a model study using benzimidazole I-55 and 
pyranone I-15α. The Pd-catalyzed N-glycosylation of benzimidazole I-55 and pyranone 
I-15 α successfully gave the desired glycosylated pyranone I-56α in good yield with 
complete stereocontrol (Scheme 8).  
Our initial attempts at post-glycosylation modification of the N-glycoside with the 
α-anomers were not encouraging. The pyranone I-56α was readily reduced to give the C-
4 allylic alcohol I-57α. This reduction, however, occurred with less stereocontrol at C-4 
(4:1) as compared to NaBH4 reduction of pyranone with C-1 α-oxygen substituents.35 
The post-glycosylation chemistry for these N-glycosides diverged with the O-glycosides 
during our attempts to modify the double bond of pyran I-57α. To our surprise, all 
attempts to either dihydroxylate or reduce I-57α were unsuccessful (Scheme 8).  
Scheme 9.  Pd-catalyzed N-glycosylation: Synthesis of N-glycosylated sugars. 
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To our relief, our difficulties with the α-anomer did not occur with the β-isomers 
(Schemes 9). The Pd-catalyzed N-glycosylation of benzimidazole I-55 and pyranone I-
16β successfully gave the desired glycosylated pyranone I-58β in good yield. Reduction 
of the pyranone I-58β using NaBH4 at -78 °C gave exclusively allylic alcohol I-59β. 
Subjecting alcohol I-59β to Myers’ reductive 1,3-transposition condition 36  (NBSH, 
PPh3/DEAD, NMM, -30 °C to rt) provided the rearranged olefin I-60β in good yield 
(65%). Dihydroxylation of I-60β using the Upjohn conditions (OsO4/NMO)20 gave the 
diol I-61β in 85% yield. In contrast to the oxidation chemistry, I-59β could also be 
reduced, although not in high yield. Thus, exposing I-60β to excess diimide precursor 
(NBSH/Et3N) gave the 2,3-dideoxypyranose I-62β in low yield (30%) but with good 
recovery of starting material (50%). While the yield of I-62β was low, this procedure was 
superior to traditional hydrogenation (H2, 5% Pd/C in MeOH), which occurred with 
complete hydrogenolysis of the C-1 benzimidazole. These successful model studies 
inspired us to synthesize the adenosine analogues.34  
 14
Scheme 10.  Enantioselective synthesis of homoadenosine and 2’-eoxy-homoadenosine. 
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Our synthesis commenced with the coupling of Boc-protected pyranone I-16β and 
commercially available 6-chloropurine I-63. Further subjection to the similar 
transformations used in model study gave homeadenosine (ent)-I-51 and 2’-
deoxyhomoadenosine (ent)-I-52 in good yields. 
 
1.5.  Summary. 
In conclusion, we have applied our practical palladium-catalyzed O-glycosylation 
reaction for the syntheses of phenol, flavonol and coumarin glycosides.  Using our three-
step protocol we have demonstrated the syntheses of coumarin and flavonol L-manno-
pyranoses with excellent stereocontrol and high yields.   
We have also developed highly enantio- and diastereoselective procedure for the 
preparation of hexopyranose adenosine analogues using palladium-catalyzed N-
glycosylation reaction in five to six steps from Boc-protected pyranone. The synthesis of 
other potential analogues and evaluation of the biological activity of these compounds are 
ongoing.  
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Chapter 2 
Asymmetric Synthesis and Medicinal Chemistry Studies of Novobiocin 
Analogues. 
2.1. Introduction and biological activity to novobiocin analogues 
The Aminocoumarin antibiotics, like novobiocin II-1, clorobiocin II-2 and 
Coumermycin A1 II-3 (Figure 2) are secondary metabolites isolated from several 
Streptomyces strains and show potent activity against Gram-positive bacteria.37  These 
coumarin antibiotics share a key structural core of a 3-acetamido-4-hydroxy-coumarin 
and a rare-sugar fragment both of which play critical role in biological activities.  These 
coumarin antibiotics bind to type II topoisomerases and DNA-gyrase B subunit and 
inhibit the enzyme catalyzed hydrolysis of ATP.38  
Figure 2.  Naturally occurring aminocoumarin antibiotics. 
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Recently Novobiocin was shown to inhibit Hsp90 through C-terminal ATP 
binding site, which is a promising target for development of cancer chemotherapeutics 
(i.e., antitumor agents capable of inhibiting all six hallmarks of cancer by restraining 
Hsp90 protein folding machinery).39   This promising biological activity and interesting 
structural features have inspired researchers to synthesize Novobiocin analogues. 
 
2.2.  Previous approaches to novobiocin analogues. 
2.2.a.  Photolabile novobiocin analogues. 
 Blagg et al. reported a convergent synthesis of four photolabile Novobiocin 
analogues in 2004.40  Their synthesis started with the known compound 4,7- dihydroxy-8-
methyl-2H-1-benzopyran-2-one II-4,41 which when treated with diazonium salt II-5 gave 
the corresponding diazocoumarin derivative II-6 (Scheme 11).  This diazaphenyl group 
serves as an amine protecting group in II-6.  Previously Blagg had prepared 3-sulphone 
coumarin analogues, which failed to selectively glycosylate (7 vs 4 phenolic positions) 
under typical Schmidt glycosylation condition.42 
Scheme 11. Synthesis of aminocoumarins. 
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In contrast when the diazocoumarin II-6 was treated with trichloroacetimidate II-
7 in the presence of BF3.OEt2, it produced the 7-noviose diazocoumarin derivative II-8 in 
good yield.  Diazacoumarin II-8 was deprotected by using hydrogenation conditions 
afford to 3-aminocoumarin II-9.  Due to the instability of II-9 to purification conditions, 
crude II-9 was subjected to DCC conditions with 3-azido or 4-azidobenzoic acids 
yielding the desired amides II-10 and II-13 (Scheme 12).  Previously Vaterlaus had 
studied the carbonate ring opening reaction to regioselectively form the desired 
carbamates.43   
Scheme 12. Synthesis of photolabile novobiocin analogues. 
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After careful optimization, Prof. Blagg group came up with a general methanolic 
ammonia (room temperature) conditions to prepare 3-carbamate noviose products II-11 
and II-14 from amides II-10 and II-13 resulted in good yields respectively.  Even under 
these optimized conditions the ring opening selectivities were less than perfect.  Thus, 
significant amounts of the 2-carbamate isomers II-12 and II-15 were also isolated as 
minor products. 
2.2.b.  Hsp90 inhibitors 
With success achieved in the initial synthesis of photolabile novobiocin 
analogues, Blagg turns to the preparation of novobiocin libraries with various coumarin 
substitution (Scheme 13).  In 2005, Blagg et al. reported the Hsp90 inhibitors identified 
from a library of novobiocin analogues.44 They started the library syntheses with a range 
of coumarins (II-A - I-E).  These II-A - II-E coumarins were coupled with 
trichloroacetimidate-noviose carbonate II-7 in the presence of BF3.OEt2 to yield five 
coumarin- carbonates (II-A1 - II-E1).  These carbonates II-A1 - II-E1 were subjected to 
methanolic ammonia (ring opening conditions) to provide 2’-carbamoyl II-A2-II-E2, 3’-
carbamoyl II-A3-II-E3, and des-carbamoyl compounds II-A4-II-E4 in good yields.  
 
Scheme 13. Syntheses of novobiocin analogues. 
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All novobiocin analogues in Scheme 3 were tested against Hsp90 client protein by 
incubating with SKBr3 breast cancer cells at a concentration of 100 µM.   Westernblot 
analysis of protein lysates showed that analogue II-A4 (Figure 2) was the most active 
compound. 
In 2006, Blagg et al. reported two more novobiocin analogues DHN1 and DHN2 
(Figure 3), which are evaluated against Hsp90 and both analogues were significantly 
more potent than the natural product novobiocin.45  The DHN2 analogue proved to be 
more active than DHN1. 
Figure 3. The DHN1 and DHN2 are selective Hsp90 inhibitors. 
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2.2.c.  Biosynthesis and Glycorandomization of novobiocin analogues  
Prof. Thorson’s group also investigated the synthesis of Novobiocin analogues 
using a biosynthetic method.  They called their approach in-vitro glycorandomization 
(IVG).46  IVG was used for the biosynthesis of sugar libraries of various complex natural 
products.47  In this study they have found a novobiocin specific glycosyl transferase 
enzyme NovM and screened it for activity with four aglycon coumarin analogues and 
~40 sugar nucleotides.  With these optimized procedure they used the NovM enzyme for 
the glycosylation of three nucleotides (II-16, II-20 and II-22) with the novobiocin 
aglycon II-18 to afford three new coumarin antibiotics (Scheme 14). Out of three 
novobiocin analogues, compound II-19 showed the best antibiotic activity (MIC 5 µg 
mL-1) compared with novobiocin II-1 (MIC 0.06 µg mL-1) and was consistent with 
novobiocin II-1 mechanism of action.2  
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Scheme 14. Biosynthesis of new coumarin antibiotics.            
O OHO
N
HOH
O
OH
O
HO OH
OTDP
OH
OH
HO OH
OTDP
OH
O
O OH
OTDP
OH
Novobiocin aglycon II-18
+ II-18
II-18
II-18
+
+
O
HO OH
O
OH
O O
N
HOH
O
OH
OH
HO OH
O
OH
O O
N
HOH
O
OH
O
O OH
O
OH
O O
N
HOH
O
OH
II-16 II-19
II-20
II-21
II-22 II-23
 
 
Presented herein are two different approaches to glycosylated coumarin antibiotic 
analogues of the novobiocin.  These approaches allowed for the preparation of analogues 
containing aminocoumarin core with various substituted deoxysugars. Interestingly, each 
group used modular synthesis with advanced building blocks and successfully addressed 
the key issues of both synthetic selectivity and biological activity.  
  
2.3. Project Description and Goals 
Since inhibitors of Hsp90 are considered to be novel target for anticancer 
therapeutics, we decided to prepare a small library of novobiocin analogues using our 
palladium-coupling chemistry.  In collaboration with Prof. Blagg’s lab, we planned to test 
our compounds on different cancer cell lines.  This we felt was an excellent opportunity 
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to test our various novobiocin analogue compounds.  A continuing theme of using 
asymmetric catalysis to improve the synthetic efficiency and atom economy of 
carbohydrate synthesis.  The retrosynthetic analysis for our synthesis of novobiocin 
analogues is shown in Scheme 15.   Several coumarin aglycones were coupled with 
pyranone ester II-30 using our Pd-catalyzed glycosylation as the key reaction.48  The 
pyranone ester II-30 can be constructed from commercially available starting material 
acylfuran II-24. 
Scheme 15.  Retrosynthesis of novobiocin analogues. 
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2.4.  Synthesis of Novobiocin Analogues 
 In this approach the pyranone asymmetry was derived by the use of a Noyori 
asymmetric hydrogenation of acylfuran II-24 to yield furan alcohol II-25.49  Pyranone II-
27 can easily be prepared from furan alcohol II-25 by an Achmatowicz rearrangement, 
followed by hemiacetal protection with Boc anhydride. The more reactive axial anomeric 
alcohols can be acylated selectively (>20:1, α:β) at -78 °C. Alternatively at room 
temperature, (1.3:1) mixture of anomers can be produced with excellent enantiomeric 
excess  >96% (Scheme 16).50 
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Scheme 16.  Synthesis of Boc-Pyranone. 
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We next turned our attention toward the preparation of manno-sugar linked 
coumarins.  The glycosylation of 7-hydroxy 4-methyl coumarin alcohol II-28 with the α-
L-pyranone II-27 in the presence of (5 mol% Pd(0)/10%PPh3) to form the glycosylated 
pyranone II-29 in 84% yield as a single diastereomer (Scheme 17).  Pyranone II-29 was 
subjected to Luche conditions 51  (NaBH4/CeCl3, -78 °C) to reduce the ketone but 
unfortunately it fails to produce the desired allylic alcohol.  
Scheme 17.  Synthesis of glycosylated pyranol. 
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After investigating with different reaction conditions in the reduction step, we 
modified our approach by shifting the glycosylation step to after the reduction and 
methylation steps (Scheme 18). In this regard, the protecting group of pyranone was 
changed from carbonate (Boc) to Piv-ester due stability reasons during the reduction step.  
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Thus, hemiacetal II-26 were subjected to PivCl to give Piv-protected enone II-30 in 
excellent yield. The ketone of pyranone II-30 was diastereoselectively reduced under 
Luche conditions forming the equatorial allylic alcohol in excellent yield (90%) followed 
by alkylation of allylic alcohol as methyl ether in neutral conditions (Ag2O, MeI,) to give 
methyl ether II-32 in 85% yield. We next explored the Pd-catalyzed glycosylation by 
subjecting allylic pivalate II-32 to coumarin II-28 under glycosylation conditions (5 mol 
% Pd(0)/10%PPh3), which afforded glycosylated coumarin II-33 with complete 
stereocontrol  in 80% yield. 
Scheme 18.  Synthesis of Glycosylated Coumarin 
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After successful completion of the glycosylation step, we move forward with 
dihydroxylation of II-33 using the Upjohn conditions20 (OsO4/NMO), which gave 
exclusively the diol II-34 in 85 % yield (Scheme 19). Then we regioselectively protected 
the C-2 axial alcohol of II-34 via ortho ester formation, and selective hydrolysis to 
provide acetate II-35 in 90% yield.52  Finally the C-5 des methyl noviose synthesis was 
completed by subjecting the free equatorial alcohol with chlorosulfonyl isocynate, 
 25
followed by hydrolysis with K2CO3/MeOH gave C3-carbamoyl analogue II-36 in good 
yield (80% two steps).53   Alternatively the dideoxy sugar analogue was prepared in 
excellent yields by exposing the allylic ether II-33 to excess diimide precursor and base 
(93% yield). 54  Thus with this successful model study, we have synthesized three 
novobiocin analogues II-34, II-36 and II-37. 
Scheme 19.  Synthesis of des-methyl-novobiocin analogues II-34, II-36 and II-37. 
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Encouraged by the above results, we prepared a set of six analogues using the 
above methodology with two biologically promising aglycones II-38 & II-44 provided 
by Prof. Blagg research group (Scheme 20).  Once again a Pd-catalyzed glycosylation of 
allylic pivalate II-32 with the acetamido coumarin II-38, followed by series of post-
glycosylation transformations gave three different analogues II-40, II-41 and II-43 with 
similar yields comparing with simple coumarin analogues (Scheme 20 & 21).  
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In this vein, we next explored the Pd-catalyzed glycosylation by subjecting allylic 
pivalate II-32 to coumarin II-38 under glycosylation conditions (5 mol% 
Pd(0)/10%PPh3), which afforded glycosylated coumarin II-39 in 80% yield (Scheme 10). 
Dihydroxylation of II-39 using the Upjohn conditions20 (OsO4/NMO), which gave 
exclusively the diol II-40 in 85 % yield. Alternatively the dideoxy sugar analogue II-41 
was prepared in excellent yields by exposing the allylic ether II-39 to excess diimide 
precursor and base (95% yield). 
Scheme 20.  Syntheses of des-novobiocin analogues II-40 and II-41. 
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Then we regioselectively protected the C-2 axial alcohol of II-40 via ortho ester 
formation, and selective hydrolysis to provide acetate II-42 in 91% yield (Scheme 21). 
Finally the C-5 des methyl novobiose synthesis was completed by subjecting the free 
equatorial alcohol with chlorosulfonyl isocynate, followed by hydrolysis with 
K2CO3/MeOH gave C-3-carbamoyl analogue II-43 in good yield (83% two steps). 
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Scheme 21.  Synthesis of des-novobiocin analogue II-43. 
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Using the same chemistry, we explored the Pd-catalyzed glycosylation by 
subjecting allylic pivalate II-32 to coumarin II-44 under glycosylation conditions (5 
mol% Pd(0)/10%PPh3) gave glycosylated coumarin II-45 in 85% yield (Scheme 22). 
Dihydroxylation of II-45 using the Upjohn conditions (OsO4/NMO) gave exclusively the 
diol II-40 in 86 % yield. Alternatively the dideoxy sugar analogue II-47 was prepared in 
excellent yields by exposing the allylic ether II-45 to excess diimide precursor and Et3N 
(96% yield). 
 
Then again we regioselectively protected the C-2 axial alcohol of II-46 via ortho 
ester formation, and selective hydrolysis to provide acetate II-48 in 90% yield (Scheme 
23). Finally the C-5 des methyl novobiose synthesis was completed by subjecting the free 
equatorial alcohol with chlorosulfonyl isocynate, followed by hydrolysis with 
K2CO3/MeOH gave C-3-carbamoyl analogue II-49 in good yield (81% two steps).  After 
successful syntheses of a small library of nine novobiocin analogues, they were sent for 
activity testing at Blagg’s lab against different cancer cell lines. 
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Scheme 22.  Syntheses of des-novobiocin analogue II-46 & II-47. 
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Scheme 23.  Synthesis of des-novobiocin analogue II-49. 
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We next investigated the removal of the second methyl group at the C-5 center of 
the sugar position of the molecule.  In this connection we have started building di-des-
 29
methyl novobiocin analogues. Our synthetic strategy (Scheme 24) started by taking furyl 
alcohol II-50 treating with NBS in aqueous THF (Achmatowicz reaction) gave 
hemiacetal II-51 in 85% yield.  
 
Scheme 24.  Synthesis of des-C-5-methy-novobiocin analogue II-55. 
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Acylation of hemiacetal II-51 with PivCl provided the Piv protected pyranone II-
52 in good yield (80%). A reduction of pyranone II-52 under Luche conditions gave 
racemic allylic alcohol II-53 in 86% yield as a single diastereomer. Using 5 mol% 
palladium/R,R Trost ligand, allylic alcohol II-53 was coupled with coumarin alcohol 
providing glycoside II-54 in 75% yield with 60% ee where as racemic material could be 
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prepared using Ph3P as the ligand. Exposing allylic alcohol II-54 to the Upjohn 
conditions20 (OsO4/NMO) gave the diol II-55 in good yield (85%). 
 
2.5.  Summary 
 In conclusion, we developed a practical 7 to 10 step diastereoselective route for 
the syntheses of nine different analogues of three aglycones all in good yields.  This route 
relies on an alternative pyranol palladium-catalyzed glycosylation reaction, 
diastereoselective dihydroxylation, regioselective carbamate installation strategy.  
Currently, the nine-novobiocin analogues are being tested against different cancer cell 
lines in Prof. Blagg’s labs.   
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Chapter 3 
Enantioselective Synthesis of Mannopeptimycin-E analogues.† 
3.1. Introduction to mannopeptimycins. 
The continuing emergence of bacterial resistance to traditional antibiotics has 
inspired a never-ending search for new antibiotics.55 The five mannopeptimycins (III-
1A-E) were isolated from the fermentation broths of Streptomyces hygroscopicus LL-
AC98 and related mutant strains.56 The key structural features of the mannopeptimycins 
are a cyclic hexapeptide core with alternating D- and L-amino acids, three of which are 
rare. Two of the amino acids (β-D-hydroxyenuricididine and D-tyrosine) are glycosylated 
with mannose sugars. The glycosylated amino acids are an N-glycosylated β-
hydroxyenuricididine with an α-mannose and an O-glycosylated tyrosine with a α-(1,4-
linked)-bis-manno-pyranosyl pyranoside.  
Figure 4. Structure of mannopeptimycin-E III-1E. 
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The unique structure and unprecedented biological activity have inspired both 
biological 57  and synthetic studies58  from labs at Wyeth Pharmaceuticals. Among the 
mannopeptimycins, mannopeptimycin-E (III-1E, Figure 4) was reported as the most 
                                                 
†
 Reproduced with permission from Org. Lett. 2006, 8, 1605-1608.  Copyright 2006, with 
permission from American Chemical Society. 
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active member against methicillin-resistant staphylococci and vancomycin-resistant 
enterococci (Table 3).59 
Table 3. Activities of mannopeptimycins. 
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A particularly interesting aspect of the SAR for the mannopeptimycins is how the 
specific placement of the isovalerate group on the bis-manno-disaccharide correlates 
with its antibacterial activity. It has been shown that C-4 isovalerate substitution on the 
terminal mannose leads to a substantial increase in antibacterial potency. For instance, 
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mannopeptimycins-C and -D, which have C-2 and C-3 isovalerate groups, respectively, 
have reduced activity, whereas mannopeptimycins-A and -B, which lack isovalerate 
substitution, have even lower activity (Table 3).59 
3.2. Previous Approaches to Mannopeptimycin Analogues. 
3.2.a.  Synthesis of Mannopeptimycin derivatives 
 The crisis associated with the capability of organisms to develop resistance 
mechanisms to antibiotics has fueled the continuous search for new antibacterial agents.55 
The mannopeptimycins, a tris-manno-glycosylated class of cyclic hexapeptides with 
alternating D and L-amino acids, were isolated as part of this mission. Of the 
mannopeptimycins, mannopeptimycin-E (III-1E) (Figure 4) is the most active member, 
displaying activity against methicillin-resistant staphylococci and vancomycinresistant 
enterococci.56  In an effort to identify compounds with improved activity and SAR 
studies, chemists at Wyeth58 have synthesized several derivatives of mannopeptimycins. 
Retrosynthetically, they envisioned that the ketal derivative III-4 could be prepared from 
fully protected linear hexapeptide III-5 using solid-phase chemistry and anticipated to 
cyclize the hexapeptide with the amide bond formation between the L-serine and 
unhindered glycine. Free amine of compound III-5 was prepared by using D-tyrosine 
containing disaccharide III-11 and five commercially available amino acids (Scheme25). 
 Scheme 25.  Retrosynthesis of mannopeptimycin derivative III-4. 
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They synthesized the peptide disaccharide derivative III-11 by coupling bis-manno-
disaccharide III-13 and protected tyrosine III-12 using N-
iodosuccinimide/trimethylsilyltriflate. Compound III-13 was prepared from sugar 
intermediates III-14 and III-15 (Scheme 26). 
Scheme 26. Retrosynthesis of tyrosine-bis-mannose III-11. 
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3.3. Project description and project goals. 
This work confirmed the importance of the C-4 isovaleryl group for antibiotic 
activity.  The critical role isovalerate substitution has on the antibacterial activity of the 
mannopeptimycin-E inspired us to pursue a synthesis of an appropriate O-glycosylated 
D-tyrosine with C-4 isovalerate substitution (e.g., III-2a and III-2b, Scheme 27).60 In 
addition to our desire to synthesize and test the mannopeptimycin analogues III-2a and 
III-2b, we felt that the synthesis of III-2a would serve as part of a model study for our 
synthesis of the natural product. In addition, the preparation of III-3b, a fully protected 
bis-glycosylated tyrosine, would be of use for the synthesis of mannopeptimycin-E. 
Herein, we report the successful implementation of our palladium-catalyzed 
glycosylation reaction61,62 for the de novo installation of both a D,D- and an L,L-bis-
manno-disaccharide fragment on a D-tyrosine. The flexibility of the approach is 
demonstrated by the syntheses of bis-2,3-dideoxy analogues in their D,D- and an L,L-
forms.63  
Scheme 27.  Retrosynthesis of mannopeptimycin-E III-1E and its key fragment III-2a. 
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Our retrosynthetic analysis of the disaccharide fragment III-2a and its fully 
protected variant III-3b is outlined in Scheme 27. We envisioned that the manno-
stereochemistry in both III-2a and III-3b could be installed by a diastereoselective 
ketone reduction and a bis-dihydroxylation of a 1,4-linked pyran/pyranone III-16. 
Similarly, we believed that the pyran/pyranone III-16 could be assembled using a 
diastereoselective palladium-catalyzed glycosylation of tyrosine III-17.61 Recently, we 
reported a diastereoselective palladium-catalyzed glycosylation reaction that used 
alcohols as nucleophiles and pyranones such as III-18 as glycosyl donors. Thus, 
sequential application of our Pd(0)-glycosylation/NaBH4 reduction/Pd(0)-glycosylation 
sequence to tyrosine III-17 and pyranone III-18 was expected to allow for the rapid 
preparation of III-16. Replacing the above-mentioned bis-dihydroxylation with a bis-
diimide reduction might also allow for the preparation of the deoxy analogue III-2b. 
Previously, we have shown that pyranone III-18 can be prepared in either enantiomeric 
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form. Thus, this procedure was expected to allow the incorporation of either D- or L-
sugars.64  
3.4.   Synthesis of key fragment of mannopeptimycin-E and its analogues.   
Our synthesis studies began with the protected D-tyrosine III-17 and pyranone 
III-18 which, when exposed to 1 mol % Pd2(dba)3.CHCl3 and 4.0 mol % of PPh3, 
underwent a diastereoselective glycosylation with complete α-selectivity to afford the 
pyranone III-20 in 92% yield. A diastereoselective 1,2-reduction of the enone III-20 
occurred, when it was subjected to NaBH4 in CH2Cl2/MeOH (1:1) at -24 °C, which 
afforded allylic alcohol III-21 as a single diastereomer (dr > 20:1). We next investigated 
the viability of the C-4 alcohol in the Pd-catalyzed glycosylation.  Exposing allylic 
alcohol III-21 to a second glycosylation using 1.2 equiv of pyranone III-18 and 1 mol % 
of Pd catalyst (1:2.5, Pd2(dba)3.CHCl3/PPh3) afforded the 1,4-linked-α-bis pyranone III-
16 in good yield (82%) and virtually complete stereocontrol (Scheme 28). 
Scheme 28.  De novo synthesis of disaccharide enone III-16.  
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 The final post-glycosylation transformation of III-16 is shown in Scheme 29. 
Treatment of 1,4-linked pyran/pyranone III-16 under the same reduction conditions as 
before (III-20 to III-21, Scheme 4)  gave allylic alcohol III-22 in excellent yield (91%) 
and diastereoselectivity (>20:1). The isovalerate group was installed by treating allylic 
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alcohol III-22 with isovaleric acid and DCC/DMAP in CH2Cl2, which provided the C-4 
isovalerate disaccharide precursor III-23 in excellent yield (96%). The manno-
stereochemistry in 3a was diastereoselectively introduced65 upon exposure of III-23 to 
the Upjohn conditions20 (OsO4/NMO, 85%).  Removal of both TBS-ethers was 
accomplished with TBAF (0 °C in THF) affording the α-1,4-linked-bis-manno-
disaccharide III-2a in good yield (76%). 
Scheme 29. Synthesis of tyrosine Bis-manno-disaccharide III-2a. 
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 Finally the bis-manno-sugar III-3a could also be converted to the fully protected 
α-1,4-linked-bis-manno-disaccharide III-3b without any ester migration (Scheme 30). 
This was easily accomplished by treating a CH2Cl2 solution of tetraol III-3a with 2,2-
dimethoxypropane and 10 mol % of CSA, which provided the bis-acetonide III-3b in 
good yield (80%). 
Scheme 30. Synthesis of fully protected Bis-manno-disaccharide III-3b. 
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 Replacing pyranone III-18 with its L-enantiomer (ent)-III-18 resulted in an 
equally efficient synthesis of the L,L-bis-manno-disaccahride diastereomer of III-2a, III-
26 (Scheme 31). Thus, in three analogous steps, D-tyrosine was converted into 
pyran/pyranone III-24 (69% overall yield). The L,L-1,4-linked pyran/pyranone III-24 
was stereoselectively reduced and acylated to form III-25 in good overall yield (86%). 
Once again, two diastereoselective dihydroxylations occurred upon exposure of III-25 to 
the Upjohn conditions. This bis-dihydroxylation occurred with near perfect stereocontrol, 
as with the diastereomeric series (cf. Scheme 29). The tetraol product was converted to 
the unprotected bis-sugar III-26 via a TBS group deprotection (TBAF, 78%) or to the 
fully protected diastereomer III-27 by means of an acetonide protection (10 mol % of 
CSA/2,2-DMP, 81%). 
Scheme 31.  Synthesis of L,L-disaccharide analogues III-26. 
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Having synthesized the key disaccharide fragment of mannopeptimycin-E (III-2a 
and III-3b) along with its L,L-diastereomers (III-26 and III-27), we turned our attention 
to the preparation of deoxy analogues (Scheme 32). The simplest 2,3-deoxy analogue III-
28 was obtained by an exhaustive diimide reduction.66 Both double bonds of III-23 were 
reduced using an excess of the diimide precursor NBSH in CH2Cl2 to afford the 2,3-
deoxybis-pyranoside III-28 in nearly quantitative yield (95%). 67  Under identical 
conditions, the diastereomeric L,L-1,4-linked bis bispyran III-25 was reduced to give an 
excellent yield of the bis-dideoxy analogue III-28 (97%).67 
Scheme 32.  Synthesis of Bis-2,3-dideoxydisaccharide analogues III-2b and III-28. 
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3.5.  Asymmetric synthesis of aza-analogue of mannoeptimycin-E disaccharide 
portion.†   
3.5.a. Retrosynthetic analysis of aza-analogue of mannopeptimycin-E key fragment. 
In particular, we were interested in the critical role of the C-4’ isovaleryl group and 
its specific location played on antibacterial activity.56,59 It has been shown that removal or 
                                                 
†
 Reproduced with permission from J. Org. Chem. 2007, 72, 4966-4969.  Copyright 2007, 
with permission from American Chemical Society. 
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migration of the C-4’ isovalerate substitution on the terminal mannose leads to a 
substantial decrease in antibacterial potency.56,59 Along this vein, we became interested in 
an aza-analogue III-3 that should be resistant to both hydrolysis and migration (Scheme 
33). 
Herein, we describe the enantioselective synthesis of the C-4’ acylated 1,4-
manno,manno-4’amino disaccharide analogue III-29 via the iterative use of highly 
diastereo- and regioselective palladium-catalyzed allylation reactions. Our retrosynthetic 
analysis of the aza-disaccharide fragment III-29 is outlined in Scheme 33. This route 
begins with allylic alcohol III-22, which we have previously prepared enroute to the 
disaccharide III-2, via the sequential application of our Pd(0)-glycosylation/post-
glycosylation transformations upon a protected tyrosine III-17.61 Key to this new 
approach to the C-4’ amido analogue III-29 is the regio- and stereoselective conversion 
of the allylic alcohol III-22 to the allylic azide III-32 by a palladium-catalyzed allylic 
substitution.68  Finally, we envisioned the manno,manno-stereochemistry in III-29 being 
installed by an azide reduction/acylation and stereoselective bis-dihydroxylation of a 1,4-
linked-C-4’ amino-bis-pyran III-30.69 Simply substituting a bis-diimide reduction for the 
above mentioned bis-dihydroxylation would also allow for the preparation of a deoxy-
analogue III-36 (vide infra). 
Scheme 33.  Retrosynthetic analysis of mannopeptimycin analogue III-29. 
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3.5.b. Synthetic approach of aza-analogue of mannopeptimycin-E key fragment. 
Our divergent approach to the aza-analogue III-29 began with the known bis-pyran 
III-22 with the conversion of the allylic alcohol portion into an pi-allyl palladium leaving 
group (Scheme 34). We chose to use the methyl carbonate group as in III-31, which was 
readily prepared by treating III-22 with methyl chloroformate in excellent yield (90%). 
Exposing carbonate III-31 to the conditions developed by Sinou (TMSN3, 
(Pd(allyl)Cl)2/1,4-bis(diphenylphosphino)butane) at room temperature afforded a single 
regio- and stereoisomeric allylic azide III-32 in good yield (88%).70 To avoid problems 
with allylic rearrangements, the allylic azide III-32 was immediately reduced with P(n-
Bu)3/THF to give allylic amine III-30 (80%).71 
Scheme 34.  Synthesis of allylic amine III-30. 
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The key isovaleryl group was easily installed by treating allylic amine III-30 with 
isovaleric acid and DCC/DMAP in CH2Cl2, which provided the C-4 isovaleryl amide 
disaccharide precursor III-33 in excellent yield (85%) (Scheme 35). The manno-
stereochemistry in III-34 was diastereoselectively introduced upon exposure of III-34 to 
the Upjohn conditions (OsO4/NMO, 80%).20,62  To complete the model system both TBS-
ethers were easily removed with TBAF (0 °C in THF) affording the 1,4-linked-bis-
manno-4’-amido-disaccharide III-29 in good yield (80%). In addition, the fully protected 
disaccharide III-35 was also prepared for macrocyclic peptide assembly. This was easily 
accomplished by converting the bis-manno-C-4’-amido disaccharide III-34 to the bis-
acetonide III-35 (10 mol % CSA/2,2-DMP, 80%). 
 
Scheme 35.  Synthesis of tyrosine-bis-manno-amido disaccharide  III-29 and III-35. 
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Finally, the 2,3-deoxy analogue III-36 was readily prepared by an exhaustive diimide 
reduction (Scheme 36). Both double bonds of III-33 were reduced with excess diimide 
precursor (NBSH) in CH2Cl2 affording the 2,3-deoxy-C4’-amido bis-pyranoside III-36 
in excellent yield (95%).66  
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Scheme 36.  Synthesis of bis-2,3-dideoxyamido disaccharide analogue III-36. 
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3.6.   Syntheses of Serine and threonine analogue of mannopeptimycin-E key 
fragment. 
After successfully making the key disaccharide fragment of mannopeptimycin E 
and its aza-analogues, we turned our attention to synthesize a small library of analogues 
of the disaccharide fragment of mannopeptimycin-E. In this vein, we replaced pyranone 
III-18 with its L-enantiomer (ent)-III-18 resulted in an equally efficient synthesis of the 
serine-L,L-bis-manno-sugar analogues III-41, III-43 (Scheme 37). Thus, in three 
analogous steps, D-serine was converted into pyran/pyranone III-39 in 67% overall yield. 
The L,L-1,4-linked pyran/pyranone III-39 was stereoselectively reduced and acylated to 
form III-40 in good overall yield (77%). Once again, two diastereoselective 
dihydroxylations occurred upon exposure of III-25 to the Upjohn conditions. This bis-
dihydroxylation occurred with near perfect stereocontrol, as with the diastereomeric 
series (cf. Scheme 29). The tetraol product was converted to the unprotected bis-sugar 
III-41 via a TBS group deprotection (TBAF, 78%) or to the fully protected diastereomer 
III-42 by means of an acetonide protection (10 mol % of CSA/2,2-DMP, 75%). Simply 
substituting a bis-diimide reduction for the above mentioned bis-dihydroxylation on 
compound III-40 will allow for the preparation of a deoxy-analogue III-36 with excellent 
yield (94%). 
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Scheme 37. Syntheses of serine analogues of mannopeptimycin-E key fragment III-41 
and III-43. 
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Because of our motivation to test similar compounds as antibiotics, we 
synthesized threonine-L,L-bis-manno-sugar analogues III-47, III-49 by using L-
pyranone (ent)-III-18 and D-threonine III-40 in an equally efficient manner (Scheme 
38). Thus, in three analogous steps, D-threonine was converted into pyran/pyranone III-
45 in 70% overall yield. The L,L-1,4-linked pyran/pyranone III-45 was stereoselectively 
reduced and acylated to form III-46 in good overall yield (84%). Once again, two 
diastereoselective dihydroxylations occurred upon exposure of III-46 to the Upjohn 
conditions. This bis-dihydroxylation occurred with near perfect stereocontrol, as with the 
diastereomeric series (cf. Scheme 29). The tetraol product was converted to the 
unprotected bis-sugar III-47 via a TBS group deprotection (TBAF, 75%) or to the fully 
protected diastereomer III-48 by means of an acetonide protection (10 mol % of 
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CSA/2,2-DMP, 78%). Simply substituting a bis-diimide reduction for the above 
mentioned bis-dihydroxylation on compound III-46 will allow for the preparation of a 
deoxy-analogue III-49 with excellent yield (96%). 
Scheme 38. Synthesis of threonine analogues of mannopeptimycin-E key fragment III-47 
and III-49. 
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3.7.  Towards asymmetric synthesis of Mannoeptimycin-E analogue.   
The key portion of mannopeptimycin-E and its analogues have been prepared 
successfully with our de novo approach towards an idea of activity testing.  Further, we 
turned our attention in developing a strategy to check the compatibility of carbohydrate 
approach with peptide sequence.  In this vein, our proposed retrosynthetic approach was 
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shown in Scheme 39. Mannopeptimycin analogue III-50 could be assambled from two 
linear tripeptide intermediates III-51 and III-52 using HBTU coupling conditions 
(Scheme 39).72 
Scheme 39. Retrosynthesis of mannopeptimycin-E analogue III-50. 
NH
N
H HN
HNH
N
NH
O
O
O
O
O
O O
OHHO
HO
Mannopeptimycin analogue
O
OHO
OH
O
OHO
OH
OH
OH
O
MeO
HNH
N
Fmoc
NH
O
O
O OR
NH
N
H NHFmoc
Ot-Bu
O
O
O
OBnTBSO
t-BuO
R = TBS
+
III-50
III-51
III-52bR = bis-mannose
III-52a
 
 Tripeptide III-51 could be synthesized from D-/L-serine.  We envisioned the other 
tripeptide III-52a could be prepared from coupling of three synthetic peptides glycine, 
phenylalanine and D-tyrosine (Scheme 40). A related procedure will be used to prepare 
the O-bismannose containing diastereomeric tripeptide III-52b. 
 
Scheme 40. Retrosynthesis of tripeptides III-51 and III-52a/b. 
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 Outlined in Scheme 41 is the synthetic approach of L-ser-D-ser-L-ser tripeptide 
III-63. Our synthesis started with the protection of the primary alcohol of D-serine III-59 
as TBS ether III-60, followed by hydrolysis of methyl ester with NaOH/MeOH, which 
gave acid III-55 in excellent yield (85%).  Peptide III-55 was coupled with L-ser-NH2 
III-56 using HBTU in presence of Et3N affording dipeptide III-61 in 83% yield.  
Exposing dipeptide III-61 under catalytic hydrogenolysis condition (Pd/C, H2, MeOH) 
afforded the dipeptide amine III-62 in good yield (90%).  Tripeptide III-63 was prepared 
by HBTU-mediated coupling between dipeptide amine III-62 and L-serine-acid III-54 in 
good yield (85%).72 
Scheme 41. Synthesis of tripeptide III-63. 
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Having synthesized the above tripeptide fragment, we turned our attention to the 
preparation of Gly-L-Phe-D-Tyr tripeptide III-52a (Scheme 42).  Treatment of Cbz-Phe-
OH III-58 with trimethylsilyl chloride in presence of methanol gave methy ester III-64.  
Subsequent treatment of compound III-64 under hydrolysis condition (Pd/C, H2, MeOH) 
afforded amine III-65 in excellent yield (90%).  Coupling of amine III-65 with Cbz-Gly-
OH III-57 using HBTU gave dipeptide III-66 in 85% yield. Further, treatment of 
dipeptide III-66 under hydrolysis conditions (LiOH/MeOH) gave carboxylic acid III-67 
in 78% yield.   
 Tyrosine amine precursor III-69 can be derived from commercially available D-
tyrosine III-68 using four synthetic steps of selective protections and deprotections.  D-
tyrosine III-68 was protected as methyl ester with MeOH/SOCl2, followed by protection 
of the amino group as its Cbz derivative under standard conditions afforded phenol III-
68a in 95% yield for two steps. 73   Subsequent O-silylation of phenol III-68a with 
TBSCl/Et3N gave fully protected tyrosine III-53 in good yield (87%).  Selective 
deprotection of Cbz group of compound III-53 using catalytic hydrogenation (Pd/C, H2, 
MeOH) gave the desired amine III-69 in good yield (89%).  Treatment of dipeptide acid 
III-67 with amine III-69 using HBTU gave tripeptide III-52a in 80% yield. 
 
Scheme 42. Synthesis of tripeptide III-52a. 
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Having successfully synthesized the Gly-L-Phe-D-Tyr tripeptide in good yield, 
the next goal was to synthesize the O-bis-manno-tripeptide III-52b using similar 
procedures (Scheme 43).  Thus, we subjected tyrosine-disaccharide fragment III-3b to 
catalytic hydrogenation (Pd/C, H2, MeOH), which afforded the Bis-manno-Tyr-amine 
III-70 in 75% yield.  There was some concern about deprotection of TBS-ether during 
the hydrogenation step, but this turned out not to be the case neutral condition and lower 
reaction times were maintained.  Under HBTU coupling conditions, the amine III-70 and 
the carboxylic acid III-67 gave desired O-bis-manno-tripeptide III-52b in good yield as 
single diastereomer (75%). 
 
Scheme 43. Synthesis of O-bis-manno-tripeptide III-52b. 
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Completion of the synthesis of mannopeptimycin-E analogue III-50 requires 
selective removal of protecting groups, followed by two coupling steps and global 
deprotection from the two advanced tripeptide intermediates III-63 and III-52b (Scheme 
44).  These efforts are ongoing in the group. 
Scheme 44. Synthesis of mannopeptimycin-E analogue III-50. 
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3.8.  Summary 
 In conclusion, an enantioselective synthesis of the manno-disaccharide fragments 
of mannopeptimycin-E and its five analogues were been achieved in seven steps and 35-
40% overall yields from D-tyrosine via an iterative palladium-glycosylation strategy. Key 
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to the success of this approach was the ease with which the C-4 isovalerate group was 
introduced, and the high diastereoselectivity of the palladium-catalyzed glycosylation and 
bis-dihydroxylation reactions. The use of this methodology gave two 1,4-linked-bis-
manno-4’-amido-disaccharide analogues of mannopeptimycin-E, which have been 
synthesized in 10 steps with 21% overall yield from D-tyrosine via a palladium-catalyzed 
azide allylation reaction for the stereoselective installation of the C-4 isovaleramide 
group. We have synthesized the two advanced intermediate tripeptides using our de novo 
and traditional peptide chemistry.  Further studies on the completion of synthesis of 
mannopeptimycin analogue III-50 and their subsequent biological investigation will be 
reported in due course.  
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Chapter 4 
Syntheses and Biosynthetic Studies of Methymycin Analogues. 
4.1. Introduction to 12-membered lactone methymycin 
The 12-membered macrolactones are an important class of antibiotics used to 
treat infections caused by Gram-positive bacteria. 74  Streptomyces venezuelae ATCC 
15439 produces these 12-membered ring polyketides methymycin IV-1, 10-
deoxymethynolide IV-2 and neomethymycin IV-3, (Figure 5). 75   These polyketides 
contain a lactone aglycone attached to rare deoxy amino sugar as an important 
component.  The biological activities of these secondary metabolites are dramatically 
decreases when the sugar is removed. Therefore modifications of these critical deoxy 
amino sugar substituents are important in order to generate new macrolide antibiotics 
with promising biological activity.76 
Figure 5. 12-membered macrolactones antibiotics. 
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A method for modifying natural products by combining existing biosynthetic 
genes from diverse allied bacteria to create a pathway for producing unnatural products 
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known as combinatorial biosynthesis, which has recently become a promising method for 
the development of new class of antibiotics. The macrolide antibiotic biosynthetic 
pathways from different species of Streptomyces has led to genetic manipulations to 
combine genes from various pathways for the biosynthesis of new hybrid macrolides with 
promising bioactivity.77  
There is a significant interest in the possibility of using combinatorial 
biosynthesis to generate new macrolactones attached with new deoxy sugar moieties. 
Recent studies on the flexibility of glycosyltransferases in accepting non-native sugars as 
substrate for attachment to specific macrolactones has made these enzymes an important 
tool for combinatorial biosynthesis of novel compounds with altered glycosylation 
patterns.78  It is assumed that this research based on a combinatorial biosynthetic strategy 
will facilitate the development of new novel antibiotics. 
 
4.2. Previous Approaches to Methymycin Analogues 
4.2.a.  Biosynthesis of methymycin and neomethymycin via glycosylation using 
DesVII/DesVIII mutants. 
 Hung-Wen Liu et al. have been making significant progress in using genetic and 
biochemical methods to develop new class of macrolide antibiotics using 
glycosyltransferase as their key biosynthetic tool.79  They have used different enzyme 
gene clusters ranging from desI-desVIII of Streptomyces venezuelae involved in the 
biosyntheses of 12-membered macrolide antibiotics like methymycin IV-1 and 
neomethymycin IV-3  (Scheme 45).  These polyketides mainly contain the single 3-
dimethylamino-3,4,6-trideoxy sugar, desoamine, and different identified gene clusters, 
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represent a model system to probe the feasibility of making new macrolides containing 
modified sugar components in vivo.80  
Scheme 45.  Biosynthesis of methymycin IV-1 and neomethymycin IV-3. 
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As shown in Scheme 45, they tried to couple the sugar donor TDP-D-deosamine 
IV-5, and the aglycone acceptor 10-deoxymethynolide IV-2 with the enzyme pair DesVII 
to get 10-deoxy methymycin IV-4.  Unfortunately no products were detected.  After 
exploring various conditions like solvent system/pH range/temperature, then surprisingly 
discovered that Des VIII as a necessary component in presence of enzyme DesVII at 
higher pH to produce the desired compound 10-deoxy methymycin IV-4.  Compound IV-
4 was further modified by another enzyme PikC.  They showed the catalytic properties of 
DesVII/DesVIII pair towards biosynthesis of various donor and acceptor substrates for 
the development of in vitro glycosylation of macrolides and other classes of natural 
products.80 
 
4.3. Project Description and Goals 
Since the deoxyaminosugar portion of macrolides is essential for their 
antimicrobial activity,81 their modification hold promise as a valuable approach towards 
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preparing new macrolide antibiotics with improved biological properties. 82   Many 
research groups have reported the use of modified biosynthetic pathways for the 
production of new glycosylated antibiotics; 83  however their use of complex sugar 
nucleotide intermediates and low-moderate yields leave room for improvement of 
macrolide antibiotics. 
The main goal of this project is to develop a diastereoselective route to install 
different sugar motifs onto complex antibiotic aglycones from simple achiral starting 
material.  In this connection our research group has initiated collaboration with Prof. 
Hung-Wen Liu’s labs and developed the de novo approach, which would allow for facile 
synthesis of various methymycin analogues and planned to test our compounds in his 
labs.   
Scheme 46.  Retrosynthesis of methymycin analogues. 
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Our retrosynthetic analysis for the synthesis of methymycin analogues is shown in 
Scheme 46. Our plan was to develop a method for the installation of various amino and 
deoxy sugars onto 10-deoxymethynolide IV-2 using our Pd-glycosylation/post 
glycosylation modification. 84   As previously discussed, all the required pyranone 
stereoisomers IV-6, IV-6a, IV-27 and IV-21 can be prepared by employing an 
enantioselective Noyori R,R/S,S reduction 85  of acyl furan IV-6b, followed by 
Achmatowicz oxidation, and diastereoselective  carbonate formation.86 
 
4.4. Synthesis of Methymycin analogues 
 Our synthetic strategy starts with a selective reduction of the double bond in 10-
deoxymethynolide IV-2 by subjecting with excess diimide precursor87 which gave the 
desired dihydro aglycone IV-7 in 95% yield (Scheme 47).  Aglycone IV-7 underwent a 
diastereoselective palladium-catalyzed glycosylation with of α-Boc-pyranone IV-6 
producing α-glycoside IV-8 as a single diastereomer and in good yield (86%). Luche 
reduction88 of enone IV-8 gave the equatorial allylic alcohol IV-9 in 82% yield. Diimide 
reduction of allylic alcohol IV-9 with excess triethylamine and O-nitrophenylsulfonyl 
hydrazide produced dideoxy analogue IV-10 in excellent yield (90%).  
 
Scheme 47.  Synthesis of methymycin analogue IV-10 and IV-11. 
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The rhamnose-sugar analogue IV-11 was achieved by diastereoselective 
dihydroxylation using Upjohn conditions20 (OsO4/NMO) in 85% yield (Scheme 47). 
 We next investigated methods for construction of various C-4-amino/azido sugar 
analogues (Scheme 48). To do this, we converted the allylic alcohol IV-9 into a methyl 
carbonate leaving group by reaction with methyl chloroformate to form C-4-carbonate 
IV-12 in 70% yield.   
 
Scheme 48.  Synthesis of methymycin analogues IV-14, IV-15 and IV-16. 
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Exposing carbonate IV-12 to the Sinou conditions70 (TMSN3, (Pd(allyl)Cl2/1,4-
bis(diphenylphosphino)butane) afforded a single regio-, and stereoisomeric allylic azide 
IV- IV-13  in 75% yield.  As before, diimide reduction of allylic azide IV-13 gave 2,3 
dideoxy analogue IV-14 in 90% yield.  Once again, a diastereoselective dihydroxylation 
(OsO4/NMO), followed by reduction of azide (Pd/C, H2, MeOH) produced amino-
mannose analogue IV-16 in 80% yield via rhamno-azide IV-15 in 85%. 
  Hydrogenolysis (Pd/C, H2, MeOH) of allylic azide IV-13 gave dideoxy amino 
sugar analogue IV-17 via one-pot reduction of both azide and allylic double bond in 82% 
yield (Scheme 49).   
With successful syntheses of amino-and deoxy-rhamnose sugar analogues of 
methymycin, next explored the synthesis of inverted amino sugar analogue IV-17 at the 
C-4-position (Scheme 49). 
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Scheme 49.  Synthesis of dideoxy-amino analogues IV-17 and IV-20. 
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 When carbonate IV-12 was subjected to Mitsunobu conditions using TMS azide 
as the nucleophile, no desired C-4-azido compound IV-19 was formed. We next turned to 
a two step SN2 reaction route.  Thus allylic alcohol IV-9 was converted into mesylate IV-
18 (MsCl/Et3N) in excellent yield 88%, followed by treating IV-18 with NaN3/THF to 
give the inverted C-4-azido compound IV-19 in 86% yield.  Reduction of the C-4-azido 
group and allylic double bond in compound IV-19 under hydrogenolysis conditions 
(Pd/C, H2, MeOH) gave C-4-deoxy-amino analogue of methymycin IV-20 in excellent 
yield 80%. 
 
Figure 6.  The reverse glycosyl transferase assay using HPLC chromatogram analysis on     
our small library of eight compounds. 
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Prof. Hung-Wen Liu group had tested all eight compounds (Compound IV-9, IV-
10, IV-11, IV-13, IV-14, IV-15, IV-16, IV-17) as sugar donors in the reactions with 
three different acceptors: 10-deoxymethynolide, narbonolide, and tylactone (Figure 6).  
They ran assays from 5 h to overnight and analyzed the reactions with narbonolide by 
HPLC and TLC, and two other sets by HPLC.  Then they did the reverse assay only (no 
aglycone acceptor added, excess of TDP) just to see if the enzyme recognizes the 
substrates.  By TLC assay, it appears that IV-9, IV-10, IV-13, IV-14, IV-17 are de-
glycosylated, and IV-11, IV-15, IV-16 are not.  These initial results imply that some (IV-
9, IV-10, IV-13, IV-14, IV-17) sugars are hydrolyzed but not transformed to the new 
substrate, which implies L-analogs are not recognized well. There may be better chance 
of success with D-analogs since they see up to 30% transfer with natural sugar.  Thus we 
plan to investigate the syntheses β-D-sugar methymycin analogues. 
In this connection, we next investigated the synthesis of 2,6 dideoxy β-D-allo-
sugar analogue IV-25 of methymycin (Scheme 50).  The methodology developed by our 
group for the synthesis of Digitoxin and its analogues has been used in the synthesis of 
2,6 dideoxy β-D-allo-sugar. Thus taking 10-dideoxymethynolide IV-7 and β-D-pyranone 
IV-21 subjecting to palladium-catalyzed glycosylation gave the β-D-glycoside IV-22 as 
single diastereomer and in good yield (90%).  Luche reduction of ketone IV-22 provided 
a mixture of diastereomeric allylic alcohols IV-23 in 83% yield. 
 
Scheme 50.  Synthesis of allose-sugar analogue IV-25. 
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Scheme 51.  Mechanism of Myers’ reductive rearrangement. 
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Further, exposing the mixture of allylic alcohols IV- 23 to the Myers’ reductive 
rearrangement conditions89 (NBSH, Ph3/DEAD, NMM, -30 °C to rt) provided olefin IV-
24 in moderate yield (63%) (Scheme 51).  Finally, dihydroxylation of olefin IV-24 using 
the Upjohn conditions (OsO4/NMO) gave exclusively the 2,6 dideoxy allose-sugar 
analogue IV-25 in 90% yield.  
Encouraged by the above results, we next investigated our palladium-catalyzed 
glycosylation reaction to methymycin aglycone IV-26 with α-D-pyranone IV-27. Our 
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strategy worked well and gave single regioselective glycosylated product IV-28 in 75% 
yield with the free tertiary alcohol left unreacted (Scheme 52). The structure of IV-28 
was confirmed using 1D NOE difference, COSY and heterocorrelation HETCOR 
experiments. 
 
Scheme 52.  Synthesis of methynolide-α-D-glycoside IV-28. 
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4.5.  Summary 
 In conclusion, a divergent and highly enantioselective route to eight various 
amino/azido/dideoxy methymycin analogues have been developed. The key to the 
success of this method is the iterative use of the palladium-catalyzed glycosylation 
reaction, Luche reduction/Myers’ reductive rearrangement, diastereoselective 
dihydroxylation, and regioselective reductions.  This unique application of our Pd-
catalyzed glycosylation efficiently prepares a challenging and important α/β-glycoside 
target.  Currently, a small library of methymycin analogues was under testing on 
glycosyltransferase assays in Prof. Hung-Wen Liu labs. 
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Chapter 5 
Experimental Section. 
General Methods and materials.   
General Methods and materials:  1H and 13C spectra were recorded on Joel 270 and 
Varian 600 spectrometers. Chemical shifts were reported relative to internal 
tetramethylsilane (δ 0.00+) or CDCl3 (δ 7.26) or CD3OD (δ 4.87) for 1H and CDCl3 (δ 
77.1) or CD3OD (δ 49.15) for 13C. Optical rotations were measured with a Jasco DIP-370 
digital polarimeter in the solvent specified. Infrared (IR) spectra were obtained on a 
prospect MIDAC FT-IR spectrometer. Flash column chromatography was performed on 
ICN reagent 60 (60-200 mesh) silica gel. Analytical thin-layer chromatography was 
performed with precoated glass-backed plates (Whatman K6F 60Å, F254) and visualized 
by quenching of fluorescence and by charring after treatment with p-anisaldehyde or 
phosphomolybdic acid or potassium permanganate stain. Rf values were obtained by 
elution in the stated solvent ratios (v/v). Ether, THF, methylene chloride and 
triethylamine were dried by passing through activated alumina (8 x 14 mesh) column 
with nitrogen gas pressure. Commercial reagents were used without purification unless 
otherwise noted. Air and/or moisture-sensitive reactions were carried out under an 
atmosphere of argon/nitrogen using oven/flamed-dried glassware and standard 
syringe/septa techniques. 
 
1-(2′-Furyl)-2-trimethylsilanylethan-1-ol (I-2a).14 
O SiMe3
OH
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Magnesium turnings (10.1 g, 0.415 mol) were placed in a 1 L-3-neck round bottom flask 
and a condenser along with a side arm addition funnel were attached.  The apparatus was 
flame dried (3x), each time flushing with nitrogen. Chloromethyltrimethylsilane (42.4 g, 
0.346 mol) in 200 mL of Et2O were added slowly to the dry magnesium.  After the 
addition, the solution was refluxed for 1 h.  Freshly distilled furfural (25.0 mL, 0.302 
mol) and 300 mL of Et2O were added slowly to the Grignard reagent at 0 oC and the 
solution was stirred for 3 h at 0 oC and 9 h at room temp.  The reaction was quenched 
with 200 mL of sat. aq. NH4Cl and extracted (3 x 100 mL) with Et2O.  The organic layer 
was washed with satd aq NaHCO3 (2 x 50 mL), brine (2 x 50 mL), dried (Na2SO4), and 
concentrated under reduced pressure to give 1-(2′-furyl)-2-trimethylsilanylethan-1-ol  I-
2a in 90% yield, 50.1 g (0.272 mol):  Rf (30% Et2O/hexanes) = 0.58; IR (thin film,  cm-1) 
3390, 2950, 2895, 1655, 1505, 1250; 1H NMR (270 MHz, CDCl3) δ 7.28 (dd, J = 1.8, 0.7 
Hz, 1H), 6.24 (dd, J = 3.1, 1.8 Hz, 1H), 6.13 (d, J = 3.3 Hz, 1H), 4.77 (dd, J = 8.8, 6.9 
Hz, 1H), 3.13 (bs, 1H), 1.28 (dd, J = 14.1, 8.8 Hz, 1H), 1.23 (dd, J = 14.1, 6.8 Hz, 1H), -
0.10 (s, 9H); 13C NMR (67.5 MHz, CDCl3) δ 157.7, 141.6, 110.1, 105.5, 65.6, 24.8, -1.4 
(3C); CIHRMS Calcd for [C9H16O2Si]+:  184.0920.  Found 184.0905. 
 
1-(2′-Furyl)-ethan-1R, 2-diol (I-2b).14 
O OH
OH
 
The β-hydroxy silane I-2a (44.2 g, 0.240 mol) and 120 mL of Et2O were added to a 500 
mL round bottom flask followed by addition of 120 mL of 1 M HCl and the solution was 
stirred for 1 h.  Phases were separated and the aq layer was extracted (2 x 50 mL) with 
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Et2O and combined with the organic layer.  The organic layer was washed (2 x 50 mL) 
with sat. aq. NaHCO3 and added to a solution of 300 mL of t-BuOH, 750 mL of H2O, 50 
g of AD-mix-α, 133 g of K3Fe(CN)6, and 56 g of K2CO3 at 0 oC.  The solution was 
vigorously stirred with a mechanical stirrer for 12 h at 0 oC.  The reaction was slowly 
quenched with (500 mL) satd aq Na2SO3.  The phases were separated and the aqueous 
layer was extracted (6 x 100 mL) with EtOAc.  The organic layer was washed with satd 
aq NaHCO3 (2 x 100 mL), brine (2 x 100 mL), dried (Na2SO4), and concentrated under 
reduced pressure.  The crude product was purified by silica gel flash chromatography 
eluting with 40% Et2O/hexanes to yield 1-(2′-furyl)-ethan-1R,2-diol I-2b 25.0 g (0.195 
mol, 85%):  Rf (50% Et2O/hexanes) = 0.37; [α]21D = +32.0 (c 2.17, CH2Cl2); IR (thin 
film, cm-1) 3390, 2933, 2881, 1684, 1505, 1464, 1228; 1H NMR (270 MHz, CDCl3) δ 
7.30 (dd, J = 1.8, 0.6 Hz, 1H), 6.27 (dd, J = 4.0, 1.8 Hz, 1H), 6.23 (dd, J = 4.0, 0.6 Hz, 
1H), 4.71 (t, J = 5.9 Hz, 1H), 4.54 (bs, 2H), 3.74 (d, J = 5.9 Hz, 2H); 13C NMR (67.5 
MHz, CDCl3) δ 153.9, 142.3, 110.5, 107.0, 68.4, 65.0; CIHRMS Calcd for [C6H8O3 + 
NH4]+:  146.0817.  Found 146.0822; Anal. Calcd for C6H8O3:  C, 56.23; H, 6.30.  Found:  
C, 56.04; H, 6.20. 
1-(2′-Furyl)-2-tert-butyldimethylsilanyloxyethan-1-R-ol (I-3).14 
O OTBS
OH
 
Diol 1-(2′-furyl)-ethan-1R,2-diol I-2b (0.986 g, 7.70 mmol), 15 mL of CH2Cl2, and 5.5 
mL of Et3N were added to a round bottom flask and cooled to 0 oC.  A catalytic amount 
(50 mg, 0.41 mmol) of DMAP was added followed by addition of tert-butyldimethylsilyl 
chloride (1.19 g, 7.89 mmol) and the solution was stirred at 0 oC for 6 h.  The reaction 
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was quenched with 1 M NaHSO4 and extracted (3 x 25 mL) with Et2O, washed with satd 
aq NaHCO3 (2 x 20 mL), and dried (Na2SO4).  The crude product was purified by silica 
gel flash chromatography eluting with 25% Et2O/hexanes to yield 1-(2′-furyl)-2-tert-
butyldimethylsilanyloxyethan-1R-ol I-3 1.69 g (6.97 mmol, 91%): Rf (30% 
Et2O/hexanes) = 0.55; [α]21D = +15.9 (c 1.37, CH2Cl2); IR (thin film, cm-1) 3447, 2954, 
2930, 2884, 2857, 1471, 1463, 1361; 1H NMR (270 MHz, CDCl3) δ 7.37 (dd, J = 1.8, 0.9 
Hz, 1H), 6.35 (dd, J = 3.3, 1.8 Hz, 1H), 6.33 (dd, J = 3.3, 0.9 Hz, 1H), 4.75 (dd, J = 6.4, 
4.6 Hz, 1H), 3.86 (dd, J = 10.1, 4.6 Hz, 1H), 3.85 (dd, J = 10.1, 6.7 Hz, 1H), 3.04 (bs, 
1H), 0.90 (s, 9H), 0.07 (s, 6H); 13C NMR (67.5 MHz, CDCl3) δ 154.0, 142.0, 110.3, 
107.1, 68.5, 65.9, 26.0 (3C), 18.4, -5.3 (2C); CIHRMS Calcd for [(C12H22O3Si)-H20]+:  
225.1310.  Found 225.1296; Anal. Calcd for C, 59.47; H, 9.16.  Found C, 59.80; H, 9.37. 
 
6-Hydroxy-(2R)-2-tert-butyldimethylsilanyloxymethyl-2H-pyran-3-(6H)-one (I-12).14 
O OTBS
O
HO
 
Compound 1-(2′-furyl)-2-tert-butyldimethylsilanyloxyethan-1R-ol I-4 (1.69 g, 6.97 
mmol), 12 mL of THF, and 3 mL of H2O were added to a round bottom flask and cooled 
to 0 oC.  Solid NaHCO3 (1.17 g, 13.9 mmol), NaOAc•3H20 (0.950 g, 6.98 mmol), and 
NBS (1.24 g, 6.97 mmol) were added to the solution and the mixture was stirred for 1 h 
at 0 oC.  The reaction was quenched with satd aq NaHCO3 (15 mL), extracted (3 x 25 
mL) with Et2O, dried (Na2SO4), concentrated under reduced pressure and purified by 
silica gel chromatography eluting with 20% EtOAc/hexanes to give 6-hydroxy-(2R)-2-
tert-butyldimethylsilanyloxymethyl-2H-pyran-3-(6H)-one I-12 1.71 g (6.62 mmol, 95%):  
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Rf (40% Et2O/hexanes) = 0.40; IR (thin film, cm-1) 3388, 2951, 2929, 2884, 2858, 1699, 
1464, 1256; 1H NMR (270 MHz, CDCl3) major isomer δ 6.93 (dd, J = 10.3, 3.3 Hz, 1H), 
6.12 (dd, J = 10.4, 0.6 Hz, 1H), 5.79 (dd, J = 5.1, 3.1 Hz, 1H), 4.59 (dd, J = 5.0, 2.8 Hz, 
1H), 4.02 (dd, J = 11.2, 5 Hz, 1H), 3.93 (dd, J = 11.2, 2.0 Hz, 1H), 0.87 (s, 9H), 0.07 (s, 
3H), 0.06 (s, 3H); 13C NMR (67.5 MHz, CDCl3) major isomer δ 194.9, 145.9, 128.1, 
88.1, 76.7, 63.5, 25.8 (3C), 18.5, -5.2, -5.3; CIHRMS Calcd for [(C12H22O4Si)+H]+:  
259.1366.  Found 259.1366; Anal. Calcd for C, 55.79; H, 8.59.  Found C, 55.86; H, 8.45. 
 
Carbonic acid tert-butyl ester 6-(tert-butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-
dihydro-2H-pyran-2-yl ester (I-15).14 
O
O
O OTBSO
O
 
6-Hydroxy-(2R)-2-tert-butyldimethylsilanyloxymethyl-2H-pyran-3-(6H)-one I-12 (2.58 
g, 10 mmol) was dissolved in CH2Cl2 (8 mL) and the solution was cooled to -78 oC.  A 
CH2Cl2 (2 mL) solution of (Boc)2O (2.61 g, 12 mmol) and a catalytic amount of DMAP 
(122 mg, 1 µmol) was added to the reaction mixture. The reaction was stirred for 1 h at -
78 oC.  The reaction was quenched with 50 mL of satd. aq NaHCO3, extracted (3 x 50 
mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude 
product was purified using silica gel flash chromatography eluting with 6% 
EtOAc/hexanes to give 2.93 g (8.20 mmol, 82%) of carbonic acid tert-butyl ester 6-(tert-
butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yl ester I-15:  Rf (20% 
Et2O/hexanes) = 0.70; [α]21D = +47.7 (c = 1.5, CH2Cl2); IR (thin film, cm-1) 2956, 2932, 
2858, 1754, 1703, 1472, 1371, 1277, 1257; 1H NMR (270 MHz, CDCl3) δ 6.88 (dd, J = 
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10.2, 3.7 Hz, 1H), 6.45 (d, J = 3.5 Hz, 1H), 6.23 (d, J = 10.2 Hz, 1H), 4.54 (dd, J = 3.5, 
3.3 Hz, 1H), 4.05 (d, J = 3.5 Hz, 1H), 4.03 (d, J = 3.5 Hz, 1H), 1.51 (s, 9H), 0.84 (s, 9H), 
0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (67.5 MHz, CDCl3) δ 193.6, 151.7, 141.4, 129.2, 
89.1, 83.5, 77.7, 62.6, 27.6 (3C), 25.8 (3C), 18.2, -5.3 (2C); CIHRMS Calcd for 
[C17H30O6Si+Na]+:  381.1716.  Found 381.1716. 
 
Carbonic acid tert-butyl ester 6-(tert-butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-
dihydro-2H-pyran-2-yl ester (I-16).14 
O
O
O OTBSO
O
 
6-Hydroxy-(2R)-2-tert-butyldimethylsilanyloxymethyl-2H-pyran-3-(6H)-one I-12 (2.58 
g, 10 mmol) was dissolved in CH2Cl2 (8 mL) and the solution was cooled to 0 oC.  A 
CH2Cl2 (2 mL) solution of (BOC)2O (2.61 g, 12 mmol) and a catalytic amount of DMAP 
(122 mg, 1 µmol) was added to the reaction mixture. The reaction was stirred for 1 h at 0 
oC.  The reaction was quenched with 50 mL of satd. aq NaHCO3, extracted (3 x 50 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 6% EtOAc/hexanes to 
give 2.57 g (7.17 mmol, 72%) of two diastereomers of carbonic acid tert-butyl ester 6-
(tert-butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yl ester 6cα and 
I-16 in 1:1 ratio  Rf (20% Et2O/hexanes) = 0.70; [α]21D = -32.27 (c = 1.5, CH2Cl2); IR 
(thin film, cm-1) 2926, 1742, 1680, 1283, 1252, 1162, 1066; 1H NMR (270 MHz, 
CDCl3) δ 6.86 (dd, J = 10.4, 2.7 Hz, 1H), 6.40 (dd, J = 2.7, 1.3 Hz, 1H), 6.25 (dd, J = 
10.4, 1.2 Hz, 1H), 4.33 (dd, J = 5.9, 3.7 Hz, 1H), 4.00 (dd, J = 11.2, 5.7 Hz, 1H), 3.94 
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(dd, J = 11.0, 3.7 Hz, 1H), 1.51 (s, 9H), 0.85 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR 
(67.5 MHz, CDCl3) δ 193.6, 152.0, 142.6, 129.2, 89.2, 83.4, 80.7, 64.4, 27.7 (3C), 25.8 
(3C), 18.3, -5.4 (2C); CIHRMS Calcd for [C17H30O6Si+Na]+:  381.1716.  Found 
381.1714. 
 
6-Benzyloxy-2-(tert-butyl-dimethyl-silanyloxymethyl)-6H-pyran-3-one (I-17). 
O
O
O OTBSPh
 
A CH2Cl2 (3.2 mL) solution of compound I-15 (1.5 g, 4.189 mmol) and benzyl alcohol  
(543 mg, 5.027 mmol) was cooled to 0 oC.  A CH2Cl2 (1 mL) solution of Pd2(DBA)3-
.CHCl3 (54 mg, 2.5 mol%) and PPh3 (43 mg, 10 mol%) was added to the reaction mixture 
at 0 oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction mixture was 
quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 6% EtOAc/hexanes to give 1.29 g 
(3.72 mmol, 89%) of I-17:  Rf (20% EtOAc/hexanes) = 0.56; [α]21D = + 27.5 (c = 1.5, 
CH2Cl2); IR (thin film, cm-1) 2929, 2359, 1699, 1253, 1133, 1037, 836; 1H NMR (270 
MHz, CDCl3) δ 7.34 (m, 5H), 6.86 (dd, J = 10.2, 3.3 Hz, 1H), 6.10 (d, J = 10.2 Hz, 1H), 
5.40 (d, J = 3.3 Hz, 1H), 4.87 (d, J = 11.6 Hz, 1H), 4.67 (d, J = 11.6 Hz, 1H), 4.50 (dd, J 
= 4.5, 2.9 Hz, 1H), 4.04 (m, 2H), 0.88 (s, 9H), 0.08 (s, 6H); 13C NMR (67.5 MHz, 
CDCl3) δ 194.6, 143.8, 136.9, 128.5, 128.2 (2C), 128.0 (2C), 92.0, 76.1, 70.4, 62.4, 25.8 
(3C), 18.2, -5.3 (2C); CIHRMS Calcd for [C19H28O4Si+H]+:  349.1835.  Found 349.1819. 
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6-Benzyloxy-2-(tert-butyl-dimethyl-silanyloxymethyl)-3,6-dihydro-2H-pyran-3-ol (I-
17b).  
OO OTBSPh
OH
 
A CH2Cl2 (2.86 mL) solution of compound I-17 (1 g, 2.86 mmol) and MeOH (2.8 mL) 
was cooled to -78 oC.  NaBH4 (108 mg, 2.86 mmol) was added and the reaction mixture 
was stirred at -78oC for 3 hours. The reaction mixture was diluted with ether (10 mL) and 
was quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 903 mg 
(2.58 mmol, 90%) of I-17b:  Rf (40% EtOAc/hexanes) = 0.32; [α]21D = - 31.0  (c = 1, 
CH2Cl2); IR (thin film, cm-1) 3442, 2929, 1462, 1255, 1043, 838; 1H NMR (270 MHz, 
CDCl3)  δ 7.35 (m, 5H), 5.93 (dd, J = 10.2, 1.1 Hz, 1H), 5.77 (ddd, J = 10.2, 2.5, 2.3 Hz, 
1H), 5.74 (dd, J = 2.5, 2.3 Hz, 1H), 5.04 (dd, J = 2.5, 1.9 Hz, 1H), 4.77 (d, J = 11.8 Hz, 
1H), 4.59 (d, J = 11.8 Hz, 1H), 4.18 (m, 1H), 3.80 (dd, J = 8.5, 3.9 Hz, 1H), 3.74 (m, 
1H), 2.88 (d, J = 3.7 Hz, 1H), 0.92 (s, 9H), 0.10 (s, 6H); 13C NMR (67.5 MHz, CDCl3) δ 
138.0, 132.9, 128.3 (2C), 127.9 (2C), 127.6, 125.7, 93.4, 70.1, 70.0, 67.0, 65.0, 25.8 (3C), 
18.2, -5.4, 5.5; CIHRMS Calcd for [C19H30O4SiNa+]: 373.1811  Found 373.1805. 
 
2-Benzyloxy-6-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran-3,4,5-triol 
(I-17c). 
OO OTBSPh
OH
OH
HO
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To a t-butanol, acetone (0.3 mL, 1:1, 1M) solution of allyl alcohol I-17b (100 mg, 0.285 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
water (0.1 mL).  Crystalline OsO4 (0.5 mg, 1 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column (1 cm × 4”) using a small amount of CH2Cl2 (0.6 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with MeOH/ether (2:98 to 
4:96).  Pure fractions were combined and concentrated to afford triol I-17c 91 mg (0.238 
mmol, 84%):  Rf   (70% EtOAc/hexanes) = 0.32; [α]21D = - 50.1 (c = 2, CH2Cl2); IR (thin 
film, cm-1) 3406, 2929, 1460, 1254, 1098, 838; 1H NMR (270 MHz, CDCl3)  δ 7.31 (m, 
5H), 4.86 (s, 1H), 4.70 (d, J = 11.8 Hz, 1H), 4.47 (d, J = 11.8 Hz, 1H), 4.27 (m, 1H), 4.02 
(m, 1H), 3.91-3.61 (m, 7H), 0.89 (s, 9H), 0.07 (s, 6H); 13C NMR (67.5 MHz, CDCl3) δ 
137.2, 128.3 (2C), 127.9 (2C), 127.7, 98.7, 71.7, 70.4, 69.6, 68.8, 67.5, 64.2, 25.8 (3C), 
18.2, -5.3, 5.4; CIHRMS Calcd for [C19H32O6SiNa+]: 407.1866  Found 407.1882. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yloxy]-
chromen-2-one (I-25). 
O
O
O OTBSOO
 
A THF
 
(0.3 mL) solution of compound I-16 (100 mg, 0.28 mmol) and 7-hydroxy cumarin  
(90 mg, 0.56 mmol) was cooled to 0 oC.  A THF
 
(0.3mL) solution of Pd2(DBA)3.CHCl3 
(7.2 mg, 2.5 mol%) and PPh3 (7.3 mg, 10 mol%) was added to the reaction mixture at 0 
oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction mixture was 
quenched with 2 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
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(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 15-20% EtOAc/hexanes to give I-25 
75 mg (0.18 mmol, 65%) of 10bα:  Rf (20% EtOAc/hexanes) = 0.36; [α]21D =  129.9 (c = 
0.7, CH2Cl2); IR (thin film, cm-1) 2927, 1735, 1732, 1696, 1231, 1125, 836; 1H NMR 
(600 MHz, CD3OD) δ 7.83 (d, J = 9.6 Hz, 1H), 7.50 (d, J = 9.6 Hz, 1H), 7.11 (dd, J = 
10.2, 2.4 Hz, 1H), 7.10 (d, J =  2.4 Hz, 1H), 7.04 (dd, J = 9.0, 1.8 Hz, 1H), 6.24 (br s, 
1H), 6.23 (d, 2.4 Hz, 1H), 6.21 (dd, J = 2.4, 1.2 Hz, 1H), 4.39 (dd, J = 6.6, 3.0 Hz, 1H), 
3.95 (dd, J = 11.4, 7.2 Hz, 1H), 3.88 (dd, J = 10.8, 3.0 Hz, 1H), 0.80 (s, 9H), -0.09 (s, 
3H), -0.16 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 198.4, 195.3, 162.9, 161.4, 145.8, 
145.4, 130.4, 129.8, 115.4(2C), 114.4, 105.1, 94.0, 81.7, 64.9,  26.1 (3C), 19.0, -5.3, -5.5; 
CIHRMS Calcd for [C21H26O6Si+Na]+: 425.1390.  Found 425.1420. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yloxy]-
chromen-2-one (I-23). 
O
O
O OTBSOO
 
A THF
 
(0.3 mL) solution of compound I-15 (100 mg, 0.28 mmol) and 7-hydroxy cumarin  
(90 mg, 0.56 mmol) was cooled to 0 oC.  A THF
 
(0.3mL) solution of Pd2(DBA)3.CHCl3 
(7.2 mg, 2.5 mol%) and PPh3 (7.3 mg, 10 mol%) was added to the reaction mixture at 0 
oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction mixture was 
quenched with 2 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 15-20% EtOAc/hexanes to give 75 mg 
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(0.18 mmol, 65%) of I-23:  Rf (20% EtOAc/hexanes) = 0.36; [α]21D =  -96.10 (c = 0.7, 
CH2Cl2); IR (thin film, cm-1) 2927, 1736, 1702, 1615, 1231, 1125, 836; 1H NMR (600 
MHz, CD3OD) δ 7.64 (d, J = 9.6 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.14 (d, J =  1.8 Hz, 
1H), 7.06 (dd, J = 9.0, 2.4 Hz, 1H), 7.02 (dd, J =  10.2, 3.0 Hz, 1H), 6.30 (d, J = 9.0 1H), 
6.29 (d, J = 10.2 Hz, 1H), 6.09 (d, J = 3.0 Hz, 1H), 4.50 (dd, J = 4.8, 3.0 Hz, 1H), 4.05 
(dd, J = 12.0, 4.2 Hz, 1H), 3.03 (dd, J = 12.0, 3.0 Hz, 1H), 0.71 (s, 9H), 0.04 (s, 3H), 0.03 
(s, 3H); 13C NMR (150 MHz, CD3OD) δ 193.8, 160.8, 159.7, 155.4, 143.0, 141.7, 129.6, 
128.8, 114.2, 114.0, 113.8(2C), 104.4, 91.7, 62.5, 25.7(3C), 18.1, -5.4(2C); CIHRMS 
Calcd for [C21H26O6Si+Na]+: 425.1390.  Found 425.1373. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-hydroxy-5,6-dihydro-2H-pyran-2-
yloxy]-chromen-2-one (I-41a).  
O
OH
O OTBSOO
 
A THF 
 
(0.2 mL) solution of compound I-23 (100 mg, 0.24 mmol) and MeOH (0.2 mL) 
was cooled to -78 oC.  NaBH4 (9.20 mg, 0.24 mmol) was added and the reaction mixture 
was stirred at -78oC for 3 hours. The reaction mixture was diluted with ether (5 mL) and 
was quenched with 5 mL of satd aq NaHCO3, extracted (2 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 90 mg 
(0.21 mmol, 90.0%) of I-41a:  Rf (30% EtOAc/hexanes) = 0.42; [α]21D =  -203.7   (c = 1, 
CH3OH); IR (thin film, cm-1) 3557, 2954, 1733, 1615, 1118, 835; 1H NMR (270 MHz, 
CDCl3)  δ 7.64 (d, J = 9.6 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H),  
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6.97 (dd, J = 9.0, 2.4 Hz, 1H), 6.28 (d, J = 9.0 Hz, 1H), 6.13 (dd, J = 10.2, 2.4 Hz, 1H), 
5.90 (ddd, J = 10.2, 2.4, 2.4  Hz, 1H), 5.70 (d, J = 2.4 Hz, 1H ), 4.30 (ddd, J = 5.4,3.0,1.2 
Hz, 1H), 3.88 (dd, J = 9.6, 5.4 Hz, 1H), 3.80 (dd, J = 9.0, 4.2 Hz, 1H), 3.75 (dd, J = 10.2, 
6.6 Hz, 1H), 3.10 (d, J = 3.6 Hz, 1H), 0.87 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H); 13C NMR 
(67.5 MHz, CDCl3) δ 161.2, 160.3, 155.5, 143.3, 134.5, 128.7, 123.9, 114.1, 113.7, 
113.4, 104.1, 92.6, 71.0, 66.5,65.0, 25.7(3C), 18.1, -5.5, -5.6; CIHRMS Calcd for 
[C21H28O6Si+Na]+: 427.1547.  Found 427.1538. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yloxy]-    
chromen-2-one (I-42a). 
O
OH
O OTBSOO
OH
HO
 
To a t-butanol, acetone (0.4 mL, 1:1, 1M) solution of allyl alcohol I-41a (160 mg, 0.363 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
water (0.2 mL).  Crystalline OsO4 (1.0 mg, 1 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column using a small amount of CH2Cl2 (0.6 mL) in three portions.  Impurities 
were eluted with ether and the product was eluted with MeOH/ether (2:98 to 4:96).  Pure 
fractions were combined and concentrated to afford triol I-42a 145 mg (0.329 mmol, 
84%):  Rf   (50% EtOAc/hexanes) = 0.29; [α]21D = - 63.4 (c = 2, CH2Cl2); IR (thin film, 
cm-1) 3449, 3420, 2955, 1742, 1618, 1129, 836; 1H NMR (600 MHz, CD3OD)  δ 7.91 (d,  
J = 9.6 Hz, 1H ), 7.57 (d, J = 9.0 Hz, 1H ), 7.16 (br s, 1H), 7.09 (d, J = 7.8 Hz, 1H), 6.30 
(d,  J = 10.2 Hz, 1H), 5.60 (br s, 1H ), 4.05 (br s, 1H), 3.95 (d, J = 11.4 Hz, 1H), 3.90 (dd, 
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J = 9.0, 3.0 Hz, 1H), 3.75 (dd, J = 10.8, 6.0 Hz, 1H), 3.65 (dd, J = 10.2, 9.0 Hz, 1H), 3.33 
(m, 3H), 0.78 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H) ; 13C NMR (150 MHz, CD3OD) δ 163.2, 
161.0, 156.8, 145.7, 130.5, 115.6, 115.3, 114.3, 105.1, 100.0, 76.6, 72.5, 71.6, 68.6, 64.4, 
26.4 (3C), 19.1, -5.0, -5.1; CIHRMS Calcd for [C21H30O8Si+Na]+: 461.1602.  Found 
461.1578. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-4-methyl-2H-pyran-
2-yloxy]-chromen-2-one (I-27). 
OOOO
O
OTBS
 
A THF
 
(0.3 mL) solution of compound I-15 (100 mg, 0.28 mmol) and 7-hydroxy cumarin  
(98.6 mg, 0.56 mmol) was cooled to 0 oC.  A THF
 
(0.3 mL) solution of Pd2(DBA)3.CHCl3 
(7.2 mg, 2.5 mol%) and PPh3 (7.3 mg, 10 mol%) was added to the reaction mixture at 0 
oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction mixture was 
quenched with 2 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 15% EtOAc/hexanes to give 98 mg 
(0.23 mmol, 82%) of I-27:  Rf (30% EtOAc/hexanes) = 0.50; [α]21D = - 75.4 (c = 0.7, 
CH2Cl2); IR (thin film, cm-1) 2928, 1726, 1700, 1611, 1262, 1134, 834; 1H NMR (600 
MHz, CDCl3) δ 7.52 (d, J = 2.4 Hz, 1H), 7.13 (d, J = 2.4 Hz, 1H), 7.07 (dd, J = 9.0, 2.4  
Hz, 1H), 7.02 (dd, J = 9.6, 3.6 Hz, 1H), 6.28 (d, J =  10.8 Hz, 1H), 6.17 (d, J = 1.2 Hz, 
1H), 6.10 (d, J = 3.6 Hz, 1H), 4.50 (dd, J = 4.8, 2.4 Hz, 1H), 4.05 (dd, J = 11.4, 4.8 Hz, 
1H), 4.02 (dd, J = 12.0, 3.0 Hz, 1H), 2.40 (d, J = 1.2 Hz, 3H), 0.81 (s, 9H), 0.04 (s, 3H), 
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0.03 (s, 3H); 13C NMR (67.5 MHz, CDCl3) δ 193.8 , 160.9, 159.6, 154.8, 152.1, 141.7, 
129.2(2C), 125.6, 115.1, 113.5, 112.9, 104.4, 91.7, 62.5, 25.7(3C), 18.6, 18.2,  -5.4, -5.5; 
CIHRMS Calcd for [C22H28O6Si+Na]+: 439.1547.  Found 439.1535. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-4-methyl2H-pyran-2-
yloxy]-chromen-2-one (I-28). 
OO OTBSOO
O
 
A THF
 
(0.3 mL) solution of compound I-16 (100 mg, 0.28 mmol) and 7-hydroxy cumarin  
(98.6 mg, 0.56 mmol) was cooled to 0 oC.  A THF
 
(0.3mL) solution of Pd2(DBA)3.CHCl3 
(7.2 mg, 2.5 mol%) and PPh3 (7.3 mg, 10 mol%) was added to the reaction mixture at 0 
oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction mixture was 
quenched with 2 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 20-25% EtOAc/hexanes to give 73 mg 
(0.17 mmol, 61%) of I-28:  Rf (30% EtOAc/hexanes) = 0.40; [α]21D = - 49 (c = 0.7, 
CH2Cl2); IR (thin film, cm-1) 2930, 1703, 1732, 1614, 1256, 1118, 836; 1H NMR (600 
MHz, CDCl3) δ 7.61 (d, J = 9.0 Hz, 1H), 7.01(dd, J = 10.2, 3.0 Hz, 1H), 6.84 (dd, J = 
9.0, 2.4 Hz, 1H), 7.72 (d, J = 3.0 Hz, 1H), 6.12 (dd, J = 1.2, 1.2 Hz, 1H), 6.09 (d J = 10.8 
Hz, 1H), 5.24 (dd, J = 3.6, 1.2 Hz, 1H), 4.42 (dd, J = 4.8, 2.4 Hz, 1H), 4.08 (dd, J = 10.8, 
4.8 Hz, 1H), 4.02 (dd, J = 11.4, 2.4 Hz, 1H), 2.44 (d, J = 1.2 Hz, 3H), 0.90 (s, 9H), 0.09 
(s, 3H), 0.08 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 196.6, 163.8, 162.9, 156.5, 155.9, 
 80
146.1, 128.6, 127.4, 114.3, 113.8, 111.2, 103.4, 95.4, 77.1, 63.8, 26.3 (3C), 19.1, 18.6,  -
5.2, -5.3; CIHRMS Calcd for [C22H28O6Si+Na]+: 439.1547.  Found 439.1554. 
 
7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-hydroxy-5,6-dihydro-4-methyl-2H-
pyran-2-yloxy]-chromen-2-one (I-41b).  
O
OH
O OTBSOO
 
A THF 
 
(0.2 mL) solution of compound I-28 (100 mg, 0.23 mmol) and MeOH (0.2 mL) 
was cooled to -78 oC.  NaBH4 (8.70 mg, 0.23 mmol) was added and the reaction mixture 
was stirred at -78oC for 3 hours. The reaction mixture was diluted with ether (5 mL) and 
was quenched with 5 mL of satd aq NaHCO3, extracted (2 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 50% EtOAc/hexanes to give 73 mg 
(0.17 mmol, 73.0%) of  I-41b:  Rf (30% EtOAc/hexanes) = 0.40; [α]21D =  -110.2   (c = 1, 
CH3OH); IR (thin film, cm-1) 3425, 2926, 1710, 1611, 1121, 835; 1H NMR (600 MHz, 
CDCl3)  δ 7.50 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.99 (dd, J = 9.0, 2.4 Hz, 
1H),  6.14 (m, 2H), 5.89 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 5.70 (m, 1H), 4.31 (dd, J = 8.4, 
1.2  Hz, 1H ), 3.88 (dd, J = 9.6, 4.8 Hz, 1H), 3.81 (ddd, J = 7.2, 4.8, 4.8 Hz, 1H), 3.75 
(dd, J = 9.6, 7.2 Hz, 1H), 3.03 (d, J = 3.0 Hz, 1H ) 2.04 (d, J = 0.6 Hz, 3H),  0.87 (s, 9H), 
0.09 (s, 3H), 0.06 (s, 3H); 13C NMR (67.5 MHz, CDCl3) δ 161.2, 160.1, 154.9, 152.4, 
134.4, 125.4, 123.9, 114.5, 113.7, 112.4, 104.1, 92.5, 70.8, 66.8, 65.2, 25.7(3C), 18.7, 
18.1, -5.5, -5.6; CIHRMS Calcd for [C22H30O6Si+Na]+: 441.1703.  Found 441.1725.  
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7-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-oxo-5,6-dihydro-4-methyl-2H-pyran-
2-yloxy]- chromen-2-one (I-42b). 
O
OH
O OTBSOO
OH
HO
                                          
To a t-butanol, acetone (0.4 mL, 1:1, 1M) solution of allyl alcohol I-41b (160 mg, 0.373 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
water (0.2 mL).  Crystalline OsO4 (1.0 mg, 1 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column (1 cm × 4”) using a small amount of CH2Cl2 (0.6 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with MeOH/ether (2:98 to 
4:96).  Pure fractions were combined and concentrated to afford triol I-42b 145 mg 
(0.329 mmol, 84%):  Rf   (50:49:1 EtOAc/hexanes/methanol) = 0.35; [α]21D = -84 (c = 2, 
CH2Cl2); IR (thin film, cm-1) 3406, 2927, 1729, 1613, 1068, 836; 1H NMR (600 MHz, 
CDCl3)  δ 7.52 (d,  J = 9.0 Hz, 1H ), 7.05 (d, J = 2.4 Hz, 1H ), 6.99 (dd, J = 8.4, 2.4  Hz, 
1H), 6.18 (d,  J = 1.2 Hz, 1H), 5.62 (d, J = 1.2 Hz, 1H ), 4.17 (d, J = 2.4 Hz, 1H), 4.07 
(ddd, J = 9.0, 3.6, 2.4 Hz, 1H ), 3.94 (dd, J = 9.6, 9.0  Hz, 1H), 3.87 (dd,  J = 10.2, 4.8 
Hz, 1H), 3.79 (dd, J = 10.2, 6.6  Hz, 1H ), 3.65 (dddd, J = 10.8, 6.6, 4.8, 4.8 Hz, 1H ), 
3.36 (s, ?H), 2.79 (d, J = 3.6 Hz, 1H ), 2.67 (d, J = 3.0 Hz, 1H ), 2.40 (d, J = 0.6 Hz, 3H ), 
0.86 (s, 9H),  0.07 (s, 3H), 0.05 (s, 3H) ; 13C NMR (150 MHz, CDCl3) δ 161.1, 158.7, 
154.8, 152.4, 125.6, 114.8, 113.3, 112.7, 104.0, 97.6, 76.5, 71.2, 71.1, 69.7, 64.6, 25.7 
(3C), 18.6, 18.1, -5.5, -5.6 ; CIHRMS Calcd for [C22H32O8Si+Na]+: 475.1758.  Found 
475.1778.  
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Methyl-7-((2S,6S)-6-((tert-butyldimethylsilyloxy)methyl)-5-oxo-5,6-dihydro-2H-
pyran-2-yloxy)-2-oxo-2H-chromene-4-carboxylate (I-30). 
O
O
O OTBSOO
COOMe
 
A THF
 
(2.0 mL) solution of compound I-15 (400 mg, 1.11 mmol) and 7-hydroxy cumarin  
(492.0 mg, 2.22 mmol) was cooled to 0 oC.  A THF
 
(1.0 mL) solution of Pd2(DBA)3-
.CHCl3 (28.7 mg, 2.5 mol%) and PPh3 (29.0 mg, 10 mol%) was added to the reaction 
mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction 
mixture was quenched with 5 mL of satd aq NaHCO3, extracted (3 x 10 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 30-50%  EtOAc/hexanes to 
give 300 mg (0.64 mmol, 57%) of I-30:  Rf (20% EtOAc/hexanes) = 0.37; [α]21D = - 68.1 
(c = 0.7, CH2Cl2); IR (thin film, cm-1) 2927, 1737, 1703, 1613, 1263, 1135, 837; 1H NMR 
(600 MHz, CD3OD) δ 7.59 (d, J = 9.0 Hz, 1H), 7.14 (d, J = 3.0 Hz, 1H), 7.08 (dd, J = 
9.6, 2.4  Hz, 1H), 6.26 (d, J = 1.8 Hz 1H), 6.23 (d, J = 7.2 Hz , 1H), 6.21 (s, 1H),  4.47 
(dd, J = 4.8, 2.4 Hz, 1H), 3.99 (m, 1H), 3.98 (dd, J = 12, 4.2 Hz, 1H), 3.94 (dd, J =  12.0, 
3.0 Hz, 1H), 3.66 (s, 3H), 0.75 (s, 9H), -0.01 (s, 3H), -0.02 (s, 3H); 13C NMR (150 MHz, 
CD3OD) δ 195.5, 171.1, 162.6, 161.4, 150.9, 143.9, 129.7, 127.7, 127.5, 115.3, 115.2, 
105.4, 92.4, 78.0, 63.5, 53.0, 38.1, 26.3 (3C), 19.0, -5.2, -5.3; CIHRMS Calcd for 
[C23H28O8SiCH2Na]+: 497.1602.  Found 497.1621. 
 
Methyl-7-((2R,6S)-6-((tert-butyldimethylsilyloxy)methyl)-5-oxo-5,6-dihydro-2H-
pyran-2-yloxy)-2-oxo-2H-chromene-4-carboxylate (I-31). 
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O
O
O OTBSOO
COOMe
 
A THF 
 
(0.1 mL) solution of compound I-16 (30 mg, 0.096 mmol) and MeOH (0.1 mL) 
was cooled to -78 oC.  NaBH4 (3.36 mg, 0.096 mmol) was added and the reaction mixture 
was stirred at -78oC for 3 hours. The reaction mixture was diluted with ether (3 mL) and 
was quenched with 2 mL of satd aq NaHCO3, extracted (2 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 100% EtOAc/hexanes to give 39 mg 
(0.083 mmol, 85%) of I-31:  Rf (30% EtOAc/hexanes) = 0.31; [α]21D = +10, C 1, 
CH2Cl2); IR (thin film, cm-1) 3384, 3034, 2975, 1656, 1634, 1047, 879; 1H NMR (600 
MHz, CDCl3)  7.56 (d,  J = 9.6 Hz, 1H), 7.09 (dd, J = 10.8, 1.8 Hz, 1H), 6.96 (d, J = 1.8 
Hz, 1H), 6.85 (dd, J = 9.0, 2.4 Hz, 1H), 6.47 (br s, 1H), 6.21 (ddd, J =10.2, 8.4, 1.8 Hz, 
1H), 5.05 (m, 1H), 4.32 (d, J = 9.0 Hz, 1H), 4.00 (dd, J = 11.4, 2.4 Hz, 1H), 3.83 (dd, J = 
11.4, 6.6 Hz, 1H), 3.75 (s, 3H), 0.76 (s, 9H), -0.09 (s, 3H), -0.11 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ 193.5, 169.2, 160.7, 155.2, 149.5, 147.5, 128.4, 125.5, 113.8, 117.7, 
103.5, 82.2, 73.8, 62.1, 53.1, 50.0, 37.9, 25.6 (3C), 18.1, -5.63, -5.65; CIHRMS Calcd for 
[C23H28O8SiCH2Na]+: 497.1602.  Found 497.1618 
 
7-((2S,6S)-6-((tert-butyldimethylsilyloxy)methyl)-5-oxo-5,6-dihydro-2H-pyran-2-
yloxy)-2-phenyl-4H-chromen-4-one (I-33). 
OOO
O
OTBS
O
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A THF
 
(0.3 mL) solution of compound I-15 (100 mg, 0.28 mmol) and 6-hydroxy flavone  
(133.3 mg, 0.56 mmol) was cooled to 0 oC.  A THF
 
(0.3 mL) solution of Pd2(DBA)3-
.CHCl3 (7.2 mg, 2.5 mol%) and PPh3 (7.3 mg, 10 mol%) was added to the reaction 
mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction 
mixture was quenched with 2 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 
120.6 mg (0.25 mmol, 90%) of I-33:  Rf (30% EtOAc/hexanes) = 0.66; [α]21D = - 95.1 (c 
= 0.7, CH2Cl2); IR (thin film, cm-1) 2927, 1701, 1637, 1455, 1255, 1129, 835; 1H NMR 
(600 MHz, CDCl3) δ 7.95 (d, J = 3.0 Hz, 1H), 7.91-7.93 (m, 2H), 7.54-7.50 (m, 4H), 7.47 
(dd, J = 9.0, 3.0 Hz, 1H), 7.04 (dd, J =  10.2, 3.6 Hz, 1H), 6.80 (s, 1H), 6.28 (d, J = 10.2 
Hz, 1H), 6.11 (d, J = 3.6 Hz, 1H), 4.56 (dd, J = 4.2, 3.0 Hz, 1H), 4.06-4.05 (m, 2H), 0.82 
(s, 9H), 0.06 (s, 3H), 0.03 (s, 3H); 13C NMR (67.5 MHz, CDCl3) δ 194.1, 177.8, 163.2, 
154.0, 151.9, 142.2, 131.7, 131.5, 129.0(3C), 126.2(2C), 124.7, 124.5(2C), 119.5, 110.8, 
106.8, 92.2, 62.6, 25.7(3C), 18.2, -5.4, -5.5; CIHRMS Calcd for [C27H30O6Si+Na]+: 
501.1703.  Found 501.1680. 
 
7-((2S,5R,6S)-6-((tert-butyldimethylsilyloxy)methyl)-5-hydroxy-5,6-dihydro-2H-
pyran-2-yloxy)-2-phenyl-4H-chromen-4-one (I-41c). 
OOO
OH
OTBS
O
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A THF 
 
(0.2 mL) solution of compound I-33 (100 mg, 0.20 mmol) and MeOH (0.2 mL) 
was cooled to -78 oC.  NaBH4 (7.90 mg, 0.20 mmol) was added and the reaction mixture 
was stirred at -78oC for 3 hours. The reaction mixture was diluted with ether (5 mL) and 
was quenched with 5 mL of satd aq NaHCO3, extracted (2 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 30% EtOAc/hexanes to give 73 mg 
(0.15 mmol, 76.0%) of I-41c:  Rf (30% EtOAc/hexanes) = 0.44; [α]21D =  -113.10   (c = 1, 
CH3OH); IR (thin film, cm-1) 3346, 2956, 1738, 1623, 1073, 831; 1H NMR (600 MHz, 
CDCl3)  δ 7.92-7.91 (m, 2H), 7.86 (d, J = 3.0 Hz, 1H), 7.23-7.50 (m, 3H),  7.40 (dd, J = 
9.6, 3.0 Hz, 1H), 6.80 (s, 1H), 6.12 (dddd, J = 10.2, 3.0, 1.2, 1.2 Hz, 1H), 5.91 (dddd, J = 
10.2,4.8, 2.4, 2.4 Hz, 1H), 5.74 (dd, J = 2.4, 1.8  Hz, 1H ), 4.31-4.29 (m, 1H), 4.11 (dd, J 
= 14.4, 7.2 Hz, 1H), 3.89 (ddd, J = 9.0, 5.4, 5.4 Hz, 1H), 3.86 (dd, J = 9.0, 4.8 Hz, 1H), 
3.78 (dd, J = 9.0, 6.6 Hz, 1H ) 3.17 (d, J = 3.0 Hz, 1H),  0.87 (s, 9H), 0.09 (s, 3H), 0.06 
(s, 3H); 13C NMR (150 MHz, CDCl3) δ 178.1, 168.2, 163.2, 1159.5, 154.5, 151.7, 134.1, 
131.8, 131.5, 129.0, 126.2, 124.8, 124.6, 124.4, 119.3, 110.2, 106.8, 93.0, 70.8, 66.9, 
65.3, 25.7(3C), 18.1, -5.5, -5.6; CIHRMS Calcd for [C27H32O6Si+Na]+: 503.1860.  Found 
503.1873. 
7-((2S,3R,4R,5R,6S)-6-((tert-butyldimethylsilyloxy)methyl)-3,4,5-trihydroxy-
tetrahydro-2H-pyran-2-yloxy)-2-phenyl-4H-chromen-4-one (I-42c). 
                                          
OOO
OH
OTBS
O OH
HO
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To a t-butanol, acetone (0.4 mL, 1:1, 1M) solution of allyl alcohol I-41c (160 mg, 0.333 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
water (0.2 mL).  Crystalline OsO4 (1.0 mg, 1 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column (1 cm × 4”) using a small amount of CH2Cl2 (0.6 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with MeOH/ether (2:98 to 
4:96).  Pure fractions were combined and concentrated to afford triol I-42c 144 mg 
(0.279 mmol, 84%):  Rf   (50:40:10 EtOAc/hexanes/methanol) = 0.24; [α]21D = -96.4 (c = 
2, CH2Cl2); IR (thin film, cm-1) 3332, 2947, 1739, 1366, 1120, 978; 1H NMR (600 MHz, 
CDCl3)  δ 7.92-7.90 (m, 2H), 7.81 (d, J = 2.4 Hz, 1H ), 7.53-7.51(m, 4H), 7.41 (dd,  J = 
9.6, 3.0 Hz, 1H), 6.80 (s, 1H ), 5.64 (d, J = 1.2 Hz, 1H ), 4.11 (dd, J = 3.0, 1.8 Hz, 1H ), 
4.00 (dd,  J = 9.0, 3.6 Hz, 1H), 3.86 (dd,  J = 6.0, 3.0 Hz, 1H), 3.84 (dd,  J = 5.4, 2.4 Hz, 
1H), 3.80 (dd,  J = 10.8, 5.4 Hz, 1H ), 3.65 (ddd, J = 9.6, 4.8, 4.8 Hz, 1H ), 1.80 (d, 3H), 
0.83 (s, 9H),  0.05 (s, 3H), 0.03 (s, 3H) ; 13C NMR (150 MHz, CDCl3) δ 179.2, 164.6, 
154.1, 152.2, 132.0, 131.7, 129.2(2C), 126.5(2C), 125.1, 124.3, 119.9, 109.9, 105.9, 
99.0,75.4, 71.4, 70.6, 67.5, 63.3,  25.2 (3C), 18.0, -6.1, -6.2 ; CIHRMS Calcd for 
[C27H34O8Si+Na]+: 537.1915.  Found 537.1894. 
 
7-((2S,5R,6S)-6-((tert-butyldimethylsilyloxy)methyl)-5-hydroxy-tetrahydro-2H-
pyran-2-yloxy)-2-phenyl-4H-chromen-4-one (I-43). 
                                              
OOO
OH
OTBS
O
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       The allyl alcohol compound I-41c  (70 mg, 0.15 mmol), O-NO2ArSO2NHNH2  
(236.5 mg, 1.16 mmol) were dissolved in 1.46 mL of CH2Cl2 in a round bottom flask and 
cooled 0 oC under nitrogen condition then triethylamine (146.5 mg, 1.5 mmol) was added 
and the reaction mixture was stirred at 0
 
oC for 12 hours and on completion monitored by 
TLC, reaction mixture is three portions.  The crude product was purified using silica gel 
flash chromatography eluting with 30% EtOAc/hexanes to give I-43 56 mg (0.11 mmol, 
80 %):  Rf (30%  EtOAc/Hexane) = 0.44; [α]21D = -95.30 (c 2, CH2Cl2); IR (thin film, cm-
1) 2985, 1737, 1372, 1252, 1097, 846; 1H NMR (600 MHz, CDCl3) δ 7.93 (m, 3H), 7.54-
7.49 (m, 5H), 6.82 (d, J = 1.8 Hz, 1H), 5.62 (d, J = 1.8 Hz, 1H), 3.80 (dd, J = 10.2, 4.2 
Hz, 1H), 3.73 (dd, J = 16.8, 7.8 Hz, 1H), 3.68 (dd, J = 10.2, 7.2 Hz, 1H), 3.66 (dd, J = 
8.4, 4.2 Hz, 1H), 2.34 (dd, J = 7.8, 7.2 Hz, 1H), 2.08-1.97 (m, 4H), 0.85 (s, 9H), 0.06 (s, 
3H), 0.03 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 180.5, 165.7, 155.8, 153.1, 133.1, 
133.0, 132.9, 130.4, 127.6, 126.3, 125.5, 124.9, 120.9, 110.8, 107.1, 106.8, 77.0, 66.6, 
64.4, 30.2, 28.1, 26.4(3C), 19.2, -5.0, -5.1; CIHRMS Calcd for [C27H34O6SiNa+]:  
505.2016.  Found 505.2025. 
 
7-((2R,6S)-6-((tert-butyldimethylsilyloxy)methyl)-5-oxo-5,6-dihydro-2H-pyran-2-
yloxy)-2-phenyl-4H-chromen-4-one (I-33). 
OOO
O
OTBS
O
 
A THF
 
(0.2 mL) solution of compound I-15 (50 mg, 0.14 mmol) and 6-hydroxy flavone  
(65.3 mg, 0.28 mmol) was cooled to 0 oC.  A THF
 
(0.2 mL) solution of Pd2(DBA)3.CHCl3 
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(3.6 mg, 2.5 mol%) and PPh3 (3.6 mg, 10 mol%) was added to the reaction mixture at 0 
oC.  The reaction mixture was stirred at 0 oC for 1 hour.  The reaction mixture was 
quenched with 2 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 52.5 mg 
(0.11 mmol, 80%) of I-33:  Rf (30% EtOAc/hexanes) = 0.60; [α]21D = 70.1 (c = 1.0, 
CH2Cl2); IR (thin film, cm-1) 2929, 1721, 1642, 1456, 1251, 1121, 839; 1H NMR (600 
MHz, CD3OD) δ 8.04 (d, J = 1.8 Hz, 1H), 8.03 (d, J = 1.8 Hz, 1H), 7.91 (d, J = 3.0 Hz, 
1H), 7.71 (d, J = 9.0 Hz, 1H), 7.60-7.54 (m, 5H), 7.19 (dd, J = 10.2, 3.6 Hz, 1H), 6.90 (br 
S, 1H), 6.25 (dd, J = 12.6, 10.2 Hz, 1H), 4.55 (dd, J = 4.8, 2.4 Hz, 1H), 4.05 (dd, J = 
11.4, 4.8 Hz, 1H), 4.01 (dd, J = 11.4, 2.4 Hz, 1H), 0.78 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 
13C NMR (150 MHz, CD3OD) δ 195.4, 179.4, 164.4, 155.5, 150.6, 144.8, 143.2, 131.9, 
131.7 (2C), 129.1, 129.0 (2C), 127.5 (2C), 123.6, 119.5, 107.6, 105.5, 76.0, 62.6, 25.1 
(3C), 17.9, -6.4 (2C); CIHRMS Calcd for [C27H30O6SiNa]+: 501.1703.  Found 501.1700. 
 
(2S,6S)-6-(1′H-benzimidazol-1′-yl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-2H-
pyran-3(6H)-one (I-58β):                              
O
O
OTBS
N
N
 
A CH2Cl2 (1.0 mL) solution of pyranone I-16β  (358 mg, 1.00 mmol) and benzimadazole 
(141.7 mg, 1.20 mmol) was cooled to 0 oC.  A CH2Cl2 (1.0 mL) solution of Pd2(DBA)3-
.CHCl3 (25.8 mg, 2.5 mol %) and PPh3 (26.2 mg, 10 mol %) was added to the reaction 
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mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 30 min.  The reaction 
mixture was quenched with 5 mL of saturated aq NaHCO3, extracted (3 x 5 mL) with 
Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 50:40:10 
EtOAc/hexanes/methanol to give (2S,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-2-(tert-butyl-
dimethyl-silanyloxymethyl)-2H-pyran-3(6H)-one I-58β (250 mg, 1.00 mmol, 82%) as 
viscous oil.  Rf (50% EtOAc/hexanes) = 0.20; [α]26  D  = -11 (c = 1.0, CH2Cl2); IR (thin 
film, cm-1) 2854, 1702, 1606, 1458, 1251, 1070, 834; 1H NMR (600 MHz, CDCl3) δ 8.00 
(s, 1H), 7.82 (dd, J = 7.2, 1.8 Hz, 1H), 7.54 (dd, J =  7.2, 1.8 Hz, 1H), 7.32 (ddd, J = 7.2, 
7.2, 1.2 Hz, 1H), 7.30 (ddd, J = 7.2, 7.2, 1.2 Hz, 1H), 7.07 (dd, J = 10.2, 1.8 Hz, 1H), 
6.55 (dd, J = 4.2, 1.8 Hz, 1H), 6.46 (dd, J = 10.2, 1.8 Hz, 1H), 4.45 (dd, J =  3.0, 1.8 Hz, 
1H), 4.44 (dd, J =  3.0, 1.8 Hz, 1H), 4.06 (dd, J =  6.6, 3.0 Hz, 1H), 0.81 (s, 9H), -0.04 (s, 
3H), -0.05 (s, 3H); 13C NMR (150 MHz, DCl3) δ 192.5, 145.0, 144.0, 141.5, 132.5, 
131.0, 123.7, 123.1, 120.6, 111.1, 81.4, 78.7, 62.2, 25.7 (3C), 18.2, -5.4, -5.5; CIHRMS 
Calcd for [C19H26N2O3SiNa]+: 381.1604, Found : 381.1599. 
 
(2S,3R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-3,6-dihydro-2-(tert-butyl-dimethyl-
silanyloxymethy)-2H-pyran-3-ol (I-59β): 
O
OH
OTBS
N
N
 
A CH2Cl2 (0.5 mL) solution of enone I-58β (170 mg, 0.454 mmol) and MeOH (0.5 mL) 
was cooled to –78 oC.  NaBH4 (20.6 mg, 0.544 mmol) was added and the reaction 
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mixture was stirred at -78
 
oC for 3 h. The reaction mixture was diluted with ether (5 mL) 
and was quenched with 5 mL of saturated aq NaHCO3, extracted (3 x 5 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 50:45:5 
EtOAc/hexanes/methanol to give (2S,3R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-3,6-
dihydro-2-(tert-butyl-dimethyl-silanyloxymethy)-2H-pyran-3-ol I-59β (135 mg, 0.37 
mmol, 79%) as viscous oil.  Rf (50% EtOAc/hexanes) = 0.20; [α]26  D  = -0.23 (c = 1.0, 
CH2Cl2); IR (thin film, cm-1) 3192, 2928, 2856, 1459, 1119, 1087; 1H NMR (600 MHz, 
CDCl3) δ 7.98 (s, 1H), 7.79 (dd, J = 6.6, 2.4 Hz, 1H), 7.46 (dd, J = 6.6, 1.8 Hz, 1H), 7.29 
(ddd, J = 7.2, 6.6, 2.4 Hz, 1H), 7.28 (ddd, J = 6.6, 6.6, 1.8 Hz, 1H), 6.29 (dd, J = 2.4, 2.4 
Hz, 1H), 6.27 (dd, J = 2.4, 1.8 Hz, 1H), 5.94 (ddd, J = 9.6, 3.0, 2.4 Hz, 1H), 4.52 (dd, J = 
8.4, 2.4 Hz, 1H), 3.97 (dd, J = 10.2, 4.8 Hz, 1H), 3.84 (ddd, J = 11.4, 5.4, 4.2 Hz, 1H), 
3.77 (dd, J = 10.2, 7.8 Hz, 1H), 3.33 (s, 1H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H); 13C 
NMR (67.5 MHz, CDCl3) δ 138.0, 133.0, 128.3 (2C), 127.9 (2C), 127.6, 125.7, 93.4, 
70.4, 70.0, 66.7, 65.1, 25.8 (3C), 18.2, -5.4, -5.5; CIHRMS Calcd for [C19H28N2O3SiH]+: 
361.1942, Found : 361.1984. 
((2R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-5,6-dihydro-2H-pyran-2-yl) tert-butyl-
dimethyl-silanyloxymethane (I-60β). 
O OTBS
N
N
 
A flask was charged with dry N-methyl morpholine ( NMM ) 25 ml, triphenyl phosphine 
(459 mg, 1.172 mmol) and was cooled to -30 oC under Ar atmosphere. 
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Diethylazodicarboxylate (251.4 µl, 1.597 mmol) was added and the reaction was stirred 
for 5 min, allylic alcohol I-59β (200 mg, 0.531 mmol) was added in a 1M solution of 
NMM and the reaction mixture was stirred for 10 min, followed by addition of o-
nitrobenzenesulfonyl hydrazide (NBSH) (323.5 mg, 1.593 mmol). The reaction was 
stirred at -30 oC for 2h and was monitored by TLC, upon consumption of starting 
material, warm up to room temperature and stirred for another 4h. The reaction mixture 
was diluted with ether (10 mL) and was quenched with 5 mL of satd. aq NaHCO3, 
extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced 
pressure.  The crude product was purified using silica gel flash chromatography eluting 
with 50% EtOAc/hexanes to give ((2R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-5,6-dihydro-
2H-pyran-2-yl) tert-butyl-dimethyl-silanyloxymethane I-60β (119 mg, 0.345 mmol, 65%) 
as viscous oil.  Rf (50:49:1 % EtOAc/hexanes/methanol) = 0.35; [α]26  D  = +72  (c = 1.0, 
CH2Cl2); IR (thin film, cm-1) 3296, 2929, 1721, 1066, 835; 1H NMR (600 MHz, CDCl3) δ 
8.04 (m, 1H), 7.79 (dd, J = 7.8, 1.8 Hz, 1H), 7.50 (dd, J = 7.2, 2.4 Hz, 1H), 7.28 (ddd, J = 
7.2, 7.2, 1.2 Hz, 1H), 7.27 (ddd, J = 7.2, 7.2, 1.2 Hz, 1H), 5.96 (dd, J = 10.2, 6.0 Hz, 1H), 
5.92 (dd, J = 10.2, 2.4 Hz, 1H), 5.77 (dd, J = 9.6, 3.0 Hz, 1H), 4.56 (br s, 1H), 3.75 (dd, J 
= 9.6, 6.0 Hz, 1H), 3.61 (dd, J = 9.6, 6.0 Hz, 1H), 2.90 (ddd, J = 10.8, 10.2, 3.0 Hz, 1H), 
2.50 (ddd, J = 10.8, 9.6, 3.0 Hz, 1H), 0.86 (s, 9H), 0.02 (s, 3H), -0.002 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 140.3, 127.8, 123.5, 123.2 (2C), 122.9, 122.7, 120.2, 111.0, 80.3, 
77.4, 65.3, 30.4, 25.7(3C), 18.2, -3.5, -5.4; CIHRMS Calcd for [C19H28N2O2SiNa+]:  
367.1812,  Found : 367.1829. 
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(2S,3R,4R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-tetrahydro-2-(tert-butyl-dimethyl-
silanyloxymethy)-2H-pyran-3,4-diol (I-61β). 
O
OH
OTBS
N
N
OH
 
To a solution of olefin I-60β  (80 mg, 0.110 mmol) in t-butanol/  acetone (0.4 mL, 1:1, 
1M) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / water 
(0.12 mL) and crystalline OsO4 (0.6 mg, 1 mol %) was added. The reaction mixture was 
stirred for 12 hours and the reaction was quenched with adding EtOAC and satd. 
NaHCO3. The organic layer was separated and concentrated. It was purified by a silica 
gel column  using 5% methaol/EtOAc.  Pure fractions were combined and concentrated 
to afford (2S,3R,4R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-tetrahydro-2-(tert-butyl-
dimethyl-silanyloxymethy)-2H-pyran-3,4-diol I-61β (36 mg, 0.094 mmol, 85%) as 
viscous oil.  Rf (10% methanol/40%EtOAc/50hexanes) = 0.40; [α]26  D  = +22 (c = 1.2, 
CH2Cl2); IR (thin film, cm-1) 3166, 2928, 1615, 1065, 777; 1H NMR (600 MHz, 
CDCl3) δ  8.29 (s, 1H), 7.67 (dd, J = 7.6, 1.8 Hz, 1H), 7.66 (dd, J = 7.6, 1.8 Hz, 1H), 7.30 
(ddd, J = 7.2, 7.2, 1.8 Hz, 1H), 7.28 (ddd, J = 7.2, 7.2, 1.8 Hz, 1H), 6.09 (dd, J = 11.4, 1.8 
Hz, 1H), 4.27 (dd, J = 5.4, 3.6 Hz , 1H), 4.03 (dd, J = 10.2, 5.2 Hz , 1H), 3.97 (dd, J = 
11.4, 2.4 Hz , 1H), 3.85 (dd, J = 11.4, 5.4 Hz , 1H), 3.72 (dd, J = 10.2, 3.6 Hz , 1H), 2.52 
(ddd, J = 13.2, 11.4, 2.4 Hz , 1H), 2.29 (ddd, J = 13.2, 3.6, 2.4 Hz , 1H), 0.85 (s, 9H), -
0.02 (s, 3H), -0.05 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 144.4, 142.4, 134.4, 124.6, 
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124.1 (2C), 120.3 (2C), 113.1, 80.3, 78.0, 68.8, 66.3, 64.6, 38.2, 26.5, 19.3, -4.9, -5.0; 
CIHRMS Calcd for [C19H30N2O4SiNa+]: 401.1867,  Found: 401.1870. 
 
(2S,3R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-tetrahydro-2-(tert-butyl-dimethyl-
silanyloxymethyl)-2H-pyran-3-ol (I-62β). 
O
OH
OTBS
N
N
 
The allyl alcohol I-59β  (200 mg, 0.53 mmol), o-NO2ArSO2NHNH2  (863 mg, 4.25 
mmol) were dissolved in 5.0 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen condition then triethylamine (760 µl, 5.31 mmol)  was added and the 
reaction mixture was stirred at 0
 
oC for 12 hours and on completion monitored by TLC. 
The reaction mixture was diluted with ether (10 mL) and was quenched with 5 mL of 
saturated NaHCO3 and aqueous layers were extracted (3 x 10 mL) with Et2O, dried over 
sodium sulphate and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 50:45:5 
EtOAc/hexanes/methanol to give (2S,3R,6S)-6-(1′H-benzo[d]imidazol-1′-yl)-tetrahydro-
2-(tert-butyl-dimethyl-silanyloxymethyl)-2H-pyran-3-ol I-62β (60 mg, 0.16 mmol, 30 %) 
as viscous oil.  Rf (50%  EtOAc/Hexane) = 0.25; [α]26  D  = +0.23 (c 1.0, CH2Cl2); IR (thin 
film, cm-1) 3195, 2952, 2928, 1459, 1252, 1237, 1085, 922, 835; 1H NMR (600 MHz, 
CDCl3) δ  8.0 (s, 1H), 7.79 (dd, J = 6.6, 2.4 Hz, 1H), 7.47 (dd, J = 6.6, 2.4 Hz, 1H), 7.30 
(ddd, J = 7.2, 7.2, 1.8 Hz, 1H), 7.29 (ddd, J = 7.2, 7.2, 1.8 Hz, 1H), 5.57 (dd, J = 10.8, 2.4 
Hz, 1H), 3.97 (dd, J = 10.2, 4.8 Hz, 1H) 3.80 (dd, J = 10.2, 7.8 Hz, 1H), 3.64 (dd, J = 4.8, 
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4.2 Hz, 1H), 2.36 (ddd, J = 12.0, 9.0, 3.6 Hz, 1H), 2.28 (ddd, J = 15.0, 9.6, 3.6 Hz, 1H), 
2.20 (dd, J = 6.6, 3.0 Hz, 1H), 2.18 (dd, J = 6.6, 3.0 Hz, 1H), 2.04 (s, 1H), 0.91 (s, 9H), 
0.09 (s, 3H), 0.09 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  140.1, 123.2, 122.6, 120.5 
(2C), 110.6 (2C), 83.0, 79.2, 69.6, 65.9, 30.8, 29.6, 25.7 (3C), 18.1, -5.5, -5.6; CIHRMS 
Calcd for [C19H30N2O3SiNa]+: 385.1917, Found : 385.1920. 
 
(2S,6R)-6-(1′H-benzo[d]imidazol-1′-yl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-2H-
pyran-3(6H)-one (I-56α) :                           
O
O
OTBS
N
N
 
A CH2Cl2 (0.8 mL) solution of pyranone I-15α  (289 mg, 0.807 mmol) and 
benzimadazole (114 mg, 1.20 mmol) was cooled to 0 oC.  A CH2Cl2 (0.8 mL) solution of 
Pd2(DBA)3.CHCl3 (20.8 mg, 2.5 mol%) and PPh3 (21.1 mg, 10 mol%) was added to the 
reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 30 min.  The 
reaction mixture was diluted with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with 
Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 50:45:5 
EtOAc/hexanes/methanol to give (2S,6R)-6-(1′H-benzo[d]imidazol-1′-yl)-2-(tert-butyl-
dimethyl-silanyloxymethyl)-2H-pyran-3(6H)-one I-56α (230 mg, 0.642 mmol, 77%) as 
viscous oil.  Rf (50% EtOAc/hexanes) = 0.35; [α]26  D  = -2 (c = 1.0, CH2Cl2); IR (thin film, 
cm-1) 3309, 2946,  1646, 1459, 1257, 1021, 744; 1H NMR (600 MHz, CDCl3) δ 7.96 (s, 
1H), 7.82 (dd, J = 7.6, 1.8 Hz, 1H), 7.55 (dd, J = 7.2, 1.8 Hz, 1H), 7.34 (ddd, J = 6.6, 6.6, 
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1.8 Hz, 1H), 7.33 (ddd, J = 7.2, 7.2, 1.8 Hz, 1H), 7.16 (dd, J =  10.2, 2.4 Hz, 1H), 6.84 
(dd, J = 2.4, 1.8 Hz, 1H), 6.53 (dd, J = 10.2, 1.8 Hz, 1H), 4.21 (dd, J =  3.6, 2.4 Hz, 1H), 
4.10 (dd, J = 11.4, 3.6 Hz, 1H), 4.05 (dd, J = 11.4, 2.4 Hz, 1H), 0.85 (s, 9H), 0.07 (s, 3H), 
0.02 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 193.4, 144.1, 142.8, 141.3, 133.0, 
131.1(2C), 123.8, 123.1, 120.6, 110.6, 78.8, 64.4, 25.7 (3C), 18.1, -5.5, -5.6; CIHRMS 
Calcd for [C19H26N2O3SiNa]+: 381.1604.  Found : 381.1602. 
 
((2S,5R,6S)-5,6-dihydro-5-hydroxy-6-methyl-2H-pyran-2-yl pivalate (II-30). 
O
OH
O
O
 
A solution of pyranone II-26 (327 mg, 1.54 mmol) in dry CH2Cl2 (1.5 mL) and 0.4 M 
CeCl3/MeOH (1.5 mL) was cooled to -78 °C. NaBH4 (58.4 mg, 1.54 mmol) was added 
and the reaction mixture was stirred for 4 h at -78 °C. The resulting solution was diluted 
with ether (10 mL) and was quenched with 5 mL of saturated NaHCO3, extracted (3 x 5 
mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure. The crude 
product was purified using silica gel chromatography eluting with 40% EtOAc/hexane to 
give enol II-30  (297 mg, 1.34 mmol, 90%) as a white solid, mp: 62.5-64.0 °C; Rf = 0.30 
(40% EtOAc/Hexane); [α]26  D   = - 28 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3391, 2972, 
2933, 2837, 1612, 1513, 1246, 1029, 999, 819; 1H NMR (600 MHz, CDCl3) δ 6.21 (dd, J 
= 2.4, 1.8 Hz, 1H), 6.04 (d, J = 9.6 Hz, 1H), 5.75 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 3.90 (d, 
J = 8.4 Hz, 1H), 3.72 (m, 1H), 1.31 (d, J = 6.6 Hz, 3H), 1.20 (s, 9H); 13C NMR (150 
MHz, CDCl3) δ 177.7, 134.7, 125.1, 88.4, 70.3, 69.2, 39.1, 27.1 (3C), 18.0; CIHRMS: 
Calculated for [C11H18O4Na+]: 237.1102.  Found: 237.1099 
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(2S,5R,6S)-5,6-dihydro-5-methoxy-6-methyl-2H-pyran-2-yl pivalate (II-32).  
O
OMe
O
O
 
To a mixture of allylic alcohol II-30 (1.7 g, 7.94 mmol) and silver (I) oxide (9.1 g, 39.7 
mmol), was added 2.5 ml CH3I. The reaction suspension was allowed to stirred for 2 days 
under room temperature, passed a celite pad with 100 ml Et2O, concentrated under 
reduced pressure and purified using silica gel flash chromatography eluting with pure 5-
7% EtOAc/Hexane to give alcohol 21 (1.6 mg, 6.98 mmol, 88%) alcohol II-32 as white 
foam; Rf = 0.52 (30% EtOAc/Hexane); [α]26  D   = - 128 (c = 2.0, CH2Cl2); IR (thin film, 
cm-1) 2973, 2954, 2111, 1738, 1277, 1130, 1042, 921; 1H NMR (600 MHz, CDCl3)  δ 
6.19 (br s, 1H), 6.15 (d, J = 10.2 Hz, 1H), 5.75 (td, J = 10.2, 2.4 Hz, 1H), 3.78 (ddd, J = 
12.0, 9.0, 6.6 Hz, 1H), 3.48 (dd, J = 9.0, 1.2 Hz, 1H), 3.42 (s, 3H), 1.29 (d, J = 6.0, Hz, 
3H), 1.18 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 201.4, 131.2, 124.9, 88.3, 77.7, 68.0, 
56.8, 38.9, 26.9 (3C), 18.1; CIHRMS: Calculated for [C12H20O4Na+]: 251.1259, Found: 
251.1253. 
7-((2S,5R,6S)-5,6-dihydro-5-methoxy-6-methyl-2H-pyran-2-yloxy)-4-methyl-2H-
chromen-2-one (II-33). 
OOOO
OMe
 
A THF
 
(8 mL) solution of Piv-enol II-32 (953 mg, 4.18 mmol) and 4-methyl coumarin 
alcohol 5 (882 mg, 6.27 mmol) was cooled to 0 oC.  A THF
 
(2.0 mL) solution of 
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Pd2(dba)3.CHCl3 (108 mg, 2.5 mol%) and PPh3 (110 mg, 10 mol%) was added to the 
reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 5 hours.  The 
reaction mixture was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 30% EtOAc/hexanes to 
give coumarin-enol II-33 (1.07 g, 3.55 mmol, 85%) as viscous oil.  Rf (20% 
EtOAc/hexane) = 0.33; [α]26  D   = - 145 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 2950, 2939, 
1731, 1613, 1389, 1134, 1067, 951; 1H NMR (600 MHz, CDCl3) δ 7.50 (d, J = 9.0 Hz, 
1H), 7.08 (d, J = 2.4 Hz, 1H), 6.98 (dd, J = 8.4, 2.4 Hz, 1H), 6.23 (d, J = 10.2 Hz, 1H), 
6.15 (d, J = 1.2 Hz, 1H), 5.91 (ddd, J = 10.2, 3.0, 1.8 Hz, 1H), 5.67 (br s, 1H), 3.87 (ddd, 
J = 12.6, 9.0, 6.6 Hz, 1H), 3.54 (dd, J = 9.6, 1.2 Hz, 1H), 3.44 (s, 3H), 2.40 (d, J = 1.2 
Hz, 3H), 1.26 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 161.2, 160.3, 125.9, 
152.4, 131.9, 125.4, 125.0, 114.4, 113.7, 112.4, 104.2, 93.0, 77.7, 67.0, 56.6, 18.6, 18.1; 
CIHRMS: Calculated for [C17H18O5H+]: 303.1232, Found: 303.1228. 
 
4-methyl-7-(tetrahydro-3,4-dihydroxy-5-methoxy-6-methyl-2H-pyran-2-yloxy)-2H-
chromen-2-one (II-34). 
O OO
OH3CO
HO OH
H
 
To a CH2Cl2 (0.2 mL) solution of diene ester II-33 (400 mg, 1.32 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.7 mL).  
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Crystalline OsO4 (17 mg, 5 mol %) was added and the reaction was stirred for 8 h.  The 
reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with MeOH/EtOAc/Hexane (10:40:50).  Pure fractions were combined and 
concentrated to afford diol II-34 (368 mg, 1.09 mmol, 83%) as viscous oil.  Rf (60% 
EtOAc/Hexane) = 0.20; [α]26  D   = -50 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3412, 2917, 
2949, 1708, 1615, 1559, 1372, 1290, 1118, 1071, 849; 1H NMR (600 MHz, CDCl3) δ 
7.51 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.98 (dd, J = 9.0, 2.0 Hz, 1H), 6.15 (d, 
J = 1.2 Hz, 1H), 5.56 (d, J = 1.2 Hz, 1H), 4.17 (d, J = 1.8 Hz, 1H), 4.05 (ddd, J = 9.0, 4.2, 
4.2 Hz, 1H), 3.65 (dddd, J = 9.6, 6.0, 6.0, 6.0 Hz, 1H), 3.58 (s, 3H), 3.19 (dd, J = 9.6, 9.6 
Hz, 1H), 3.07 (dd, J = 4.2 Hz, 1H), 2.92 (d, J = 4.8 Hz, 1H), 2.39 (d, J = 1.2 Hz, 3H), 
1.27 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  161.2, 158.9, 154.8, 152.5, 125.6, 114.7, 
113.2, 112.6, 104.0, 97.5, 82.6, 71.0, 70.6, 68.5, 60.9, 18.6, 17.6; CIHRMS Calcd for 
[C17H20O7Na+]:  359.1106.  Found 359.1102. 
 
4-methyl-7-(tetrahydro-3-hydroxy-4-acetoxy-5-methoxy-6-methyl-2H-pyran-2-
yloxy)-2H-chromen-2-one (II-35). 
O OO
OH3CO
HO OAc
H
 
To a solution of diol II-34 (110 mg, 0.31 mmol) and trimethyl orthoacetate (1.02 ml, 8.1 
mmol) mixture in THF (0.6 ml) was added p-toluenesulfonic acid monohydrate (2.6 mg, 
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0.02 mmol), stirring for 0.5 h. The solvent was removed under reduced pressure and 
residue was dissolved in 1.5 ml THF/H2O (1:1, v/v) solution.  Then p-toluenesulfonic 
acid (26.3 mg 0.15 mmol) was added. Stirring was continued until hydrolysis was 
complete as seen by TLC. The reaction was quenched with adding EtOAc and satd. 
NaHCO3.  The organic layer was separated, dried (Na2SO4), concentrated under reduced 
pressure and purified by silica gel flash chromatography eluting with 70% EtOAc/hexane 
to give acetate II-35 (104 mg, 0.28 mmol, 90%) as white foam.  Rf = 0.35 (50% 
EtOAc/Hexane); [α]26  D   = -121 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3437, 2938, 1728, 
1611, 1389, 1232, 1067, 976, 850; 1H NMR (600 MHz, CDCl3)  δ 7.51 (d, J = 9.0 Hz, 
1H), 7.03 (d, J = 2.4 Hz, 1H), 6.94 (dd, J = 9.0, 4.2 Hz, 1H), 6.17 (d, J = 1.2 Hz, 1H), 
5.51 (d, J = 1.2 Hz, 1H), 5.29 (dd, J = 3.6, 1.8 Hz, 1H), 4.21 (ddd, J = 9.0, 5.4, 3.6 Hz, 
1H), 3.69 (dddd, J = 9.0, 6.6, 6.6, 6.6 Hz, 1H), 3.60 (s, 3H), 3.15 (dd, J = 9.6, 9.0 Hz, 1H), 
2.40 (d, J = 1.8 Hz, 3H), 2.28 (d, J = 4.8 Hz, 1H), 2.21 (s, 3H), 1.29 (d, J = 6.6 Hz, 3H); 
13C NMR (150 MHz, CDCl3) δ 170.6, 160.9, 158.7, 154.9, 152.1, 125.6, 114.9, 113.2, 
112.8, 104.1, 95.6, 82.9, 71.9, 69.6, 68.7, 61.0, 20.9, 18.6, 17.9; CIHRMS: Calculated for 
[C19H22O8Na+]: 401.1212, Found: 401.1206. 
 
2-(7-hydroxy-4-methyl-2H-chromen-2-one)-tetrahydro-3-hydroxy-5-methoxy-6-
methyl-2H-pyran-4-yl carbamate (II-36). 
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O OO
OH3CO
O
H2N O
OH
H
 
To a CH2Cl2 (1.5 mL, 0.1M) solution of  acetate alcohol II-35 (70 mg, 0.17 mmol) at 0 
oC was added trichloro acetyl isocyanate (32 µL, 0.26 mmol)  and the reaction was stirred 
for 1 h.  The solvent was removed under reduced pressure and residue was dissolved in 
2.0 ml MeOH/H2O (2:1, v/v) solution.  Then potassium carbonate (72.5 mg 0.53 mmol) 
was added at 0 oC. Stirring was continued until hydrolysis was complete as seen by TLC. 
The reaction was quenched with adding EtOAc and satd. NaHCO3.  The organic layer 
was separated, dried (Na2SO4), concentrated under reduced pressure and purified by 
silica gel flash chromatography eluting with MeOH/EtOAc/Hexane (10:40:50).  Pure 
fractions were combined and concentrated to afford carbamate II-36 (53 mg, 0.14 mmol, 
80 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.25; [α]26  D   = - 44 (c 0.5, CH2Cl2); IR 
(thin film, cm-1) 3436, 2852, 1708, 1611, 1376, 1103, 1067, 992, 786; 1H NMR (600 
MHz, CDCl3) δ δ 7.68 (d, J = 9.0 Hz, 1H), 7.07 (dd, J = 9.0, 2.4 Hz, 1H), 7.05 (d, J = 4.2 
Hz, 1H), 6.17 (d, J = 1.2 Hz, 1H), 5.51 (d, J = 1.8 Hz, 1H), 5.01 (dd, J = 9.6, 3.6 Hz, 1H), 
4.15 (dd, J = 3.6, 1.8 Hz, 1H), 3.62 (m, 1H), 3.48 (s, 3H), 3.32 (dd, J = 9.0, 9.0 Hz, 1H), 
2.42 (d, J = 1.8 Hz, 3H), 1.21 (d, J = 6.0 Hz, 3H);  NMR (150 MHz, CDCl3) δ  163.4, 
160.8, 159.1, 156.2, 155.6, 127.6, 116.2, 115.1, 113.1, 104.8, 99.8, 81.5, 75.4, 70.4, 70.2, 
61.1, 18.7, 18.2; CIHRMS Calcd for [C18H21NO8Na+]:  402.1164.  Found 402.1161. 
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4-methyl-7-(tetrahydro-5-methoxy-6-methyl-2H-pyran-2-yloxy)-2H-chromen-2-one 
(II-37). 
O OO
OH3CO
H
 
The ene compound II-33 (60 mg, 0.20 mmol) and o-NO2C6H4SO2NHNH2  (322 mg, 1.80 
mmol) were dissolved in 2.0 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen atmosphere then triethylamine (288 µL, 2.0 mmol)  was added and the 
reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with 25% EtOAc/hexanes to give deoxy 
compound II-37 (54 mg, 0.18 mmol, 90 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 
0.40; [α]26  D   = - 140 (c 1, CH2Cl2); IR (thin film, cm
-1) 2934, 2929, 1729, 1511, 1390, 
1104, 1067, 849; 1H NMR (600 MHz, CDCl3) δ 7.49 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 2.4 
Hz, 1H), 6.98 (dd, J = 9.0, 2.4 Hz, 1H),  6.14 (dd, J = 2.4, 1.2 Hz, 1H), 5.53 (dd, J = 3.6, 
1.2 Hz, 1H), 3.39 (s, 3H), 3.64 (ddd, J = 12.0, 9.6, 6.6 Hz, 1H), 2.93 (m, 1H), 2.39 (d, J = 
1.2 Hz, 3H), 2.11 (m, 2H), 1.86 (m, 2H), 1.18 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 161.2, 159.8, 155.0, 152.3, 125.3, 114.2, 113.5, 112.3, 103.9, 94.9, 80.2, 69.2, 
56.5, 29.0, 23.0, 18.6, 18.1; CIHRMS Calcd for [C17H20O5H+]: 305.1389. Found 
305.1384. 
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N-(7-(5,6-dihydro-5-methoxy-6-methyl-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-
chromen-3-yl)acetamide (II-39). 
O O
N
O
H
O
OH3CO
H
 
A THF
 
(1.5 mL) solution of Piv-enol II-32 (115 mg, 0.50 mmol) and acetamido coumarin 
alcohol 5 (128.7 mg, 0.55 mmol) was cooled to 0 oC.  A THF
 
(0.5 mL) solution of 
Pd2(dba)3.CHCl3 (21.4 mg, 2.5 mol%) and PPh3 (21.8 mg, 10 mol%) was added to the 
reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 4 hours.  The 
reaction mixture was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 40% EtOAc/hexanes to 
give coumarin-enol II-39 (158 g, 0.44 mmol, 80%) as viscous oil.  Rf (50% 
EtOAc/hexane) = 0.373; [α]26  D   = - 132 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 2936, 
1698, 1671, 1604, 1501, 1365, 1090, 1031, 976, 808; 1H NMR (600 MHz, CDCl3) δ 8.62 
(s, 1H), 7.97 (s, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 9.0 Hz, 1H), 6.24 (d, J = 10.2 
Hz, 1H), 5.94 (ddd, J = 7.2, 4.8, 2.4 Hz, 1H), 5.65 (d, J = 2.4 Hz, 1H), 3.92 (ddd, J = 
12.0, 9.6, 6.0 Hz, 1H), 3.54 (ddd, J = 9.0, 3.0, 1.8 Hz, 1H), 3.45 (s, 3H), 2.30 (s, 3H), 
2.22 (s, 3H), 1.29 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 169.1, 159.1, 
157.0, 149.0, 131.5, 125.5, 125.4, 124.2, 121.6, 115.5, 114.1, 112.5, 93.6, 77.8, 67.0, 
56.7, 24.6, 18.1, 8.3; CIHRMS: Calculated for [C19H21O6Na+]: 382.1266, Found: 
382.1262. 
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N-(8-methyl-2-oxo-7-(tetrahydro-3,4-dihydroxy-5-methoxy-6-methyl-2H-pyran-2-
yloxy)-2H-chromen-3-yl)acetamide (II-40). 
O O
N
O
H
O
OH3CO
HO OH
H
 
To a CH2Cl2 (1.0 mL) solution of ene compound II-39 (150 mg, 0.417 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (208 µL).  
Crystalline OsO4 (6 mg, 5 mol %) was added and the reaction was stirred for 10 h.  The 
reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with EtOAc/Hexane (90:10).  Pure fractions were combined and concentrated 
to afford diol II-40 (148 mg, 0.35 mmol, 85%) as viscous oil.  Rf (100% EtOAc) = 0.30; 
[α]26  D   = - 65 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3336, 2917, 2950, 1714, 1607, 1529, 
1376, 1250, 1120, 980; 1H NMR (600 MHz, CDCl3) δ 8.61 (s, 1H), 7.98 (s, 1H), 7.30 (d, 
J = 9.0 Hz, 1H), 7.15 (d, J = 9.0 Hz, 1H), 5.57 (d, J = 1.2 Hz, 1H), 4.21 (dd, J = 5.4, 3.0 
Hz, 1H), 4.06 (ddd, J = 9.0, 8.4, 3.0 Hz, 1H), 3.68 (m, 1H), 3.59 (s, 3H), 3.19 (dd, J = 
9.6, 9.6 Hz, 1H), 2.59 (m, 2H), 2.29 (s, 3H), 2.23 (s, 3H), 1.29 (d, J = 6.0 Hz, 3H); 13C 
NMR (150 MHz, CDCl3) δ  161.9, 159.0, 155.3, 149.0, 125.6, 124.1, 121.8, 114.7, 114.3, 
111.4, 97.4, 82.9, 71.3, 70.8, 68.5, 61.0, 24.6, 18.0, 8.2; CIHRMS Calcd for 
[C19H23NO8Na+]: 416.1321.  Found 416.1317. 
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N-(8-methyl-2-oxo-7-(tetrahydro-3-acetoxy,4-hydroxy-5-methoxy-6-methyl-2H-
pyran-2-yloxy)-2H-chromen-3-yl)acetamide (II-42). 
O O
N
O
H
O
OH3CO
HO OAc
H
 
To a solution of diol II-40 (80 mg, 0.20 mmol) and trimethyl orthoacetate (130 µL, 0.30 
mmol) mixture in THF (0.4 mL) was added p-toluenesulfonic acid monohydrate (1.7 mg, 
0.02 mmol), stirring for 0.5 h. The solvent was removed under reduced pressure and 
residue was dissolved in 1.5 ml THF/H2O (1:1, v/v) solution.  Then p-toluenesulfonic 
acid (18.0 mg 0.15 mmol) was added. Stirring was continued until hydrolysis was 
complete as seen by TLC. The reaction was quenched with adding EtOAc and satd. 
NaHCO3.  The organic layer was separated, dried (Na2SO4), concentrated under reduced 
pressure and purified by silica gel flash chromatography eluting with 75% EtOAc/hexane 
to give acetate II-42 (83 mg, 0.19 mmol, 95%) as white foam.  Rf = 0.30 (50% 
EtOAc/Hexane); [α]26  D   = -141 (c = 0.5, CH2Cl2); IR (thin film, cm
-1) 3448, 2937, 1728, 
1712, 1611, 1368, 1234, 1067, 990, 851; 1H NMR (600 MHz, CDCl3)  δ 8.60 (s, 1H), 
7.99 (s, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 5.52 (d, J = 1.8 Hz, 1H), 
5.31 (dd, J = 3.6, 1.8 Hz, 1H), 4.23 (ddd, J = 9.0, 5.4, 3.0 Hz, 1H), 3.70 (ddd, J = 12.0, 
9.6, 6.0 Hz, 1H), 3.61 (s, 3H), 3.16 (dd, J = 9.6, 9.6 Hz, 1H), 2.33 (s, 1H), 2.29 (s, 3H), 
2.22 (s, 3H), 2.20 (s, 3H), 1.30 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 170.6, 
169.2, 158.9, 155.2, 149.0, 125.6, 124.0, 121.9, 114.5, 111.4, 95.6, 83.0, 79.9, 72.1, 69.8, 
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68.8, 61.0, 24.6, 20.9, 17.9, 8.2; CIHRMS: Calculated for [C21H25NO9H+]: 436.1607.  
Found: 436.1604. 
 
2-(N-(7-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl)acetamide)-tetrahydro-3-
hydroxy-5-methoxy-6-methyl-2H-pyran-4-yl carbamate (II-43). 
O O
N
O
H
O
OH3CO
O
H2N O
OH
H
 
To a CH2Cl2 (0.9 mL, 0.1M) solution of  acetate alcohol II-42 (40 mg, 0.10 mmol) at 0 
oC was added trichloro acetyl isocyanate (20 µL, 0.46 mmol)  and the reaction was stirred 
for 1 h.  The solvent was removed under reduced pressure and residue was dissolved in 
1.0 ml MeOH/H2O (2:1, v/v) solution.  Then potassium carbonate (38 mg 0.28 mmol) 
was added at 0 oC. Stirring was continued until hydrolysis was complete as seen by TLC. 
The reaction was quenched with adding EtOAc and satd. NaHCO3.  The organic layer 
was separated, dried (Na2SO4), concentrated under reduced pressure and purified by 
silica gel flash chromatography eluting with MeOH/EtOAc/Hexane (10:40:50).  Pure 
fractions were combined and concentrated to afford carbamate II-43 (31 mg, 0.07 mmol, 
70 %) as viscous oil.  Rf (70% EtOAc/Hexane) = 0.35; [α]26  D   = - 42 (c 0.5, CH2Cl2); IR 
(thin film, cm-1) 3397, 3291, 2932, 1718, 1667, 1529, 1111, 1065, 990, 771; 1H NMR 
(600 MHz, CDCl3) δ 8.40 (s, 1H), 7.33 (d, J = 9.0 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 5.48 
(d, J = 1.8 Hz, 1H), 5.09 (dd, J = 9.6, 3.0 Hz, 1H), 4.50 (br s, 1H), 4.19 (dd, J = 3.0, 2.4 
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Hz, 1H), 3.63 (m, 1H), 3.55 (s, 3H), 3.33 (dd, J = 9.6, 9.6 Hz, 1H), 2.28 (s, 3H), 2.16 (s, 
3H), 2.11 (br s, 1H), 1.21 (d, J = 6.0 Hz, 3H);  NMR (150 MHz, CDCl3) δ  172.6, 159.1, 
157.0, 126.9, 123.4, 115.8, 112.8, 99.9, 97.7, 84.2, 81.5, 75.6, 74.5, 70.4, 61.1, 45.9, 23.9, 
23.1, 18.2, 8.4; CIHRMS Calcd for [C20H24N2O9Na+]:  459.1379.  Found 459.1376. 
 
N-(8-methyl-2-oxo-7-(tetrahydro-5-methoxy-6-methyl-2H-pyran-2-yloxy)-2H-
chromen-3-yl)acetamide (II-41). 
O O
N
O
H
O
OH3CO
H
 
The ene compound II-39 (10 mg, 0.03 mmol) and o-NO2C6H4SO2NHNH2  (33 mg, 0.16 
mmol) were dissolved in 0.2 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen atmosphere then triethylamine (39 µL, 0.27 mmol)  was added and the 
reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with 40% EtOAc/hexanes to give deoxy 
compound II-41 (9.5 mg, 0.02 mmol, 95 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 
0.35; [α]26  D   = - 23 (c 1, CH2Cl2); IR (thin film, cm
-1) 3352, 2951, 2929, 1712, 1677, 
1374, 1138, 1086, 977, 783; 1H NMR (600 MHz, CDCl3) δ 8.61 (s, 1H), 7.96 (s, 1H), 
7.28 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 5.56 (br s, 1H), 3.65 (ddd, J = 12.0, 
9.0, 6.6 Hz, 1H), 3.40 (s, 3H), 2.94 (ddd, J = 10.8, 9.0, 4.8 Hz, 1H), 2.33 (s, 3H), 2.22 (s, 
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3H), 2.14 (m, 2H), 1.90 (m, 2H), 1.19 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 
169.1, 159.2, 156.2, 149.1, 125.5, 124.4, 121.4, 114.7, 113.8, 111.6, 94.8, 80.4, 69.2, 
56.5, 29.3, 24.6, 23.2, 18.2, 8.2; CIHRMS Calcd for [C19H23NO6Na+]: 384.1423. Found 
384.1418. 
 
N-(7-(5,6-dihydro-5-methoxy-6-methyl-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-
chromen-3-yl)-4-methoxy-3-3'-methoxyphenylbenzamide (II-45). 
O O
N
O
H
O
OH3CO
H
OMe
OMe
 
A THF
 
(0.5 mL) solution of Piv-enol II-32 (47 mg, 0.28 mmol) and coumarin alcohol II-
44 (60 mg, 0.14 mmol) was cooled to 0 oC.  A THF
 
(0.5 mL) solution of Pd2(dba)3.CHCl3 
(7.2 mg, 2.5 mol%) and PPh3 (7.3 mg, 10 mol%) was added to the reaction mixture at 0 
oC.  The reaction mixture was stirred at 0 oC for 5 hours.  The reaction mixture was 
quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 35% EtOAc/hexanes to give 
coumarin-enol II-45 (64 mg, 0.12 mmol, 83%) as viscous oil.  Rf (50% EtOAc/hexane) = 
0.30; [α]25D = - 26 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 2934, 1706, 1669, 1603, 1364, 
1088, 939, 817; 1H NMR (600 MHz, CDCl3) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.92 (dd, J = 
8.4, 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 9.0 Hz, 
1H), 7.20 (d, J = 9.0 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 7.09 (d, J = 2.4, 1.2 Hz, 1H), 7.06 
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(d, J = 8.4 Hz, 1H), 6.93 (dd, J = 7.8, 3.0 Hz, 1H), 6.23 (d, J = 10.2 Hz, 1H), 5.94 (td, J = 
12.6, 2.4 Hz, 1H), 5.66 (br s, 1H), 3.93 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.54 (dd, J = 
10.2, 1.8 Hz, 1H), 3.46 (s, 3H), 2.33 (s, 3H), 1.30 (d, J = 6.0 Hz, 3H); 13C NMR (150 
MHz, CDCl3) δ 165.4, 159.7, 159.4, 159.3, 157.0, 149.0, 138.6, 131.5, 131.0, 129.9, 
129.1, 128.1, 126.1, 125.6, 125.4, 124.1, 122.0 (2C), 115.5, 115.2, 114.3, 113.1, 112.6, 
111.0, 93.6, 77.8, 67.0, 56.7, 55.8, 55.3, 18.1, 8.3; CIHRMS: Calculated for 
[C32H31NO8H+]: 558.2127, Found: 558.2126. 
 
N-(7-(tetrahydro-3,4-dihydroxy-5-methoxy-6-methyl-2H-pyran-2-yloxy)-8-methyl-2-
oxo-2H-chromen-3-yl)-4-methoxy-3-3'-methoxyphenylbenzamide (II-46). 
O O
N
O
H
O
OH3CO
HO OH
H
OMe
OMe
 
To a CH2Cl2 (0.8 mL) solution of ene compound II-45 (50 mg, 0.09 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (45 µL).  
Crystalline OsO4 (2 mg, 5 mol %) was added and the reaction was stirred for 12 h.  The 
reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with MeOH/EtOAc/Hexane (10:40:50).  Pure fractions were combined and 
concentrated to afford diol II-46 (43 mg, 0.07 mmol, 80%) as viscous oil.  Rf (80% 
EtOAc/Hexane) = 0.20; [α]26  D   = - 25 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3465, 2984, 
1737, 1670, 1371, 1291, 1140, 1091, 984; 1H NMR (600 MHz, CDCl3) δ 8.80 (s, 1H), 
 109
8.70 (s, 1H), 7.92 (dd, J = 6.0, 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.35 (m, 2H), 7.17 
(d, J = 9.0 Hz, 1H), 7.12 (d, J = 9.0 Hz, 1H), 7.09 (dd, J = 2.4, 1.8 Hz, 1H), 7.07 (d, J = 
9.0 Hz, 1H), 6.93 (dd, J = 8.4, 1.8 Hz, 1H), 5.58 (d, J = 1.2 Hz, 1H), 4.22 (dd, J = 3.6, 1.2 
Hz, 1H), 4.09 (dd, J = 9.0, 3.6 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.68 (ddd, J = 9.6, 6.0, 
3.6 Hz, 1H), 3.60 (s, 3H), 3.20 (dd, J = 9.6, 9.6 Hz, 1H), 2.55 (br s, 2H), 2.31 (s, 3H), 
1.30 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 165.5, 159.8, 159.3, 155.3, 
149.0, 138.6, 131.1, 129.9, 129.1, 128.1, 126.0, 125.7, 124.0, 122.1, 122.0 (2C), 115.2, 
114.7, 114.5, 113.1, 111.4, 111.0, 97.4, 82.9, 71.3, 70.5, 68.5, 61.0, 55.8, 55.3, 18.0, 8.2; 
CIHRMS Calcd for [C32H33NO10Na+]:  614.2002.  Found 614.2002. 
 
N-(7-(tetrahydro-3-acetoxy,4-hydroxy-5-methoxy-6-methyl-2H-pyran-2-yloxy)-8-
methyl-2-oxo-2H-chromen-3-yl)-4-methoxy-3-3'-methoxyphenylbenzamide (II-48). 
O O
N
O
H
O
OH3CO
HO OAc
H
OMe
OMe
 
To a solution of diol II-46 (65 mg, 0.11 mmol) and trimethyl orthoacetate (71 µL, 0.55 
mmol) mixture in THF (0.3 ml) was added p-toluenesulfonic acid monohydrate (1.0 mg, 
0.01 mmol), stirring for 0.5 h. The solvent was removed under reduced pressure and 
residue was dissolved in 1.0 ml THF/H2O (1:1, v/v) solution.  Then p-toluenesulfonic 
acid (10.0 mg 0.05 mmol) was added. Stirring was continued until hydrolysis was 
complete as seen by TLC. The reaction was quenched with adding EtOAc and satd. 
NaHCO3.  The organic layer was separated, dried (Na2SO4), concentrated under reduced 
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pressure and purified by silica gel flash chromatography eluting with 65% EtOAc/hexane 
to give acetate II-48 (64 mg, 0.10 mmol, 92%) as white foam.  Rf = 0.37 (10:40:50% 
MeOH/EtOAc/Hexane); [α]26  D  = - 6 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3455, 2980, 
1735, 1693, 1382, 1290, 1128, 1042, 978; 1H NMR (600 MHz, CDCl3)  δ 8.80 (d, J = 3.0 
Hz, 1H), 8.71 (s, 1H), 7.92 (dd, J = 9.0, 2.4 Hz, 1H), 7.89 (d, J = 1.8 Hz, 1H), 7.36 (m, 
1H), 7.16 (d, J = 8.4 Hz, 1H), 7.12 (m, 1H), 7.09 (m, 1H), 6.92 (ddd, J = 8.4, 2.4, 1.2 Hz, 
1H), 5.54 (br s, 1H), 5.37 (dd, J = 9.0, 3.0 Hz, 1H), 4.32 (m, 1H), 4.12 (dd, J = 13.8, 7.2 
Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.78 (m, 1H), 3.62 (br s, 1H), 3.51 (s, 3H), 3.69 (m, 
1H), 2.36 (s, 3H), 2.20 (s, 3H), 2.17 (dd, J = 13.8, 3.6 Hz, 1H), 1.32 (d, J = 6.0 Hz, 1H); 
13C NMR (150 MHz, CDCl3) δ 170.6, 169.8, 165.5, 159.8, 159.3, 155.2, 149.1, 138.6, 
131.1, 129.9, 129.1, 128.1, 125.6, 123.9, 122.0, 115.2, 113.1, 111.4, 111.0, 97.6, 65.7, 
83.0, 79.9, 73.7, 69.5, 68.8, 60.5, 60.3, 55.8, 55.3, 21.1, 17.8, 14.1, 8.3; CIHRMS: 
Calculated for [C34H35NO11Na+]: 656.2107.  Found: 656.2105. 
 
N-(7-(tetrahydro-3-hydroxy,4-carbamoyl-5-methoxy-6-methyl-2H-pyran-2-yloxy)-8-
methyl-2-oxo-2H-chromen-3-yl)-4-methoxy-3-3'-methoxyphenylbenzamide (II-49). 
O O
N
O
H
O
OMe
OMe
OH3CO
O
H2N O
OH
H
 
To a CH2Cl2 (0.5 mL, 0.1M) solution of acetate alcohol II-48 (35 mg, 0.06 mmol) at 0 oC 
was added trichloro acetyl isocyanate (11 µL, 0.08 mmol) and the reaction was stirred for 
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1 h.  The solvent was removed under reduced pressure and residue was dissolved in 1.0 
ml MeOH/H2O (2:1, v/v) solution.  Then potassium carbonate (22.9 mg 0.17 mmol) was 
added at 0 oC. Stirring was continued until hydrolysis was complete as seen by TLC. The 
reaction was quenched with adding EtOAc and satd. NaHCO3.  The organic layer was 
separated, dried (Na2SO4), concentrated under reduced pressure and purified by silica gel 
flash chromatography eluting with MeOH/EtOAc/Hexane (10:40:50).  Pure fractions 
were combined and concentrated to afford carbamate II-49 (23 mg, 0.04 mmol, 78 %) as 
viscous oil.  Rf (70% EtOAc/Hexane) = 0.30; [α]26  D   = - 43 (c 0.5, CH2Cl2); IR (thin film, 
cm-1) 3434, 2930, 2852, 1712, 1606, 1366, 1265, 1099, 987, 810; 1H NMR (600 MHz, 
CDCl3) δ 8.80 (s, 1H), 7.92 (dd, J = 6.6, 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.35 (m, 
3H), 7.15 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 7.09 (dd, J = 2.4, 1.8 Hz, 1H), 
6.93 (dd, J = 8.4, 2.4 Hz, 1H), 5.55 (d, J = 1.8 Hz, 1H), 5.26 (dd, J = 9.0, 3.6 Hz, 1H), 
4.36 (br s, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.80 (ddd, J = 9.6, 6.0, 5.4 Hz, 1H), 3.52 (s, 
3H), 3.36 (m, 2H), 2.36 (s, 3H), 2.17 (s, 1H), 1.32 (d, J = 6.0 Hz, 3H);  NMR (150 MHz, 
CDCl3) δ  160.0, 159.5, 155.6, 149.2, 138.8, 131.2, 130.1, 129.3, 128.3, 126.1, 125.9, 
125.8, 124.3, 122.2 (2C), 115.4, 115.3, 114.7, 113.3, 111.7, 111.2, 98.1, 96.2, 80.2, 74.6, 
69.4, 69.0, 60.5, 56.0, 55.5, 29.8, 18.0, 8.4; CIHRMS Calcd for [C33H34N2O11Na+]: 
657.2060.  Found 657.2057. 
 
N-(7-(tetrahydro-5-methoxy-6-methyl-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-
chromen-3-yl)-4-methoxy-3-3'-methoxyphenylbenzamide (II-47). 
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H
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OMe
 
The ene compound II-45 (20 mg, 0.03 mmol) and o-NO2C6H4SO2NHNH2  (59 mg, 0.29 
mmol) were dissolved in 0.3 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen atmosphere then triethylamine (53 µL, 0.36 mmol) was added and the 
reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with 30% EtOAc/hexanes to give deoxy 
compound II-47 (19 mg, 0.03 mmol, 92 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 
0.35; [α]26  D   = - 31 (c 1, CH2Cl2); IR (thin film, cm
-1) 2927, 2853, 1708, 1670, 1605, 
1392, 1239, 1090, 979, 786; 1H NMR (600 MHz, CDCl3) δ  8.80 (s, 1H), 8.70 (s, 1H), 
7.92 (dd, J = 8.4, 2.4 Hz, 1H), 7.89 (d, J = 1.8 Hz, 1H), 7.34 (m, 2H), 7.18 (d, J = 9.0 Hz, 
1H), 7.13 (d, J = 7.8 Hz, 1H), 7.09 (dd, J = 2.4, 1.8 Hz, 1H), 7.06 (s, 1H), 6.93 (dd, J = 
7.8, 2.4 Hz, 1H), 5.57 (br s, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.67 (ddd, J = 9.6, 6.0, 4.8 
Hz, 1H), 3.50 (s, 3H), 2.94 (ddd, J = 10.2, 9.0, 4.8 Hz, 1H), 2.35 (s, 3H), 2.16 (m, 2H), 
1.91 (m, 2H), 1.19 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 165.4, 159.7, 
159.5, 156.2, 149.1, 138.6, 131.0, 129.9, 129.1, 128.1, 126.1, 125.5, 124.3, 122.0, 121.8, 
115.2, 114.7, 113.9, 113.1, 111.6, 111.0, 94.8, 80.4, 69.2, 56.5, 55.8, 55.3, 29.6, 29.3, 
23.2, 18.2, 8.2; CIHRMS Calcd for [C32H33NO8H+]: 560.2284. Found 560.2281             
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5,6-dihydro-5-oxo-2H-pyran-2-yl pivalate (II-52). 
O
O
O
O
(+/-)
 
The furfuryl alcohol II-50 (20.0 g, 203.8 mmol), 326 mL of THF, and 81 mL of H2O 
were added to a round bottom flask and cooled to 0 oC.  Solid NaHCO3 (34.2 g, 407.6 
mmol), NaOAc•3H20 (27.7 g, 203.8 mmol), and NBS (36.3 g, 203.8 mmol) were added 
to the solution and the mixture was stirred for 1 h at 0 oC.  The reaction was quenched 
with satd aq NaHCO3 (200 mL), extracted (3 x 100 mL) with Et2O, dried (Na2SO4), 
concentrated under reduced pressure and purified by silica gel chromatography eluting 
with 20% EtOAc/hexanes to give hemiacetal II-51.  The hemiacetal II-51 (16.0 g, 140.3 
mmol) was dissolved in CH2Cl2 (350 mL) and the solution was cooled to -78 oC.  A 
CH2Cl2 (50 mL) solution of Piv-Cl  (19.2 mL, 154.3 mmol), a catalytic amount of DMAP 
(856 mg, 7.0 mmol)  and Et3N (21 mL, 154.3 mmol) were added to the reaction mixture. 
The reaction was stirred for 6 h at -78 oC.  The reaction was quenched with 200 mL of 
satd. aq NaHCO3, extracted (3 x 150 mL) with Et2O, dried (Na2SO4), and concentrated 
under reduced pressure.  The crude product was purified using silica gel flash 
chromatography eluting with 10 % EtOAc/hexanes to give Piv-enone II-52 (33.5 g, 169.1 
mmol, 83 %).  Rf (50% EtOAc/hexanes) = 0.52; IR (thin film, cm-1) 2955, 2928, 2859, 
1765, 1713, 1417, 1379, 1265, 950; 1H NMR (600 MHz, CDCl3) δ 6.92 (dd, J = 10.2, 3.6 
Hz, 1H), 6.46 (d, J = 3.6 Hz, 1H), 6.25 (d, J = 10.8 Hz, 1H), 4.47 (d, J = 16.8 Hz, 1H), 
4.20 (d, J = 16.8 Hz, 1H), 1.22 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 193.4, 176.9, 
142.4, 128.6, 86.5, 67.3, 39.2, 26.9 (3C); CIHRMS Calcd for [C10H14O4Na]+: 221.0789.  
Found 221.0784. 
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5,6-dihydro-5-hydroxy-2H-pyran-2-yl pivalate (II-52). 
O
OH
O
O
(+/-)
 
A solution of pyranone II-52 (1.17 g, 5.46 mmol) in dry CH2Cl2 (4.5 mL) and 0.4 M 
CeCl3/MeOH (4.5 mL) was cooled to -78 °C. NaBH4 (258 mg, 5.46 mmol) was added 
and the reaction mixture was stirred for 2 h at -0 °C. The resulting solution was diluted 
with ether (50 mL) and was quenched with 25 mL of saturated NaHCO3, extracted (3 x 
25 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure. The crude 
product was purified using silica gel chromatography eluting with 30% EtOAc/hexane to 
give enol II-53 (1.08 g, 5.02 mmol, 92%) as a semi solid; Rf = 0.38 (50% 
EtOAc/Hexane); IR (thin film, cm-1) 3395 2965, 2938, 1674, 1519, 1245, 1054, 987; 1H 
NMR (600 MHz, CDCl3)  δ 6.56 (br s, 1H), 6.11 (dd, J = 10.2, 2.4 Hz, 1H), 5.75 (ddd, J 
= 10.2, 2.4, 2.4 Hz, 1H), 4.35 (m, 1H), 3.90 (m, 1H), 3.61 (m, 1H), 2.05 (d, J = 7.2 Hz, 
1H), 1.21 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 177.6, 134.6, 125.1, 87.7, 64.3, 62.5, 
38.9, 26.9 (3C); CIHRMS Calcd for [C10H16O4Na]+: 223.0946.  Found 223.0942. 
 
7-((2S,5R)-5,6-dihydro-5-hydroxy-2H-pyran-2-yloxy)-4-methyl-2H-chromen-2-one 
(II-54). 
OOOO
OH
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Method 1: A THF
 
(1.0 mL) solution of Piv-enol II-53 (150 mg, 0.69 mmol) and 4-
methyl coumarin alcohol 5 (61.1 mg, 0.35 mmol) was cooled to 0 oC.  A THF
 
(0.3 mL) 
solution of Pd2(dba)3.CHCl3 (18 mg, 2.5 mol%) and R,R-Trost ligand (27.5 mg, 5 mol%) 
was added to the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 4 
hours.  The reaction mixture was quenched with 3 mL of satd. aq. NaHCO3, extracted (3 
x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude 
product was purified using silica gel flash chromatography eluting with 50% 
EtOAc/hexanes to give coumarin-enol II-54 (143 mg, 0.52 mmol, 75%) as viscous oil.  
Method 2: A THF
 
(1.0 mL) solution of Piv-enol II-53 (130 mg, 0.60 mmol) and 4-
methyl coumarin alcohol 5 (53 mg, 0.30 mmol) was cooled to 0 oC.  A THF
 
(0.6 mL) 
solution of Pd2(dba)3.CHCl3 (15 mg, 2.5 mol%) and PPh3 (15.7 mg, 10 mol%) was added 
to the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 3 hours.  The 
reaction mixture was quenched with 3 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 50-60% EtOAc/hexanes 
to give coumarin-enol II-54 (140 mg, 0.51 mmol, 85%) as viscous oil. Rf (50% 
EtOAc/hexane) = 0.42; [α]26  D   = - 145 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3440, 2950, 
2942, 1731, 1613, 1389, 1134, 1067, 961; 1H NMR (600 MHz, CDCl3) δ 7.50 (d, J = 
10.2 Hz, 1H), 7.03 (d, J = 2.4, 1.2 Hz, 1H), 6.98 (ddd, J = 7.2, 3.6, 1.2 Hz, 1H), 6.19 (m, 
1H), 6.14 (dd, J = 7.2, 2.4 Hz, 1H), 5.89 (m, 1H), 5.67 (br s, 1H), 4.34 (m, 1H), 3.88 (dd, 
J = 10.8, 6.0 Hz, 1H), 3.69 (ddd, J = 18.6, 8.4, 1.8 Hz, 1H), 2.38 (d, J = 1.2 Hz, 3H), 2.06 
(br s, 1H); 13C NMR (150 MHz, CDCl3) δ 161.4, 160.0, 154.8, 152.5, 135.2, 125.5, 
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125.0, 114.6, 113.6, 112.4, 104.2, 92.4, 63.7, 62.3, 18.5; CIHRMS: Calculated for 
[C15H14O5Na+]: 297.0739, Found: 297.0736. 
 
7-((2S,3R,4R,5S)-tetrahydro-3,4,5-trihydroxy-2H-pyran-2-yloxy)-4-methyl-2H-
chromen-2-one (II-55). 
OOOO
OH
OH
HO
 
To a CH2Cl2 (3.6 mL) solution of diene II-54 (100 mg, 0.36 mmol) at 0 oC was added a 
solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.2 mL).  Crystalline 
OsO4 (4.6 mg, 5 mol %) was added and the reaction was stirred for 12 h.  The reaction 
mixture was concentrated and was pipetted directly on to a silica gel column using 
CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product was 
eluted with MeOH/EtOAc/Hexane (5:45:50).  Pure fractions were combined and 
concentrated to afford diol II-55 (95 mg, 0.30 mmol, 85%) as viscous oil.  Rf (60% 
EtOAc/Hexane) = 0.25; [α]26  D   = -50 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3420, 2927, 
2939, 1728, 1655, 1559, 1371, 1285, 1117, 1071, 862; 1H NMR (600 MHz, CDCl3) δ 
7.70 (d, J = 9.0 Hz, 1H), 7.07 (dd, J = 9.0, 2.4 Hz, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.18 (d, 
J = 1.2 Hz, 1H), 5.49 (d, J = 3.0 Hz, 1H), 4.52 (s, 1H), 3.98 (t, J = 3.0 Hz, 1H), 3.86 (m, 
2H), 3.77 (ddd, J  = 11.5, 3.9, 1.8 Hz, 1H), 3.48 (m, 1H), 2.43 (d, J = 1.2 Hz, 3H); 13C 
NMR (150 MHz, CDCl3) δ  163.3, 161.1, 156.0, 155.4, 127.3, 116.0, 114.8, 112.8, 104.8, 
100.2, 72.5, 71.0, 68.4, 65.1, 18.6; CIHRMS Calcd for [C15H16O7Na+]:  331.0793.  Found 
331.0791. 
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(2S,6R)-6-[(2’S)-2’- N-Carbobenzyloxy-D-tyrosine methoxycarbonyl)-2-tert-butyl-
dimethyl-silanyloxymethyl-6H-pyran-3-one (III-20). 
O
O
O OTBS
N
CO2CH3Cbz
H
 
A CH2Cl2 (0.7 mL) solution of compound III-18 (260 mg, 0.72 mmol) and Cbz-D-
tyrosine methyl ester III-17 (238 mg, 0.726 mmol) was cooled to 0 oC.  A CH2Cl2 (0.7 
mL) solution of Pd2(dba)3.CHCl3 (18 mg, 2.5 mol%) and PPh3 (16 mg, 10 mol%) was 
added to the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 3 
hours.  The reaction mixture was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 
x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude 
product was purified using silica gel flash chromatography eluting with 14% 
EtOAc/hexanes to give enone III-20 (380 mg, 0.66 mmol, 92%) as viscous oil.  Rf (30% 
EtOAc/hexanes) = 0.42; [α]26  D  = + 0.8 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3351, 2952, 
1752, 1725, 1509, 1256, 1219, 1151, 995, 836; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 
5H), 7.05 (m, 4H), 6.97 (dd, J = 10.2, 3.6 Hz, 1H), 6.22 (d, J = 10.8 Hz, 1H), 5.93 (d, J = 
3.6 Hz, 1H), 5.30 (d, J = 7.8 Hz, 1H), 5.10 (d, J = 12.6 Hz, 1H), 5.07 (d, J = 12.6 Hz, 
1H), 4.62 (dd, J = 13.8, 6.0 Hz, 1H), 4.54 (dd, J = 4.8, 3.0 Hz, 1H), 4.05 (dd, J = 11.4, 
4.8 Hz, 1H), 4.02 (dd, J = 11.4, 2.4 Hz, 1H), 3.71 (s, 3H), 3.10 (dd, J = 13.2, 5.4 Hz, 1H), 
3.04 (dd, J = 14.4, 6.0 Hz, 1H), 0.84 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ  194.2, 174.8, 156.1, 155.4, 151.6, 150.0, 142.6, 136.0, 130.3(2C), 130.0, 
 118
128.6, 128.4(2C), 128.0, 127.9, 117.0, 91.9, 76.6, 66.8, 62.5, 54.7, 52.2, 37.2, 25.7(3C), 
18.1, -5.44, -5.48; CIHRMS Calcd for [C30H39NO8SiNa+]:  592.2337.  Found 592.2290. 
 
3-{4-[6-(tert-Butyl-dimethylsilanyloxymethyl)-5-hydroxy-5,6-dihydro-2H-pyran-2-
yloxy]-phenyl}-2- N-carbobenzyloxy-D-tyrosine methyl ester  (III-21).  
O
OH
O OTBS
N
CO2CH3
H
Cbz
 
The enone compound III-20 (320 mg, 0.562 mmol) was dissolved in 0.5 mL of CH2Cl2 
and 0.5 mL MeOH in round bottom flask and cooled -78 oC then  NaBH4 (21 mg, 0.562 
mmol) was added and the reaction mixture was stirred at -78 oC for 3 hours and on 
completion, monitored by TLC, reaction mixture was diluted with ether and was 
quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 18% EtOAc/hexanes to give III-21 
(300 mg, 0.525 mmol, 87%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.30; [α]26  D   = + 
29.0 (c = 1, CH2Cl2); IR (thin film, cm-1) 3386, 2925, 1459, 1255, 1069, 1027, 838; 1H 
NMR (600 MHz, CDCl3) δ 7.32 (m, 5H), 6.98 (m, 4H), 6.08 (d, J = 10.2 Hz, 1H), 5.88 
(ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 5.57 (d, J =  1.8 Hz, 1H), 5.21 (d, J = 7.8 Hz, 1H), 5.11 
(d, J = 13.2 Hz, 1H), 5.08 (d, J =  12.0 Hz, 1H), 4.62 (dd, J = 13.2, 5.4 Hz, 1H), 4.28 (dd, 
J = 9.0, 1.8 Hz, 1H), 3.89 (dd, J = 10.2, 4.8 Hz, 1H), 3.84 (dqd, J = 12.0, 7.2, 4.8 Hz, 
1H), 3.75 (dd, J = 9.6, 6.6 Hz, 1H), 3.32 (s, 3H), 3.08 (dd, J = 13.8, 5.4 Hz, 1H), 3.04 
(dd, J = 13.8, 5.4 Hz, 1H), 3.02 (d, J = 3.0 Hz, 1H), 0.88 (s, 9H), 0.08 (s, 3H), 0.07 (s, 
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3H); 13C NMR (150 MHz, CDCl3) δ  171.9, 156.5, 133.3, 130.3, 130.2(2C), 128.5(2C), 
128.4, 128.1, 128.0, 124.8, 116.9(2C), 115.5, 92.8, 70.7, 66.9, 66.5, 65.1, 54.8, 52.3, 
52.2, 37.2, 25.7(3C), 18.1, -5.5, -5.6; CIHRMS Calcd for [C30H41NO8SiNa+]: 594.2493  
Found 594.2467. 
 
(1'S, 4'S, 5'R, 1S, 5R)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5-(tert-
butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl) -1H-pyran-4-one (III-16). 
O
O
O OTBS
N
CO2CH3
H
Cbz
O
O
OTBS
 
A CH2Cl2 (0.5 mL) solution of compound III-16 (280 mg, 0.49 mmol) and alcohol III-21 
(175 mg, 0.49 mmol) was cooled to 0 oC.  A CH2Cl2 (0.5 mL) solution of Pd2(dba)3-
.CHCl3 (12 mg, 2.5 mol%) and PPh3 (11 mg, 10 mol%) was added to the reaction mixture 
at 0 oC.  The reaction mixture was stirred at 0 oC for 2 hours.  The reaction mixture was 
quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 16% EtOAc/hexanes to give dienone 
III-16 (328 mg, 0.40 mmol, 82%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.44; [α]26  D  
= + 0.15 (c = 1, CH2Cl2); IR (thin film, cm-1) 3351, 2952, 1752, 1725, 1509, 1256, 1219, 
1151, 995, 836; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 7.05 (m, 4H), 6.84 (dd, J = 
10.2, 3.6 Hz, 1H), 6.23 (d, J = 10.8 Hz, 1H), 6.14 (d, J = 10.2 Hz, 1H), 5.95 (ddd, J = 
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10.2, 2.4, 1.8 Hz, 1H), 5.62 (d, J = 3.6 Hz, 1H), 5.60 (d, J = 1.8 Hz, 1H), 5.26 (d, J = 8.4 
Hz, 1H), 5.10 (d, J = 13.2 Hz, 1H), 5.07 (d, J = 12.6 Hz, 1H), 4.62 (dd, J = 13.8, 6.0 Hz, 
1H), 4.59 (d, J = 9.0 Hz, 1H), 4.44 (dd, J = 3.6, 2.4 Hz, 1H), 4.13 (d, J = 3.6 Hz, 1H), 
4.10 (dd, J = 10.2, 4.2 Hz, 1H), 3.96 (dd, J = 10.2, 2.4 Hz, 1H), 3.86 (dq, J = 9.6, 1.8 Hz, 
1H), 3.81 (dd, J = 10.2, 1.8 Hz, 1H), 3.70 (s, 3H), 3.08 (dd, J = 13.8, 5.4 Hz, 1H), 3.03 
(dd, J = 13.8, 6.0 Hz, 1H), 0.86 (s, 9H), 0.85 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H), 0.03 (s, 
3H), 0.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  194.5, 171.8, 156.4, 155.5, 143.8, 
136.1, 130.1(2C), 130.0, 129.0, 128.5, 128.4(2C), 128.0, 127.9(2C), 126.4, 116.9, 92.8, 
89.7, 76.5, 71.1, 66.8, 66.3, 62.8, 62.4, 60.2, 54.7, 52.1, 37.2, 25.78(3C), 25.76(3C), 
18.28, 18.23, -5.4, -5.3, -5.4, -5.2; CIHRMS Calcd for [C42H61NO11Si2Na+]:  834.3675.  
Found 834.3638. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[ N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-(tert-
butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl)-1,4-dihydro-5H-pyran-4-ol (III-22). 
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The enone compound III-16 (200 mg, 0.246 mmol) was dissolved in 0.3 mL of CH2Cl2 
and 0.3 mL MeOH were added to a round bottom flask and cooled to -78 oC then (9 mg, 
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0.246 mmol) NaBH4 was added and the reaction mixture was stirred at -78oC for 6 hours 
and on completion, as monitored by TLC, reaction mixture is diluted with ether and was 
quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give enol III-
22 (182 mg, 0.223 mmol, 91%) as viscous oil.  Rf (40% EtOAc/hexanes) = 0.44; [α]26  D  = 
+ 49 (c = 1, CH2Cl2); IR (thin film, cm-1) 3420, 2930, 2855, 1725, 1717, 1510, 1256, 
1219, 1151, 995, 836; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 7.05 (m, 4H), 6.15 (d, 
J = 10.2 Hz, 1H), 5.96 (d, J = 10.2 Hz, 1H), 5.92 (dq, J = 10.2, 1.2 Hz, 1H), 5.68 (dd, J = 
10.2, 2.4 Hz, 1H), 5.59 (d, J = 1.8 Hz, 1H), 5.25 (d, J = 7.8 Hz, 1H), 5.18 (d, J = 1.8 Hz, 
1H), 5.10 (d, J = 12.6 Hz, 1H), 5.08 (d, J = 12.6 Hz, 1H), 4.62 (dd, J = 13.2, 5.4 Hz, 1H), 
4.37 (d, J = 9.0 Hz, 1H), 4.24 (d, J = 8.4 Hz, 1H), 3.97 (dd, J = 9.6, 4.2 Hz, 1H), 3.89 
(ddd, J = 10.2, 5.4, 2.4 Hz, 1H), 3.85 (dd, J = 10.2, 1.8 Hz, 1H), 3.81 (dd, J = 12.0, 5.4 
Hz, 1H), 3.75 (dd, J = 10.2, 7.2 Hz, 1H), 3.70 (s, 3H), 3.71 (m, 1H), 3.08 (d, J = 3.0 Hz, 
1H), 3.05 (dd, J = 8.4, 6.0 Hz, 1H), 3.02 (d, J = 6.0 Hz, 1H), 0.91 (s, 9H), 0.84 (s, 9H), 
0.12 (s, 3H), 0.11 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  
174.7, 171.8, 156.5, 155.5, 136.1, 133.1, 130.5, 130.0(2C), 128.4(2C), 128.0, 127.9(2C), 
126.0, 125.3, 117.1(2C), 92.7, 91.0, 71.3, 70.1, 66.8, 66.6, 66.5, 65.1, 62.6, 54.8, 52.1, 
37.2, 25.8(3C), 25.7(3C), 18.3, 18.1, -5.1, -5.2, -5.5, -5.6; CIHRMS Calcd for 
[C42H63NO11Si2Na+]:  836.3831.  Found 836.3818. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-
(tert-butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy] -5-(tert-
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butyl-dimethylsilanyloxymethyl)-1,4-dihydro-5H-pyran-O-4'-isovalaric ester (III-
23). 
O
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The alcohol compound III-22 (140 mg, 0.171 mmol), isovaleric acid (21 mg, 0.206 
mmol) and DCC (42 mg, 0.206 mmol) were dissolved in 0.3 mL of CH2Cl2 in a round 
bottom flask and cooled to 0 oC then DMAP (2 mg, 0.01 mmol) was added and the 
reaction mixture was stirred at 0
 
oC for 6 hours and on completion, as monitored by TLC, 
the reaction mixture was diluted with ether and was quenched with 5 mL of satd. aq. 
NaHCO3, extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under 
reduced pressure.  The crude product was purified using silica gel flash chromatography 
eluting with 15% EtOAc/hexanes to give III-23 (148 mg, 0.164 mmol, 96%) as viscous 
oil.  Rf (30% EtOAc/hexanes) = 0.62; [α]26  D  = + 90 (c = 1, CH2Cl2); IR (thin film, cm
-1) 
2956, 2928, 1738, 1733, 1510, 1253, 1219, 1123, 986, 835; 1H NMR (600 MHz, 
CDCl3) δ 7.34 (m, 5H), 7.00 (m, 4H), 6.20 (dd, J = 10.2, 2.4 Hz, 1H), 5.93 (m, 2H), 5.74 
(dd, J = 10.2, 1.8 Hz, 1H), 5.59 (d, J = 1.2 Hz, 1H), 5.42 (dd, J = 10.2, 1.8 Hz, 1H), 5.28 
(d, J = 1.2 Hz, 1H), 5.24 (d, J = 8.4 Hz, 1H), 5.10 (d, J = 12.6 Hz, 1H), 5.08 (d, J = 12.6 
Hz, 1H), 4.62 (dd, J = 13.2, 5.4 Hz, 1H), 4.42 (d, J = 9.0 Hz, 1H), 3.89 (ddd, J = 10.2, 
5.4, 2.4 Hz, 1H), 3.85 (dd, J = 10.2, 1.8 Hz, 1H), 3.81 (dd, J = 11.4, 5.4 Hz, 1H), 3.78 
(dd, J = 10.2, 1.8 Hz, 1H), 3.75 (m, 1H),  3.70 (s, 3H), 3.71 (m, 1H), 3.08 (dd, J = 13.8, 
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5.4 Hz, 1H), 3.04 (dd, J = 13.8, 6.0 Hz, 1H), 2.20 (d, J = 1.2 Hz, 2H), 2.10 (m, 1H), 0.96 
(d, J = 6.6 Hz, 6H), 0.89 (s, 9H), 0.85 (s, 9H), 0.05 (s, 6H), 0.03 (s, 3H), 0.02 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ  172.1, 171.8, 156.6, 155.5, 136.2, 130.3, 130.0(2C), 129.8, 
128.4(2C), 128.0(2C), 127.9, 127.2, 126.1, 117.2(2C), 92.9, 90.9, 71.4, 69.6, 66.8, 66.3, 
64.6, 62.8, 62.1, 54.7, 52.1, 43.3, 37.2, 25.9, 25.8(6C), 25.6, 22.3, 22.2 18.38, 18.36, -5.1, 
-5.2, -5.41, -5.45; CIHRMS Calcd for [C47H71NO12Si2Na+]:  920.4407.  Found 920.4385. 
 
1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-di-1,4-α-D-mannose -O-4' isovalaric ester (III-3a). 
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To a t-butanol-acetone (0.2 mL, 1:1) solution of diene ester III-23 (100 mg, 0.11 mmol) 
at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.1 
mL).  Crystalline OsO4 (1.4 mg, 5 mol %) was added and the reaction was stirred for 12 
h.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the 
product was eluted with MeOH/ether (2:98 to 4:96).  Pure fractions were combined and 
concentrated to afford bis-α-D-manno-tetrol III-3a (91 mg, 0.094 mmol, 85 %) as 
viscous oil.  Rf (90% EtOAc/MeOH) = 0.56; [α]26  D   = + 61.9 (c = 2, CH2Cl2); IR (thin 
film, cm-1) 2956, 2928, 1738, 1733, 1510, 1253, 1219, 1123, 986, 835; 1H NMR (600 
 124
MHz, CDCl3) δ 7.31 (m, 5H), 6.99 (m, 4H), 5.45 (d, J = 1.2 Hz, 1H), 5.36 (d, J = 1.8 Hz, 
1H), 5.26 (d, J = 8.4 Hz, 1H), 5.10 (d, J = 12.6 Hz, 1H), 5.07 (d, J = 12.6 Hz, 1H), 5.02 
(dd, J = 10.2, 9.0 Hz, 1H), 4.62 (dd, J = 6.0, 1.8 Hz, 1H), 4.22 (ddd, J = 10.2, 6.0, 3.6,  
Hz, 1H), 4.13 (dd, J = 10.2, 6.6 Hz, 1H), 4.03 (dd, J = 4.2, 1.8 Hz, 1H), 3.97 (ddd, J = 
10.8, 7.2, 2.4 Hz, 1H), 3.93 (dd, J = 10.2, 4.2 Hz, 1H), 3.89 (dd, J = 10.2, 9.6 Hz, 1H), 
3.86 (dd, J = 11.4, 10.2 Hz, 1H), 3.78 (dd, J = 10.2, 4.8 Hz, 1H), 3.72 (dd, J = 10.2, 4.8 
Hz, 1H), 3.70 (s, 3H), 3.70 (m, 2H), 3.45 (d, J = 3.6 Hz, 1H), 3.25 (d, J = 7.2 Hz, 1H), 
3.10 (d, J = 1.2 Hz, 1H), 3.06 (dd, J = 13.8, 6.0 Hz, 1H), 3.02 (dd, J = 15.0, 5.4 Hz, 1H), 
2.24 (dd, J = 15.0, 7.2 Hz, 1H), 2.20 (dd, J = 13.8.0, 7.2 Hz, 1H), 2.16 (d, J = 1.8 Hz, 
1H), 2.08 (m, 1H), 0.96 (d, J = 6.6 Hz, 6H), 0.89 (s, 9H), 0.84 (s, 9H), 0.07 (s, 3H), 0.06 
(s, 3H), 0.02 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  173.5, 171.9, 155.6, 
155.4, 136.1, 130.2(2C), 128.4(3C), 128.1(2C), 128.0, 116.8(2C), 98.3, 97.7, 73.7, 71.6, 
71.2, 70.8, 70.1, 70.0, 69.8, 66.9, 62.8, 54.8, 52.2, 43.4(2C), 37.2, 25.9, 25.9(3C), 
25.8(3C), 25.7, 22.3, 22.2, 18.4, 18.3, -5.2, -5.3, -5.40, -5.47; CIHRMS Calcd for 
[C47H75NO16Si2Na+]:  988.4516.  Found 988.4459. 
 
1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-2,3,2’,3’-di acetonide-bis-1,4-α-D-mannose-O-4'-
isovalaric ester (III-3b). 
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To a CH2Cl2 (0.1 mL, 1.0M) solution of D-manno-tetrol III-3a (20 mg, 0.02 mmol) and 
2,2-dimethoxypropane (4.6 mg, 0.04 mmol) at 0 oC was added CSA (0.50 mg, 10 mol%) 
and the reaction was stirred for 6 h.  The reaction mixture was concentrated and was 
pipetted directly on to a silica gel column using CH2Cl2 (1 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with EtOAc/Hexane 
(40:60).  Pure fractions were combined and concentrated to afford III-3b (17 mg, 0.02 
mmol, 80 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.45; [α]26  D   = +49 (c 1, 
CH2Cl2); IR (thin film, cm-1) 2955, 2935, 1728, 1511, 1226, 1101, 1017, 833; 1H NMR 
(600 MHz, CDCl3) δ 7.35 (m, 5H), 7.29 (m, 4H), 5.97 (d, J = 10.2 Hz, 1H), 5.92 (ddd, J 
= 10.2, 3.0 1.8 Hz, 1H), 5.40 (br s, 1H), 5.04 (br s, 2H), 4.94 (dd, J = 9.6, 7.8 Hz, 1H), 
4.79 (d, J = 12.0 Hz, 1H), 4.56 (d, J = 12.0 Hz, 1H), 4.38 (ddd, J = 9.0, 4.2, 4.2 Hz, 1H), 
4.26 (d, J = 6.0 Hz, 1H), 4.21 (dd, J = 13.2, 5.4 Hz, 1H), 4.09 (dd, J = 11.4, 5.4 Hz, 1H), 
4.01 (m, 1H), 3.78 (d, J = 5.4 Hz, 1H), 3.74 (dd, J = 10.2, 2.4 Hz, 1H), 3.72 (br s, 1H), 
3.68 (d, J = 6.0 Hz, 1H), 3.67 (s, 3H), 3.61 (d, J = 10.2 Hz, 1H), 3.06 (dd, J = 7.2, 6.0 Hz, 
1H), 2.95 (s, 1H), 2.88 (s, 1H), 2.26 (dd, J = 15.0, 6.6 Hz, 1H), 2.18 (dd, J = 15.0, 7.2 Hz, 
1H), 1.93 (m, 3H), 1.85 (m, 3H), 1.63 (m, 3H), 1.50 (m, 3H), 0.97 (s, 6H), 0.95 (s, 9H), 
0.90 (s, 9H), 0.10 (s, 3H), 0.09 (s, 6H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  
173.2, 172.6, 154.2, 137.5, 130.3, 128.7, 128.6(2C), 128.5, 128.4(2C), 128.1, 128.0(2C), 
127.8, 116.7, 110.0, 92.9(2C), 75.1, 69.9(3C), 69.5(2C), 66.6, 62.8(2C), 58.8(2C), 53.2, 
50.4, 40.1, 38.1, 29.3, 28.7(2C), 28.4, 26.0(3C), 25.9(3C), 22.3(2C), 18.6, 18.3(2C), -5.0, 
-5.2(2C), -5.3; CIHRMS Calcd for [C53H83NO16Si2Na+ - C3H62+ ]: 1028.5142.  Found 
1028.4585. 
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1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(hydroxy methyl)-di-1,4-α-
D-mannose –O-4' isovaleric ester (III-2a). 
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To a THF (0.5 mL, 0.1M) solution of  D-manno-tetrol III-3a (50 mg, 0.05 mmol) at 0 oC 
was added a solution of TBAF in THF (50 µL, 1.0M)  and the reaction was stirred for 1 
h.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the 
product was eluted with MeOH/EtOAc/Hexane (10:40:50).  Pure fractions were 
combined and concentrated to afford III-2a (31 mg, 0.04 mmol, 80 %) as viscous oil.  Rf 
(10:50:40% MeOH/EtOAc/Hexane) = 0.20; [α]26  D   = + 71 (c 0.5, CH3OH); IR (thin film, 
cm-1) 3337, 2956, 2926, 1738, 1611, 1510, 1228, 1217, 1094, 976, 834; 1H NMR (600 
MHz, CDCl3) δ 7.36 (m, 5H), 7.17 (m, 4H), 5.48 (d, J = 1.8 Hz, 1H), 5.42 (d, J = 1.8 Hz, 
1H), 5.09 (br s, 2H), 4.59 (br s, 1H), 4.45 (ddd, J = 7.8, 6.6, 1.8 Hz, 1H), 4.08 (dd, J = 
10.2, 1.8 Hz, 1H), 4.05 (m, 3H), 4.00 (br s, 1H), 3.89 (dd, J = 9.6, 2.4 Hz, 1H), 3.80 (dd, 
J = 10.2, 2.4 Hz, 1H), 3.74 (m, 4H), 3.68 (m, 1H), 3.62 (m, 1H), 3.36 (m, 3H), 3.15 (ddd, 
J = 10.2, 4.8, 4.8 Hz, 1H), 2.93 (m, 2H), 2.29 (m, 1H), 2.13 (m, 1H), 1.34 (m, 1H), 1.03 
(d, J = 6.6 Hz, 6H);  NMR (150 MHz, CDCl3) δ  172.1, 155.8, 155.3, 136.4, 130.5(2C), 
129.9, 128.4(2C), 128.2(2C), 116.6, 103.2, 102.4, 98.1, 71.8, 71.3, 67.1(2C), 61.1, 55.1, 
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52.5(2C), 43.6, 43.1, 37.5, 36.6, 31.6, 30.5, 29.8, 28.6, 25.9, 23.1, 22.5(2C); CIHRMS 
Calcd for [C35H47NO16Na+]:  760.2787.  Found 760.2798. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-(tert-
butyl-dimethylsilanyloxymethyl)-tetrahydro-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl) -tetrahydro-pyran-O-4'-isovalaric ester (III-2b). 
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The dienone ester compound III-23 (27 mg, 0.03 mmol) and o-NO2C6H4SO2NHNH2  (20 
mg, 0.02 mmol) were dissolved in 0.2 mL of CH2Cl2 in a round bottom flask and cooled 
0 oC under nitrogen atmosphere then triethylamine (17 mg, 0.17 mmol) was added and 
the reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with 15% EtOAc/hexanes to give III-2b (18 mg, 
0.02 mmol, 95 %) as viscous oil.  Rf (30% EtOAc/Hexane) = 0.46; [α]26  D   = + 35 (c 1, 
CH2Cl2); IR (thin film, cm-1) 2952, 2929, 1735, 1510, 1254, 1220, 1123, 996, 836; 1H 
NMR (600 MHz, CDCl3) δ 7.34 (m, 5H), 6.98 (m, 4H), 5.45 (br s, 1H),  5.24 (d, J = 7.8 
Hz, 1H), 5.09 (br s, 2H), 5.08 (d, J = 2.4 Hz, 1H), 4.73 (ddd, J = 10.2, 9.6, 4.8 Hz, 1H), 
4.60 (ddd, J = 7.8, 5.4, 5.4 Hz, 1H), 3.84 (d, J = 11.4 Hz, 1H), 3.79-3.67 (m, 6H), 3.70 (s, 
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3H), 3.05 (dd, J = 13.2, 6.0 Hz, 1H), 3.01 (dd, J = 13.2, 5.4 Hz, 1H), 2.15 (m, 3H), 2.06 
(m, 1H), 2.00 (m, 2H), 1.80 (m, 3H), 1.71 (m, 2H), 0.89 (d, J = 6.6 Hz, 6H), 0.86 (s, 9H), 
0.84 (s, 9H), 0.03 (s, 6H), 0.01 (s, 6H); 13C NMR (67.5 MHz, CDCl3) δ  172.0, 172.2, 
156.4, 136.5, 130.2, 128.4(2C), 128.2(2C), 128.1, 128.0(2C), 116.7(2C), 94.8, 90.5, 75.1, 
73.4, 71.5, 67.7, 66.8, 66.4, 63.1, 62.6, 54.6, 52.0, 43.6, 37.5, 28.6, 25.8(3C), 25.7(3C), 
25.7, 23.6, 22.2(3C), 22.0, 18.4, 18.2, -5.1, -5.3, -5.40, -5.44; CIHRMS Calcd for 
[C47H75NO12Si2Na+]:  924.4720.  Found 924.4702. 
 
3-{4-[6-(tert-Butyl-dimethylsilanyloxymethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yloxy]-
phenyl}-2-N-carbobenzyloxy-D-tyrosine methyl ester (III-24a). 
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       A CH2Cl2 (0.6 mL) solution of compound (ent)- III-18 (200 mg, 0.55 mmol) and 
Cbz-D-tyrosine methyl ester III-17 (220 mg, 0.67 mmol) was cooled to 0 oC.  A CH2Cl2 
(0.6 mL) solution of Pd2(dba)3.CHCl3 (14 mg, 2.5 mol%) and PPh3 (14 mg, 10 mol%) 
was added to the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 3 
hours.  The reaction mixture was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 
x 5 mL) with Et2O, dried over Na2SO4, and concentrated under reduced pressure.  The 
crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexanes to give III-24a (278 mg, 0.50 mmol, 90%) as viscous oil.  Rf (40% 
EtOAc/hexanes) = 0.40; [α]26  D   = (c 0.64, CH2Cl2); IR (thin film, cm
-1) 3351, 2952, 
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1752, 1725, 1509, 1256, 1219, 1151, 995, 836; 1H NMR (270 MHz, CDCl3) δ 7.35 (m, 
5H), 7.05 (m, 4H), 6.97 (dd, J = 10.2, 3.5 Hz, 1H), 6.22 (d, J = 10.2 Hz, 1H), 5.94 (d, J = 
3.3 Hz, 1H), 5.33 (dd, J =  8.5, 4.2 Hz, 1H), 5.09 (br s, 2H), 4.62 (dd, J = 13.2, 5.7 Hz, 
1H), 4.53 (dd, J = 4.1, 3.1 Hz, 1H), 4.15-4.00 (m, 2H), 3.71 (s, 3H), 3.69 (m, 2H), 0.84 
(s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (67.5 MHz, CDCl3) δ  194.2, 177.7, 156.1, 
155.4, 151.6, 150.0, 142.6, 136.0, 133.1, 130.2, 130.0, 128.5, 128.3, 128.0, 127.9, 121.2, 
116.9, 91.8, 83.3, 66.8, 62.4, 54.7, 52.2, 37.1, 25.1(3C), 18.1, -5.46, -5.49; CIHRMS 
Calcd for [C30H39NO8SiNa+]:  592.2343.  Found 592.2369. 
 
3-{4-[6-(tert-Butyl-dimethylsilanyloxymethyl)-5-hydroxy-5,6-dihydro-2H-pyran-2-
yloxy]-phenyl}-2- N-carbobenzyloxy-D-tyrosine methyl ester (III-24b). 
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The enone compound III-24a (300 mg, 0.527 mmol), dissolved in 0.5 mL of CH2Cl2 and 
0.5 mL MeOH, was added to a round bottom flask and cooled to -24 oC then  (20 mg, 
0.527 mmol) NaBH4 was added and the reaction mixture was stirred at -24 oC for 1 hour 
and on completion, as monitored by TLC, the reaction mixture was diluted with ether and 
was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
over Na2SO4, and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 25% EtOAc/hexanes to give III-24b 
(270 mg, 0.47 mmol, 89%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.30; [α]26  D   = - 
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82 (c 1, CH2Cl2); IR (thin film, cm-1) 3357, 2928, 1722, 1611, 1439, 1225, 1054, 985, 
835; 1H NMR (600 MHz, CDCl3) δ 7.33 (m, 5H), 6.97 (m, 4H), 6.07 (dd, J = 10.2, 1.2 
Hz, 1H), 5.85 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 5.56 (dd, J =  2.4, 1.2 Hz, 1H), 5.20 (d, J = 
7.8 Hz, 1H), 5.09 (d, J = 12.0 Hz, 1H), 5.07 (d, J = 12.0 Hz, 1H), 4.61 (dd, J = 13.2, 5.4 
Hz, 1H), 4.26 (dd, J = 9.0, 1.8 Hz, 1H), 3.89 (dd, J = 10.2, 4.8 Hz, 1H), 3.83 (ddd, J = 
9.0, 7.2, 4.8 Hz, 1H), 3.73 (dd, J = 9.6, 6.6 Hz, 1H), 3.31 (s, 3H), 3.08 (dd, J = 13.8, 5.4 
Hz, 1H), 3.04 (dd, J = 13.8, 5.4 Hz, 1H), 3.01 (d, J = 3.0 Hz, 1H), 0.87 (s, 9H), 0.07 (s, 
3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  171.9, 156.6, 136.2, 133.3, 130.2, 
130.2(2C), 128.5(2C), 128.1, 128.0, 124.8, 116.9(2C), 116.6, 92.8, 70.7, 66.9, 66.8, 65.3, 
54.8, 52.3, 52.2, 37.3, 25.7(3C), 18.1, -5.5, -5.6; CIHRMS Calcd for [C30H41NO8SiNa+]: 
594.2493  Found 594.2500. 
 
(1'R, 4'R, 5'S, 1R, 5S)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5-(tert-
butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl) -1H-pyran-4-one (III-24). 
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A CH2Cl2 (0.5 mL) solution of compound (ent)-III-18 (163 mg, 0.45 mmol) and alcohol 
III-24b (260 mg, 0.45 mmol) was cooled to 0 oC.  A CH2Cl2 (0.5 mL) solution of 
Pd2(dba)3.CHCl3 (11.8 mg, 2.5 mol%) and PPh3 (12 mg, 10 mol%) was added to the 
reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 2 hours.  The 
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reaction mixture was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) 
with Et2O, dried over Na2SO4, and concentrated under reduced pressure.  The crude 
product was purified using silica gel flash chromatography eluting with 16% 
EtOAc/hexanes to give dienone III-24 (313 mg, 0.38 mmol, 85%) as viscous oil.  Rf 
(30% EtOAc/hexanes) = 0.44; [α]26  D   = -63 (c 1, CH2Cl2); IR (thin film, cm
-1) 3341, 
2952, 1725, 1700, 1509, 1252, 1226, 1123, 984, 836; 1H NMR (600 MHz, CDCl3) δ 7.34 
(m, 5H), 7.00 (m, 4H), 6.84 (dd, J = 10.2, 3.6 Hz, 1H), 6.23 (d, J = 10.2 Hz, 1H), 6.14 (d, 
J = 10.8 Hz, 1H), 5.95 (ddd, J = 10.2, 3.0, 1.2 Hz, 1H), 5.62 (d, J = 3.6 Hz, 1H), 5.61 (d, 
J = 1.8 Hz, 1H), 5.18 (d, J = 7.8 Hz, 1H), 5.10 (br s, 2H), 4.62 (dd, J = 13.8, 6.0 Hz, 1H), 
4.59 (d, J = 9.0 Hz, 1H), 4.44 (dd, J = 3.6, 2.4 Hz, 1H), 4.13 (d, J = 3.6 Hz, 1H), 4.10 
(dd, J = 10.2, 4.2 Hz, 1H), 3.96 (dd, J = 10.2, 2.4 Hz, 1H), 3.86 (dq, J = 12.0, 3.6 Hz, 
1H), 3.80 (dd, J = 12.0, 4.2 Hz, 1H), 3.72 (s, 3H), 3.07 (dd, J = 13.8, 5.4 Hz, 1H), 3.03 
(dd, J = 13.8, 6.0 Hz, 1H), 0.86 (s, 9H), 0.84 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H), 0.02 (s, 
3H), 0.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  194.6, 171.9, 156.4, 155.6, 143.9, 
136.2, 133.3, 130.2(2C), 130.1, 129.1, 128.6, 128.5(2C), 128.1, 128.0, 126.6(2C), 117.0, 
92.9, 89.8, 76.7, 71.3, 66.9, 66.5, 62.9, 62.5, 54.8, 52.2, 37.3, 25.9(3C), 25.8(3C), 18.4, 
18.3, -5.1, -5.3(2C), -5.4; CIHRMS Calcd for [C42H61NO11Si2Na+]:  834.3675.  Found 
834.3648. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-(tert-
butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl)-1,4-dihydro-5H-pyran-4-ol (III-25a). 
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The dienone compound III-24 (300 mg, 0.37 mmol), dissolved in 0.4 mL of CH2Cl2 and 
0.4 mL MeOH, was added to a round bottom flask and cooled to -24 oC then  NaBH4 (14 
mg, 0.37 mmol) was added and the reaction mixture was stirred at -24
 
oC for 1 hour and 
on completion, as monitored by TLC, the reaction mixture is diluted with ether and was 
quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried over 
Na2SO4, and concentrated under reduced pressure.  The crude product was purified using 
silica gel flash chromatography eluting with 25% EtOAc/hexanes to give III-25a (271 
mg, 0.333 mmol, 90%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.30; [α]26  D   = -72 (c 
1, CH2Cl2); IR (thin film, cm-1) 3433, 2928, 2857, 1724, 1509, 1253, 1226, 1123, 1044, 
981, 836; 1H NMR (600 MHz, CDCl3) δ 7.34 (m, 5H), 7.00 (m, 4H), 6.15 (d, J = 10.8 
Hz, 1H), 5.97 (dd, J = 10.2, 1.8 Hz, 1H), 5.92 (ddd, J = 10.2, 3.0, 1.8 Hz, 1H), 5.68 (ddd, 
J = 10.2, 2.4, 1.8 Hz, 1H), 5.59 (d, J = 1.8 Hz, 1H), 5.18 (br s, 2H), 5.09 (br s, 2H), 4.61 
(dd, J = 13.2, 5.4 Hz, 1H), 4.36 (d, J = 8.4 Hz, 1H), 4.24 (d, J = 8.4 Hz, 1H), 3.97 (dd, J 
= 9.6, 4.2 Hz, 1H), 3.89 (dddd, J = 5.4, 3.6, 1.8, 1.8 Hz, 1H), 3.85 (dd, J = 11.4, 2.4 Hz, 
1H), 3.80 (dd, J = 11.4, 5.4 Hz, 1H), 3.73 (dd, J = 10.2, 1.8 Hz, 1H), 3.72 (s, 3H), 3.69 
(m, 1H), 3.06 (d, J = 6.0 Hz, 1H), 3.05 (d, J = 5.4 Hz, 1H), 3.02 (d, J = 2.4 Hz, 1H), 0.92 
(s, 9H), 0.84 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ  171.9, 156.7, 155.6, 136.2, 133.1, 130.5, 130.1(2C), 130.0, 129.0, 
128.4(2C), 128.1, 128.0, 126.1, 125.4, 117.2, 116.9, 92.8, 91.1, 71.4, 70.0, 66.9, 66.9, 
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66.7, 65.3, 62.6, 54.8, 52.2, 37.3, 25.8(3C), 25.8(3C), 18.3, 18.2, -5.0, -5.1, -5.4, -5.6; 
CIHRMS Calcd for [C42H63NO11Si2Na+]:  836.3831.  Found 836.3844. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-
(tert-butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy] -5-(tert-
butyl-dimethylsilanyloxymethyl)-1,4-dihydro-5H-pyran-O-4'-isovalaric ester (III-
25). 
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The alcohol compound III-25a (135 mg, 0.17 mmol), isovaleric acid (20 mg, 0.20 mmol) 
and DCC (41 mg, 0.20 mmol) were dissolved in 0.3 mL of CH2Cl2 in a round bottom 
flask and cooled to 0 oC then DMAP (2 mg, 0.016 mmol) was added and the reaction 
mixture was stirred at 0
 
oC for 6 hours and on completion, as monitored by TLC, the 
reaction mixture was diluted with ether and was quenched with 5 mL of satd. aq. 
NaHCO3, extracted (3 x 5 mL) with Et2O, dried over Na2SO4, and concentrated under 
reduced pressure.  The crude product was purified using silica gel flash chromatography 
eluting with 15% EtOAc/hexanes to give III-25 (141.5mg, 0.16 mmol, 95%) as viscous 
oil.  Rf (30% EtOAc/hexanes) = 0.60; [α]26  D   = - 99 (c 1, CH2Cl2); IR (thin film, cm
-1) 
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2956, 2929, 1737, 1509, 1253, 1219, 1123, 986, 835; 1H NMR (600 MHz, CDCl3) δ 7.34 
(m, 5H), 7.00 (m, 4H), 6.20 (d, J = 10.2 Hz, 1H), 5.94 (dd, J = 2.4, 1.8 Hz, 1H)), 5.92 
(dd, J = 2.4, 1.8 Hz, 1H)), 5.76 (dd, J = 3.0, 1.8 Hz, 1H), 5.74 (ddd, J = 10.2, 2.4, 2.4 Hz, 
1H), 5.59 (d, J = 1.8 Hz, 1H), 5.41 (dd, J = 10.2, 1.8 Hz, 1H), 5.28 (d, J = 1.8 Hz, 1H)), 
5.17 (d, J = 7.8 Hz, 1H)) 5.10 (br s, 2H), 4.62 (dd, J = 13.2, 5.4 Hz, 1H), 4.41 (d, J = 9.0 
Hz, 1H), 3.90 (dddd, J = 10.2, 5.4, 2.4, 2.4 Hz, 1H), 3.85 (dd, J = 11.4, 2.4 Hz, 1H), 3.80 
(dd, J = 11.4, 5.4 Hz, 1H), 3.77 (dd, J = 6.0, 2.4 Hz, 1H), 3.75 (m, 1H),  3.72 (s, 3H), 
3.06 (dd, J = 9.6, 4.2 Hz, 1H), 3.04 (dd, J = 9.6, 5.4 Hz, 1H), 2.20 (d, J = 1.8 Hz, 2H), 
2.10 (m, 1H), 0.96 (d, J = 7.6 Hz, 6H), 0.89 (s, 9H), 0.84 (s, 9H), 0.05 (s, 6H), 0.02 (s, 
3H), 0.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  172.2, 171.9, 156.7,  136.2, 130.4, 
130.1(2C), 129.9, 128.5(2C), 128.1(2C), 128.0, 127.3, 126.2, 117.3, 117.2(2C), 92.9, 
91.0, 71.5, 69.7, 66.9, 66.4, 64.7, 62.9, 62.2, 54.8, 52.2, 43.4, 37.3, 25.94(3C), 25.92(3C), 
25.7, 22.4, 22.3, 20.2, 18.45(2C), -5.1, -5.2, -5.4, -5.3; CIHRMS Calcd for 
[C47H71NO12Si2Na+]:  920.4407.  Found 920.4401. 
 
1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-di-1,4-α-l-mannose–O-4'-isovalaric ester (III-26a):  
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To a CH2Cl2 (1.6 mL, 0.1M) solution of dienone III-25 (148 mg, 0.16 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.1 mL).  
Crystalline OsO4 (4.2 mg, 10 mol %) was added and the reaction was stirred for 12 h.  
The reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with MeOH/EtOAc/Hexane (10:40:50).  Pure fractions were combined and 
concentrated to afford manno-tetrol III-26a (137 mg, 0.142 mmol, 86 %) as viscous oil.  
Rf (60% EtOAc/Hexane) = 0.20; [α]26  D   = -20 (c 1, CH3OH); IR (thin film, cm
-1) 3441, 
2928, 2855, 1726, 1611, 1510, 1252, 1227, 1107, 1020, 835; 1H NMR (600 MHz, 
CDCl3) δ 7.36 (m, 5H), 7.10 (m, 4H), 5.47 (d, J = 1.8 Hz, 1H), 5.44 (d, J = 1.8 Hz, 1H), 
5.20 (dd, J = 10.2, 9.6 Hz, 1H), 5.10 (br s, 2H), 4.87 (br s, 4H), 4.59 (m, 1H), 4.45 (dd, J 
= 9.0, 5.4 Hz, 1H), 4.08 (dd, J = 9.0, 3.0 Hz, 1H), 4.02 (dd, J = 3.0, 2.4 Hz, 1H), 4.00 (d, 
J = 1.8 Hz, 1H), 3.98 (dd, J = 9.0, 1.8 Hz, 1H), 3.90 (dd, J = 10.2, 9.0 Hz, 1H), 3.88 (ddd, 
J = 10.2, 6.6, 2.4 Hz, 1H), 3.87 (dd, J = 10.2, 9.6 Hz, 1H), 3.84 (dd, J = 4.8, 1.8 Hz, 1H), 
3.83 (m, 1H), 3.75 (m, 3H), 3.74 (dd, J = 4.2, 1.8 Hz, 1H), 3.69 (ddd, J = 9.6, 6.6, 1.8 Hz, 
1H), 3.13 (dd, J = 13.8, 5.4 Hz, 1H), 2.92 (dd, J = 13.8, 9.0 Hz, 1H), 2.29 (dd, J = 15.0, 
7.2 Hz, 1H), 2.24 (dd, J = 15.0, 7.2 Hz, 1H), 2.13 (m, 1H), 1.03 (d, J = 7.2 Hz, 6H), 0.95 
(s, 9H), 0.89 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ  173.8, 171.9, 155.6, 136.2, 130.3(2C), 128.5(3C), 128.2, 128.0, 
116.6(2C), 97.5, 96.9, 73.9, 71.49, 71.40, 71.0, 70.8, 70.3(2C), 68.8, 66.9, 63.0, 62.9, 
54.8, 52.3, 43.4(2C), 37.4, 25.9(3C), 25.8(3C), 25.8, 22.3(2C), 22.3, 18.4, 18.3, -5.2, -5.3, 
-5.40, -5.46; CIHRMS Calcd for [C47H75NO16Si2Na+]:  988.4516.  Found 988.4485. 
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1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(hydroxy methyl)-di-1,4-α-l-
mannose -O-4' isovaleric ester (III-26). 
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 To a THF (0.8 mL, 0.1M) solution of manno-tetrol III-26a (67 mg, 0.16 mmol) at 0 oC 
was added a solution of TBAF in THF (138 µL, 1.0M)  and the reaction was stirred for 1 
h.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the 
product was eluted with MeOH/EtOAc/Hexane (10:40:50).  Pure fractions were 
combined and concentrated to afford III-26 (40 mg, 0.054 mmol, 78 %) as viscous oil.  
Rf (10:50:40% MeOH/EtOAc/Hexane) = 0.20; [α]26  D   = - 110 (c 0.5, CH3OH); IR (thin 
film, cm-1) 3337, 2956, 2926, 1738, 1611, 1510, 1228, 1217, 1094, 976, 834; 1H NMR 
(600 MHz, CDCl3) δ 7.35 (m, 5H), 7.10 (m, 4H), 5.48 (d, J = 1.8 Hz, 1H), 5.42 (d, J = 
2.4 Hz, 1H), 5.12 (dd, J = 9.6, 9.6 Hz, 1H), 5.07 (br s, 2H), 4.59 (s, 1H), 4.45 (ddd, J = 
12.6, 9.6, 1.2 Hz, 1H), 4.10 (dd, J = 9.0, 3.6 Hz, 1H), 4.02-4.08 (m, 4H), 4.00 (dd, J = 
3.6, 1.8 Hz, 1H), 3.89 (dd, J = 9.6, 3.0 Hz, 1H), 3.83 (dd, J = 5.4, 3.0 Hz, 1H), 3.80 (dd, J 
= 7.2, 5.4 Hz, 1H), 3.77-3.72 (m, 1H), 3.75 (s, 3H), 3.67 (s, 1H), 3.62 (dd, J = 6.0, 3.0 
Hz, 1H), 3.35 (br s, 4H), 3.14 (dd, J = 13.8, 4.2 Hz, 1H), 2.92 (dd, J = 13.8, 9.0 Hz, 1H), 
2.31 (dd, J = 14.4, 7.2 Hz, 1H), 2.30 (dd, J = 7.2, 2.4 Hz, 1H), 2.27 (dd, J = 14.4, 7.2 Hz, 
 137
1H), 2.14 (m, 1H), 1.02 (d, J = 6.6 Hz, 6H); NMR (150 MHz, CDCl3) δ  173.6, 172.0, 
155.7, 136.1, 130.3(2C), 128.4(3C), 128.1, 127.9, 116.3(2C), 101.6, 97.9, 73.9, 71.9, 
71.6(2C), 71.1, 70.6, 69.3, 66.9, 60.9, 60.6, 60.4, 54.8, 52.2, 43.3, 42.9, 37.2, 29.5, 25.6, 
22.23, 22.20; CIHRMS Calcd for [C35H47NO16Na+]:  760.2787.  Found 760.2750. 
 
1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-2,3,2’,3’-bis acetonide-di-1,4-α-l-mannose-O-4'-isovalaric 
ester (III-27). 
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To a CH2Cl2 (0.1 mL, 1.0M) solution of manno-tetrol III-26a (25 mg, 0.02 mmol) and 
2,2-dimethoxypropane (5.7 mg, 0.05 mmol) at 0 oC was added CSA (0.60 mg, 10 mol%) 
and the reaction was stirred for 6 h.  The reaction mixture was concentrated and was 
pipetted directly on to a silica gel column using CH2Cl2 (1 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with EtOAc/Hexane 
(40:60).  Pure fractions were combined and concentrated to afford III-27 (22 mg, 0.02 
mmol, 81 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.44; [α]26  D   =  -31 (c 1, 
CH2Cl2); IR (thin film, cm-1) 2953, 2928, 1726, 1510, 1220, 1091, 1019, 833; 1H NMR 
(600 MHz, CDCl3) δ 7.31 (m, 5H), 6.96 (m, 4H), 5.51 (d, J = 1.2 Hz, 1H), 5.42 (d, J = 
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1.8 Hz, 1H), 5.06 (br s, 2H), 4.96 (dd, J = 10.2, 7.8 Hz, 2H), 4.62 (dd, J = 13.8, 5.4 Hz, 
1H), 4.25 (dd, J = 9.6, 3.6,  Hz, 1H), 4.16 (dd, J = 12.6, 5.4 Hz, 1H), 4.10 (d, J = 5.4 Hz, 
1H), 4.00 (m, 1H), 3.91 (m, 1H), 3.89 (dd, J = 10.2, 6.0 Hz, 1H), 3.86 (dd, J = 9.6, 4.8 
Hz, 1H), 3.84 (d, J = 9.0 Hz, 1H), 3.75 (m, 2H), 3.69 (s, 3H), 3.64 (d, J = 5.4 Hz, 1H), 
3.02 (m, 2H), 3.03 (d, J = 6.0 Hz, 1H), 2.73 (s, 1H), 2.56 (s, 1H), 2.24 (dd, J = 14.4, 7.2 
Hz, 1H), 2.20 (m, 1H), 2.16 (s, 1H), 2.12 (dd, J = 13.2, 6.0 Hz, 1H), 0.94 (d, J = 6.6 Hz, 
6H), 0.87 (s, 9H), 0.81 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H), -0.08 (s, 3H), -0.01 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ  172.0, 171.9, 155.5, 155.4, 130.3(2C), 128.4(3C), 128.1(2C), 
128.0, 116.8(2C), 109.9 (2C), 97.7, 95.0, 76.0, 75.8, 73.8, 71.2, 70.8, 69.8, 69.1(2C), 
66.9, 63.1, 62.9, 54.8, 54.7, 52.2, 43.3(2C), 37.2, 29.6, 27.4, 26.3, 25.85(3C), 25.81(3C), 
25.6, 22.3, 22.2, 18.4, 18.3, -5.3(2C), -5.47, -5.57; CIHRMS Calcd for 
[C53H83NO16Si2Na+ - C3H62+ ]: 1028.5142.  Found 1028.4585. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-
(tert-butyl-dimethylsilanyloxymethyl)-tetrahydro-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl)-tetrahydro-pyran-O-4'-isovalaric ester (III-28): 
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The diene ester III-25 (27 mg, 0.03 mmol) and o-NO2C6H4SO2NHNH2  (91.6 mg, 0.45 
mmol) were dissolved in 0.3 mL of CH2Cl2 in a round bottom flask and cooled to 0 oC 
under nitrogen atmosphere then triethylamine (60.6 mg, 0.60 mmol)  was added and the 
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reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with 15% EtOAc/hexanes to give III-28 (26.2 
mg, 0.03 mmol, 97 %) as viscous oil.  Rf (30% EtOAc/Hexane) = 0.46; [α]26  D   = -59 (c 2, 
CH2Cl2); IR (thin film, cm-1) 2955, 2928, 1738, 1510, 1252, 1219, 1122, 996, 835; 1H 
NMR (600 MHz, CDCl3) δ 7.33 (m, 5H), 6.97 (m, 4H), 5.44 (br s, 1H),  5.24 (d, J = 7.8 
Hz, 1H), 5.08 (br s, 2H), 5.07 (d, J = 2.4 Hz, 1H), 4.73 (ddd, J = 10.2, 9.6, 4.8 Hz, 1H), 
4.60 (ddd, J = 7.8, 5.4, 5.4 Hz, 1H), 3.85 (d, J = 11.4 Hz, 1H), 3.78-3.64 (m, 6H), 3.70 (s, 
3H), 3.05 (dd, J = 13.2, 6.0 Hz, 1H), 3.01 (dd, J = 13.2, 5.4 Hz, 1H), 2.13 (m, 3H), 2.06 
(ddd, J = 13.2, 6.6, 6.6 Hz, 1H), 2.00 (m, 2H), 1.80 (m, 3H), 1.71 (m, 2H), 0.93 (d, J = 
6.6 Hz, 6H), 0.88 (s, 9H), 0.84 (s, 9H), 0.02 (s, 6H), 0.018 (s, 3H), 0.004 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ  172.1, 172.0, 156.2, 136.2, 130.1(2C), 128.6, 128.4(2C), 
128.1, 128.0, 116.9(2C), 94.9, 90.5, 75.0, 73.3, 71.5, 67.5, 66.9, 66.3, 63.2, 62.6, 54.8, 
52.2, 43.6, 37.3, 28.7, 25.92(3C), 25.91(3C), 25.7, 23.6, 22.3(2C), 22.2(2C), 22.0, 18.4, 
18.3, -5.1, -5.3, -5.43, -5.46; CIHRMS Calcd for [C47H75NO12Si2Na+]:  924.4720.  Found 
924.4717. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-
(tert-butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy] -5-(tert-
butyl-dimethylsilanyloxymethyl)-1,4-dihydro-5H-pyran-O-4-methyl carbonate (III-
31). 
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To a solution of allylic alcohol III-22 (400 mg, 0.50 mmol) in dry CH2Cl2 (1.0 ml) at 0 
oC, was added pyridine (237 mg, 3.00 mmol), DMAP (30 mg), and methyl chloroformate 
(283 mg, 3.00 mmol). After stirring 24 h at room temperature, water (3 ml) was added 
and then the mixture was extracted with EtOAc (3 x 10 ml), dried (Na2SO4), concentrated 
under reduced pressure. The crude product was purified using silica gel flash 
chromatography eluting with 15% EtOAc/hexane to give carbonate III-31 (370.6 mg, 
0.43 mmol, 85%) as viscous oil.  Rf (30% EtOAc/hexane) = 0.65; [α]26  D  = + 50 (c = 1, 
CH2Cl2); IR (thin film, cm-1) 2928, 2885, 1748, 1441, 1509, 1266, 1090, 981, 865; 1H 
NMR (600 MHz, CDCl3) δ 7.34 (m, 5H), 7.00 (m, 4H), 6.18 (d, J = 10.2 Hz, 1H), 6.01 
(d, J = 10.2 Hz, 1H), 5.94 (dd, J = 2.4, 1.8 Hz, 1H), 5.92 (ddd, J = 10.8, 2.4, 1.8 Hz, 1H), 
5.77 (ddd, J = 10.2, 3.0, 1.8 Hz, 1H), 5.59 (d, J = 1.8 Hz, 1H), 5.31 (dd, J = 3.0, 1.8 Hz, 
1H), 5.29 (dd, J = 3.0, 2.4 Hz, 1H), 5.11 (d, J = 12.6 Hz, 1H), 5.08 (d, J = 12.6 Hz, 1H), 
4.61 (ddd, J = 8.4, 6.0, 5.4 Hz, 1H), 4.43 (d, J = 9.6 Hz, 1H), 3.88 (dd, J = 5.4, 2.4 Hz, 
1H), 3.86 (dd, J = 6.0, 2.4 Hz, 1H), 3.84 (dd, J = 4.8, 1.8 Hz, 1H), 3.83 (dd, J = 4.8, 2.4 
Hz, 1H), 3.81 (dd, J = 4.8, 1.8 Hz, 1H), 3.79 (s, 3H), 3.76 (s, 1H), 3.71 (s, 3H), 3.07 (ddd, 
J = 8.4, 5.4, 5.4 Hz, 1H), 3.05 (ddd, J = 7.8, 6.0, 5.4 Hz, 1H), 0.89 (s, 9H), 0.84 (s, 9H), 
0.06 (s, 3H), 0.05 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 
178.3, 171.9, 156.6, 155.6, 155.0, 136.2, 130.3, 130.1, 129.4, 129.0, 128.5 (2C), 128.1, 
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128.0, 127.6, 126.2, 117.2, 117.0, 109.9, 92.9, 91.0, 71.4, 69.3, 68.4, 66.9, 66.4, 62.7, 
62.0, 54.9, 54.8, 52.2, 37.4, 25.93 (3C), 25.91 (3C), 18.43, 18.42, -5.0, -5.2, -5.4 (2C); 
CIHRMS Calcd for [C44H65NO13Si2Na+]:  894.3892.  Found 894.3890. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-(tert-
butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl)-4-azido-1,4-dihydro-5H-pyran (III-32). 
O
O
O OTBS
N
CO2CH3
H
Cbz
O
N3
OTBS
 
To a mixture of carbonate III-31 (210 mg, 0.24 mmol), allylpalladium chloride dimer 
(13.2 mg, 0.03 mmol) and 1,4-bis(diphenylphosphino)butane (61.6 mg, 0.13 mmol) in 
dry THF (0.25 ml) was added TMSN3 (277 mg, 1.20 mmol) under argon atmosphere. The 
solution was stirred at room temperature for 3 h.  Then the mixture was evaporated with a 
amount of silica gel under reduced pressure, purified using silica gel flash 
chromatography eluting with 15% EtOAc/hexane to give allylic azide III-32 (162 mg, 
0.19 mmol, 80%) as viscous oil.  Rf (30% EtOAc/hexane) = 0.70; [α]26  D  = + 65 (c = 1, 
CH2Cl2); IR (thin film, cm-1) 2952, 2929, 2856, 2103, 1726, 1510, 1253, 1043, 993, 830; 
1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 6.99 (m, 4H), 6.18 (d, J = 10.2 Hz, 1H), 
6.00 (d, J = 10.2 Hz, 1H), 5.94 (ddd, J =10.8, 2.4, 1.8 Hz, 1H), 5.83 (ddd, J = 10.2, 3.0, 
2.4 Hz, 1H), 5.59 (d, J = 2.4 Hz, 1H), 5.26 (d, J = 1.8 Hz, 1H), 5.11 (d, J = 12.6 Hz, 1H), 
5.08 (d, J = 12.6 Hz, 1H), 4.62 (ddd, J = 7.8, 6.0, 5.4 Hz, 1H), 4.42 (d, J = 9.0 Hz, 1H), 
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4.14 (dd, J = 3.8, 1.8 Hz, 1H), 4.12 (dd, J = 10.2, 1.8 Hz, 1H), 3.92 (d, J = 3.0 Hz, 1H), 
3.90 (d, J = 3.0 Hz, 1H), 3.88 (ddd, J = 4.2, 3.6, 3.0 Hz, 1H), 3.86 (d, J = 1.8 Hz, 1H), 
3.80 (dd, J = 4.2, 2.4 Hz, 1H), 3.71 (s, 3H), 3.65 (ddd, J = 9.0, 3.0, 1.8 Hz, 1H), 3.08 
(ddd, J = 8.4, 6.0, 5.4 Hz, 1H), 3.04 (ddd, J = 8.4, 6.0, 5.4 Hz, 1H), 0.91 (s, 9H), 0.85 (s, 
9H), 0.099 (s, 3H), 0.094 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) 
δ 171.9, 156.6, 155.6, 136.2, 130.3, 130.1 (2C), 129.0 (2C), 128.5 (2C), 128.1, 128.0 
(2C), 126.2, 117.2 (2C), 109.9, 92.9, 90.8, 71.3, 70.5, 66.9, 66.2, 62.6, 62.4, 54.8, 53.4, 
52.2, 37.3, 25.9 (6C), 18.4 (2C), -5.0, -5.2 (2C), -5.3; CIHRMS Calcd for 
[C42H62N4O10Si2Na+]: 861.3902.  Found 861.3910.  
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'-N -carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-
(tert-butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-
butyl-dimethylsilanyloxymethyl)-4-amino-1,4-dihydro-5H-pyran-( III-30). 
O
O
O OTBS
N
CO2CH3
H
Cbz
O
NH2
OTBS
 
To a solution of Azide III-32 (140 mg, 0.16 mmol) in THF/H2O (9:1, v/v, 0.3 ml) was 
added (n-Bu)3P (84 mg, 0.41 mmol), the mixture was stirred at room temperature for 1 h.  
Then the reaction mixture was dried with a little silica gel under reduced pressure and the 
crude product was purified using silica gel flash chromatography eluting with 
MeOH/EtOAc/hexane (10:40:50) to give allylic amine III-30 (100 mg, 0.12 mmol, 70%) 
as a colorless oil, Rf = 0.50 (10:40:50% MeOH/EtOAc/Hexane); [α]26  D  = + 24 (c = 1, 
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CH2Cl2); IR (thin film, cm-1) 3361, 2944, 2833, 1740, 1448, 1374, 1240, 1120, 1040, 
981, 847; 1H NMR (600 MHz, CD3OD) δ 7.27 (m, 5H), 6.99 (m, 4H), 6.21 (d, J = 9.6 
Hz, 1H), 5.91 (d, J = 10.2 Hz, 1H), 5.84 (ddd, J = 10.2, 10.2, 8.4 Hz, 1H), 5.69 (ddd, J = 
11.4, 10.2, 10.2 Hz, 1H), 5.59 (d, J = 2.4 Hz, 1H), 5.22 (br s, 1H), 5.02 (d, J = 12.6 Hz, 
1H), 4.95 (d, J = 12.6 Hz, 1H), 4.36 (m, 1H), 4.27 (d, J = 9.0 Hz, 1H), 3.91 (dd, J = 10.8, 
4.2 Hz, 1H), 3.86 (m, 1H), 3.83 (dd, J = 6.0, 3.0 Hz, 1H), 3.80 (dd, J = 10.2, 4.2 Hz, 1H), 
3.75 (dd, J = 10.8, 6.0 Hz, 1H), 3.65 (s, 3H), 3.50 (ddd, J = 9.6, 4.2, 3.6 Hz, 1H), 3.46 
(ddd, J = 9.0, 4.8, 4.2 Hz, 1H), 3.36 (dd, J = 11.4, 9.6 Hz, 1H), 3.03 (ddd, J = 8.4, 6.0, 5.4 
Hz, 1H), 2.85 (ddd, J = 8.4, 6.0, 5.4 Hz, 1H), 2.11 (s, 2H), 0.89 (d, J = 4.2 Hz, 9H), 0.79 
(d, J = 5.4 Hz, 9H), 0.77 (d, J = 4.2 Hz, 6H), -0.00 (s, 3H), -0.02 (d, J = 2.4 Hz, 3H); 13C 
NMR (150 MHz, CDCl3) δ  172.3, 172.0, 156.6, 155.7, 136.2, 131.7, 130.1 (2C), 129.1 
(2C), 128.4 (2C), 128.1 (2C), 126.4, 117.3 (2C), 92.9, 90.7, 71.6, 66.9, 63.6, 63.2, 54.8, 
52.2, 46.1, 44.0, 37.2, 26.1, 25.9 (3C), 25.8 (3C), 22.3, 18.4, 18.3, -5.1, -5.2, -5.3, -5.4; 
CIHRMS Calcd for [C42H64N2O10Si2H+]:  813.4177.  Found 813.4177. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-
(tert-butyl-dimethylsilanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy] -5-(tert-
butyl-dimethylsilanyloxymethyl)-1,4-dihydro-5H-pyran-N-4-isovalaric amide (III-
33).    
O
O
O OTBS
N
CO2CH3
H
Cbz
O
NH
OTBS
O
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The amine compound III-30 (100 mg, 0.12 mmol), isovaleric acid (15 mg, 0.15 mmol) 
and DCC (30 mg, 0.14 mmol) were dissolved in 0.3 mL of CH2Cl2 in a round bottom 
flask and cooled to 0 oC then DMAP (2 mg, 0.01 mmol) was added and the reaction 
mixture was stirred at 0
 
oC for 6 hours and on completion, as monitored by TLC, the 
reaction mixture was diluted with ether and was quenched with 5 mL of satd. aq. 
NaHCO3, extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under 
reduced pressure.  The crude product was purified using silica gel flash chromatography 
eluting with 30% EtOAc/hexanes to give amide III-33 (94 mg, 0.10 mmol, 85%) as 
viscous oil.  Rf (30% EtOAc/hexanes) = 0.70; [α]26  D  = + 4 (c = 1, CH2Cl2); IR (thin film, 
cm-1) 2985, 2927, 1736, 1447, 1372, 1253, 1098, 1043, 938, 846; 1H NMR (600 MHz, 
CDCl3) δ 7.33 (m, 5H), 7.00 (m, 4H), 6.20 (d, J = 10.8 Hz, 1H), 5.92 (ddd, J = 10.2, 3.0, 
1.8 Hz, 1H), 5.81 (d, J = 10.2 Hz, 1H), 5.71 (ddd, J = 10.2, 3.0, 2.4 Hz, 1H), 5.56 (d, J = 
2.4 Hz, 1H), 5.21 (m, 1H), 5.07 (br s, 2H), 4.58 (dd, J = 10.2, 5.4 Hz, 1H), 4.52 (d, J = 
8.4 Hz, 1H), 4.32 (d, J = 9.0 Hz, 1H), 3.90 (m, 1H), 3.86 (d, J = 11.4 Hz, 1H), 3.82 (m, 
2H), 3.76 (ddd, J = 11.4, 5.4, 4.8 Hz, 1H), 3.72 (dd, J = 11.4, 3.0 Hz, 1H), 3.69 (s, 3H), 
3.66 (dd, J = 3.0, 2.4 Hz, 1H), 3.64 (dd, J = 4.2, 2.4 Hz, 1H), 3.03 (m, 2H), 2.11 (m, 1H), 
2.00 (d, J = 7.8 Hz, 2H), 0.93 (d, J = 6.6 Hz, 6H), 0.87 (s, 9H), 0.80 (s, 9H), 0.04 (s, 3H), 
0.03 (s, 3H), 0.00 (s, 3H), -0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 171.9, 156.6, 
155.6, 136.2, 133.1, 130.5, 130.1, 129.0, 128.4 (2C), 128.1 (2C), 128.0 (2C), 126.1, 125.4 
(2C), 117.2 (2C), 92.8, 91.1, 71.4, 70.0, 66.9 (2C), 66.8, 66.7, 65.3 (2C), 62.6, 54.8, 52.2, 
37.3, 27.3, 25.9 (3C), 25.8 (3C), 24.0, 18.3, 18.2, -5.0, -5.1, -5.4, -5.6; CIHRMS Calcd 
for [C47H72N2O11Si2Na+]:  919.4572.  Found 919.4543. 
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1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-di-1,4-α-D-mannose -N-4 isovalaric amide (III-34): 
O
O
O OTBS
N
CO2CH3
H
Cbz
O
NH
OTBS
OOH
HO
OH
HO
 
To a CH2Cl2 (1.3 mL) solution of diene amide III-33 (120 mg, 0.13 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.1 mL).  
Crystalline OsO4 (3.4 mg, 10 mol %) was added and the reaction was stirred for 12 h.  
The reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with MeOH/EtOAc/hexanes (10:40:50).  Pure fractions were combined and 
concentrated to afford bis-manno-amido-tetrol III-34 (101 mg, 0.10 mmol, 78 %) as 
viscous oil.  Rf (90% EtOAc/MeOH) = 0.40; [α]26  D   = + 12.5 (c = 1, CH2Cl2); IR (thin 
film, cm-1) 2956, 2928, 1738, 1733, 1510, 1253, 1219, 1123, 986, 835; 1H NMR (600 
MHz, CDCl3) δ 7.30 (m, 5H), 6.98 (m, 4H), 5.45 (d, J = 1.2 Hz, 1H), 5.34 (d, J = 1.8 Hz, 
1H), 5.22 (d, J = 1.8 Hz, 1H), 5.01 (d, J = 12.6 Hz, 1H), 5.00 (d, J = 12.6 Hz, 1H), 4.50 
(br s, 1H), 4.37 (dd, J = 8.4, 5.4 Hz, 1H), 4.34 (dd, J = 9.0, 4.8 Hz, 1H), 4.06 (dd, J = 
14.4, 7.2 Hz, 1H), 4.02 (dd, J = 6.6, 6.6 Hz, 1H), 3.99 (dd, J = 9.0, 4.2 Hz, 1H), 3.93 (dd, 
J = 6.0, 4.2 Hz, 1H), 3.91 (m, 1H), 3.85 (d, J = 11.4 Hz, 1H), 3.82 (dd, J = 6.0, 5.4 Hz, 
1H), 3.81 (dd, J = 9.6, 5.4 Hz, 1H), 3.73 (dd, J = 6.6, 3.0 Hz, 1H), 3.72 (d, J = 3.0 Hz, 
1H), 3.70 (dd, J = 3.0, 1.8 Hz, 1H), 3.68 (dd, J = 6.0, 1.8 Hz, 1H), 3.65 (s, 3H), 3.60 (m, 
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1H), 3.03 (dd, J = 9.6, 4.8 Hz, 1H), 3.02 (dd, J = 9.0, 4.8 Hz, 1H), 2.86 (dd, J = 9.0, 4.2 
Hz, 1H), 2.84 (dd, J = 9.6, 4.2 Hz, 1H), 2.15 (m, 1H), 2.04 (dd, J = 5.4, 1.8 Hz, 1H), 2.02 
(dd, J = 4.8, 1.2 Hz, 1H), 0.87 (d, J = 6.0 Hz, 6H), 0.81 (s, 9H), 0.80 (s, 9H), 0.05 (s, 3H), 
0.03 (s, 3H), 0.00 (s, 3H), -0.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  173.0, 172.9, 
157.3, 155.9, 137.1, 131.1, 130.3 (2C), 128.4 (2C), 127.9, 127.6 (2C), 116.9 (2C), 101.1, 
99.0, 73.7, 73.5, 72.5, 72.1, 71.3 (2C), 69.7, 69.4, 66.5, 64.1, 63.3, 56.0, 51.6, 43.5 (2C), 
36.81, 30.9, 28.8, 25.8 (2C), 25.5 (3C), 21.8, 18.3, 18.2, -5.7, -5.9, -6.1, -6.3; CIHRMS 
Calcd for [C47H76N2O15Si2Na+]:  987.4682.  Found 987.4680. 
 
1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(hydroxy methyl)-di-1,4-α-
D-mannose –N-4 isovaleric amide (III-29). 
O
O
O OH
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OH
HO
 
To a THF (0.4 mL, 0.1 M) solution of  D-manno-tetrol III-34 (40 mg, 0.04 mmol) at 0 oC 
was added a solution of TBAF in THF (85 µL, 0.08 mmol)  and the reaction was stirred 
for 1 h.  The reaction mixture was concentrated and was pipetted directly on to a silica 
gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and 
the product was eluted with MeOH/EtOAc/Hexane (20:40:40).  Pure fractions were 
combined and concentrated to afford hexol III-29 (31 mg, 0.04 mmol, 80 %) as viscous 
oil.  Rf (10:50:40% MeOH/EtOAc/Hexane) = 0.20; [α]26  D   = + 15 (c 0.5, CH3OH); IR 
 147
(thin film, cm-1) 3330, 2960, 2928, 1735, 1621, 1511, 1232, 1092, 983, 829; 1H NMR 
(600 MHz, CDCl3) δ 7.30 (m, 5H), 6.99 (m, 4H), 5.39 (d, J = 1.2 Hz, 1H), 5.33 (d, J = 
1.8 Hz, 1H), 5.23 (d, J = 1.8 Hz, 1H), 5.00 (m, 2H), 4.37 (dd, J = 5.4, 4.8 Hz, 1H), 4.35 
(dd, J = 5.4, 4.2 Hz, 1H), 4.16 (dd, J = 11.4, 6.6 Hz, 1H), 4.01 (dd, J = 9.0, 3.6 Hz, 1H), 
3.96 (dd, J = 9.6, 6.6 Hz, 1H), 3.91 (dd, J = 3.6, 1.8 Hz, 1H), 3.80 (dd, J = 9.6, 3.0 Hz, 
1H), 3.74 (dd, J = 8.4, 4.8 Hz, 1H), 3.71 (dd, J = 8.4, 4.2 Hz, 1H), 3.67 (d, J = 3.0 Hz, 
1H), 3.65 (m, 3H), 3.60 (dd, J = 9.0, 4.2 Hz, 1H), 3.58 (dd, J = 9.6, 4.2 Hz, 1H), 3.53 (dd, 
J = 5.4, 3.0 Hz, 1H), 3.15 (dd, J = 5.4, 2.4 Hz, 1H), 3.05 (dd, J = 9.0, 4.8 Hz, 1H), 3.04 
(dd, J = 9.6, 4.8 Hz, 1H), 2.84 (m, 2H), 2.22 (dd, J = 4.8, 1.8 Hz, 1H), 2.19 (dd, J = 5.4, 
1.8 Hz, 1H), 2.04 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H);  NMR (150 MHz, CDCl3) δ 174.5, 
174.0, 158.4, 156.8, 138.2, 132.2, 131.4 (2C), 129.5 (2C), 129.0, 128.7 (2C), 117.8, 
102.8, 103.4, 100.1, 75.7, 74.9, 74.0, 73.8, 73.6, 73.0, 72.5, 70.6, 67.6, 65.2, 62.8, 62.4, 
57.1, 52.8, 44.4, 37.9, 26.8, 22.9; CIHRMS Calcd for [C35H48N2O15Na+]:  759.2947.  
Found 759.2940. 
 
1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-2,3,2’,3’-di acetonide-bis-1,4-α-D-mannose-N-4-
isovalaric amide (III-35). 
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O OTBS
N
CO2CH3
H
Cbz
O
NH
OTBS
OO
O
O
O
 
 148
To a CH2Cl2 (0.1 mL, 1.0M) solution of D-manno-amido-tetrol III-34 (10 mg, 0.01 
mmol) and 2,2-dimethoxypropane (2.4 mg, 0.02 mmol) at 0 oC was added CSA (0.23 mg, 
10 mol%) and the reaction was stirred for 3 h.  The reaction mixture was concentrated 
and was pipetted directly on to a silica gel column using CH2Cl2 (1 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with EtOAc/Hexane 
(50:50).  Pure fractions were combined and concentrated to afford di-acetonide III-35 (9 
mg, 0.01 mmol, 80 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.40; [α]26  D   = +65 (c 
1, CH2Cl2); IR (thin film, cm-1) 2951, 2930, 1731, 1498, 1228, 1009, 831; 1H NMR (600 
MHz, CDCl3) 7.34 (m, 5H), 6.98 (m, 4H), 5.77 (d, J = 10.8 Hz, 1H), 5.39 (d, J = 8.4 
Hz, 1H), 5.20 (d, J = 7.8 Hz, 1H), 5.09 (br s, 2H), 4.62 (dd, J = 7.2, 4.8 Hz, 1H), 4.44 
(dd, J = 6.0, 1.2 Hz, 1H), 4.32 (d, J = 5.4 Hz, 1H), 4.16 (d, J = 5.4 Hz, 1H), 4.09 (d, J = 
4.8 Hz, 1H), 4.08 (dd, J = 10.2, 4.8 Hz, 1H), 3.95 (m, H), 3.72 (s, 3H), 3.69 (m, 2H), 3.69 
(m, 1H), 3.62 (d, J = 3.6 Hz, 1H), 3.55 (dd, J = 10.2, 3.0 Hz, 1H), 3.09 (dd, J = 13.2, 6.0 
Hz, 1H), 3.03 (dd, J = 12.8, 6.0 Hz, 1H), 2.16 (s, 1H), 2.15 (m, 1H), 2.12 (dd, J = 4.8, 1.2 
Hz, 1H), 2.09 (m, 1H), 2.05 (d, J = 3.6 Hz, 1H), 1.65 (s, 3H), 1.50 (s, 3H), 1.38 (s, 3H), 
1.35 (s, 3H), 0.95 (d, J = 6.6 Hz, 6H), 0.87 (s, 9H), 0.84 (s, 9H), 0.42 (s, 3H), 0.03 (s, 
6H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) 173.1, 171.8, 155.5, 137.5, 130.3, 128.7 
(2C), 128.6 (2C), 128.5, 128.4 (2C), 128.0 (2C), 127.8, 116.7, 109.9, 97.5, 92.9 (2C), 
76.1, 75.7, 71.4, 70.0, 69.9 (2C), 69.5 (2C), 69.3, 62.7 (2C), 58.8(2C), 56.4, 52.2, 43.3, 
38.5, 34.5, 28.8(2C), 28.7 (2C), 27.5, 26.4, 25.9 (2C), 25.7, 18.6, 18.3, -5.1, -5.2 (2C), -
5.3; CIHRMS Calcd for [C53H84N2O15Si2H+]: 1045.5488.  Found 1045.5503. 
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(1'S,4'S,5'R,1S,4S,5R)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-(tert-
butyl-dimethylsilanyloxymethyl)-tetrahydro-pyran-4'-yloxy]-5-(tert-butyl-
dimethylsilanyloxymethyl) -tetrahydro-pyran-N-4-isovalaric amide (III-36). 
O
O
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The dieno-amide compound III-33 (70 mg, 0.07 mmol) and o-NO2C6H4SO2NHNH2 (170 
mg, 1.17 mmol) were dissolved in 0.8 mL of CH2Cl2 in a round bottom flask and cooled 
0 oC under nitrogen atmosphere then triethylamine (112 mg, 1.56 mmol) was added and 
the reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with 25% EtOAc/hexanes to give di-deoxy 
pyranoside III-36 (68 mg, 0.07 mmol, 95 %) as viscous oil.  Rf (30% EtOAc/Hexane) = 
0.50; [α]26  D   = + 37 (c 1, CH2Cl2); IR (thin film, cm
-1) 2932, 2927, 1725, 1509, 1220, 
1055, 965, 836; 1H NMR (600 MHz, CDCl3) δ 7.33 (m, 5H), 6.98 (m, 4H), 5.43 (br s, 
1H),  5.26 (d, J = 7.8 Hz, 1H), 5.07 (br s, 2H), 4.58 (dd, J = 12.8, 5.4 Hz, 1H), 3.87 (dd, J 
= 9.0, 7.2 Hz, 1H), 3.73 (d, J = 3.0 Hz, 1H), 3.72 (m, 2H), 3.69 (m, 3H), 3.65 (dd, J = 
6.0, 5.4 Hz, 1H), 3.63 (dd, J = 6.0, 4.8 Hz, 1H), 3.50 (dd, J = 10.2, 4.2 Hz, 1H), 3.47 (m, 
1H), 3.03 (dd, J = 14.4, 5.4 Hz, 1H), 3.01 (dd, J = 14.4, 5.4 Hz, 1H), 2.13 (m, 1H), 2.01 
(dd, J = 13.2, 7.8 Hz, 1H), 1.99 (dd, J = 13.2, 7.8 Hz, 1H), 1.95 (m, 1H), 1.85 (dd, J = 
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8.4, 4.2 Hz, 1H), 1.82 (m, 1H), 1.79 (dd, J = 8.4, 3.6 Hz, 1H), 1.76 (dd, J = 7.8, 3.6 Hz, 
1H), 1.74 (dd, J = 7.8, 4.2 Hz, 1H), 1.68 (m, 2H), 1.06 (m, 2H), 0.88 (d, J = 6.0 Hz, 6H), 
0.81 (s, 9H), 0.80 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H), -0.02 (s, 3H), -0.03 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ  172.0, 156.2, 136.2, 130.0 (2C), 128.6 (2C), 128.4 (2C), 
128.1 (2C), 128.0 (2C), 116.9 (2C), 94.9, 90.8, 74.0, 73.5, 72.1, 67.2, 66.9, 64.3, 63.5, 
54.8, 54.7, 52.2 (2C), 47.3, 47.2, 37.3, 29.4, 28.7, 26.0 (3C), 25.9 (3C), 25.8, 22.2, 18.36, 
18.33,  -5.0, -5.1, -5.2, -5.3; CIHRMS Calcd for [C47H76N2O11Si2Na+]:  923.4885.  Found 
923.4886. 
 
(1R,5S)-1-N-Carbobenzyloxy-L-serine methyl ester-5-(tert-butyl-dimethyl-
silanyloxymethyl)-1H-pyran-2-one (III-39a). 
OO OTBS
N
O
Cbz H
H3CO
O
 
 
A CH2Cl2 (1 mL) solution of compound (ent)-III-18 (358 mg, 1 mmol) and N-
carbobenyloxy-L-serine methyl ester 9h (506 mg, 2 mmol) was cooled to 0 °C.  A 
CH2Cl2 (1 mL) solution of Pd2(DBA)3•CHCl3 (25 mg, 2.5 mol%) and PPh3 (26 mg, 10 
mol%) was added to the reaction mixture at 0 °C.  The reaction mixture was stirred at 0 
°C for 3 hours.  The reaction mixture was quenched with 5 mL of satd aq NaHCO3, 
extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced 
pressure.  The crude product was purified using silica gel flash chromatography eluting 
with 14% EtOAc/hexanes to give 430 mg (0.87 mmol, 87%) of III-39a:  Rf (40% 
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EtOAc/hexanes) = 0.46; [α]26  D   = -2 (c = 1.5, CH2Cl2); IR (thin film, cm
-1) 2956, 1726, 
1701, 1518, 1213, 1021, 836; 1H NMR (270 MHz, CDCl3) δ 7.34 (m, 5H), 6.77 (dd, J = 
10.0, 3.5  Hz, 1H), 6.06 (d, J = 10.2 Hz, 1H), 5.70 (d, J = 8.7 Hz, 1H), 5.26 (d, J = 3.3 
Hz, 1H), 5.12 (br s, 2H), 4.60 (ddd, J = 8.7, 3.1, 3.1 Hz, 1H), 4.26 (m, 2H), 4.24 (d, J = 
3.5 Hz, 1H), 3.99 (m, 2H) 3.84 (dd, J = 9.8, 3.1 Hz,  1H), 3.72 (s, 3H), 0.85 (s, 9H), 0.05 
(s, 6H); 13C NMR (67.5 MHz, CDCl3) δ 194.4, 170.2, 156, 143.1, 136, 128.6, 128.5, 
128.3, 128.2, 93.1, 76.2, 68.5, 67.2, 62.6, 54.0, 52.7, 25.8 (3C), 18.3, -5.3(2C); CIHRMS 
Calcd for [C24H35NO8Si+H]+:  494.2210.  Found 494.2244. 
 
3-{4-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-hydroxy-5,6-dihydro-2H-pyran-2-
yloxy]-phenyl}-2- N-Carbobenzyloxy-L-serine methyl ester (III-39b). 
OO OTBS
N
OH
Cbz H
H3CO
O
 
 
A CH2Cl2 (0.7 mL) solution of compound III-39a (352 mg, 0.713 mmol) and MeOH (0.7 
mL) was cooled to -78 °C.  NaBH4 (26 mg, 0.713 mmol) was added and the reaction 
mixture was stirred at -78°C for 3 hours. The reaction mixture was diluted with ether (10 
mL) and was quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 25% EtOAc/hexanes to give 
310 mg (0.685 mmol, 87%) of III-39b:  Rf (50% EtOAc/hexanes) = 0.34; [α]26  D   = + 1 (c 
= 0.7, CH2Cl2); IR (thin film, cm-1) 3437, 2953, 1725, 1517, 1213, 1076, 1009, 838; 1H 
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NMR (270 MHz, CDCl3) δ 7.36 (m, 5H), 5.90 (d, J = 10.1  Hz, 1H), 5.73 (d, J = 8.6  Hz, 
1H), 5.64 (ddd, J = 10.1, 2.4, 2.4 Hz, 1H), 5.10 (br s, 2H), 4.87 (s, 1H), 4.55 (ddd, J = 
6.6, 3.2, 3.2 Hz, 1H), 4.15 (ddd, J = 9.8, 3.2, 3.2 Hz, 2H), 3.86 (dd, J = 10.3, 5.2 Hz, 1H), 
3.78-3.66 (m, 5H), 3.54 (dd, J = 8.9, 5.9 Hz, 1H), 3.12 (s, 1H), 0.89 (s, 9H), 0.89 (s, 6H); 
13C NMR (67.5 MHz, CDCl3) δ  170.4, 155.9, 136.0, 133.1, 128.4 (2C), 128.1, 128.0 
(2C), 124.9, 93.8, 70.3, 67.6, 66.9, 66.1, 64.7, 54.1, 52.4, 25.7 (3C), 18.1, -5.6 (2C); 
CIHRMS Calcd for [C24H37NO8SiNa+]: 518.2186  Found 518.2187. 
 
(1'R, 4'R, 5'S, 1R, 5S)-1-[1'-N-Carbobenzyloxy-L-serine methyl ester -5-(tert-butyl-
dimethyl-silanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethyl-silanyloxymethyl) -1H-pyran-4-one (III-39). 
 
O
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O O
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O
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A CH2Cl2 (0.3 mL) solution of compound (ent)-III-18 (120 mg, 0.23 mmol) and alcohol 
III-39b (101 mg, 0.28 mmol) was cooled to 0 oC.  A CH2Cl2 (0.3 mL) solution of 
Pd2(DBA)3.CHCl3 (6 mg, 2.5 mol%) and PPh3 (6.1 mg, 10 mol%) was added to the 
reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 2 hours.  The 
reaction mixture was quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with 
Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 
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III-39 (149 mg, 0.20 mmol, 85%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.30; [α]26  D   
= +19 (c = 1, CH2Cl2); IR (thin film, cm-1) 3350, 2927, 1723, 1700, 1507, 1251, 1015, 
830;  1H NMR (600 MHz, CDCl3) δ 7.36 (m, 5H), 6.80 (dd, J = 10.2, 3.6 Hz, 1H), 6.23 
(d, J = 10.2 Hz, 1H), 6.06 (d, J = 10.2 Hz, 1H), 5.76 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 5.62 
(d, J = 8.4 Hz, 1H), 5.55 (d, J = 3.0 Hz, 1H), 5.12 (br s, 1H), 4.96 (d, J = 7.2 Hz, 1H), 
4.56 (ddd, J = 7.8, 3.0, 3.0 Hz, 1H), 4.43 (dd, J = 9.6, 1.8 Hz, 1H), 4.40 (dd, J = 4.2, 2.4 
Hz, 1H), 4.19 (dd, J = 9.6,3.6 Hz, 1H), 4.12 (dd, J = 13.8, 6.6 Hz, 1H), 4.09 (dd, J = 11.4, 
4.2 Hz, 1H), 3.95 (dd, J = 10.8, 2.4 Hz, 1H), 3.80 (dd, J = 11.4, 1.8 Hz, 1H), 3.75 (dd, J = 
11.4, 4.8 Hz, 1H), 3.73 (s, 3H), 3.63 (dd, J = 4.8, 1.8 Hz, 1H), 3.62 (dd, J = 5.4, 2.4 Hz, 
1H), 0.88 (s, 9H), 0.85 (s, 9H), 0.06 (s, 6H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (150 
MHz, CDCl3) δ  194.6, 170.4, 155.9, 143.9 (2C), 136.1, 129.2, 128.5 (2C), 128.5, 128.2, 
128.1, 126.8, 94.0, 89.7, 70.5, 67.6, 67.0, 66.8, 62.9, 62.7, 60.3, 54.1, 52.5, 25.9 (3C), 
25.8 (3C), 18.4, 18.3, -5.1, -5.3, -5.3, -5.4; CIHRMS Calcd for [C36H57NO11Si2Na+]: 
758.3362. Found 758.3378. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[ N-Carbobenzyloxy-L-serine methyl ester -5'-(tert-butyl-
dimethyl-silanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethyl-silanyloxymethyl)-1,4-dihydro-5H-pyran-4-ol (III-40a). 
O
OTBS
O O
OTBS
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OH
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The ketone compound III-39 (328 mg, 0.439 mmol), was dissolved in 0.4 mL of CH2Cl2 
and 0.4 mL MeOH were added to a round bottom flask and cooled -78 oC then (16.6 mg,  
0.439 mmol) NaBH4 was added and the reaction mixture was stirred at -78oC for 6 hours 
and on completion monitored by TLC, reaction mixture is diluted with ether and was 
quenched with 5 mL of satd. aq NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 25% EtOAc/hexanes to give III-40a 
(279.6 mg, 0.37 mmol, 85%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.25;  [α]26  D   = -
5 (c = 1, CH2Cl2); IR (thin film, cm-1) 3450, 2929, 17.16, 1500, 1249, 1039, 829, 777; 1H 
NMR (600 MHz, CDCl3) δ 7.36 (m, 5H), 5.98 (d, J = 10.2 Hz, 1H), 5.95 (dd, J = 10.2, 
1.2 Hz, 1H), 5.73 (ddd, J = 9.6, 3.0, 1.8 Hz, 1H), 5.65 (dd, J = 2.4, 1.8 Hz, 1H), 5.64 (dd, 
J = 2.4, 1.8 Hz, 1H), 5.13 (br s, 2H ), 5.11 (br s, 1H ),  4.91 (d, J = 1.2 Hz, 1H), 4.56 
(ddd, J = 7.2, 3.0, 3.0 Hz, 1H), 4.23 (dd, J = 9.0, 2.4 Hz, 1H), 4.23 (dd, J = 9.6, 1.8 Hz, 
1H), 4.20 (ddd, J = 10.8, 1.8, 1.8 Hz, 1H), 3.94 (dd, J = 9.6, 4.2 Hz, 1H), 3.87 (dd, J = 
10.2, 1.8 Hz, 1H), 3.74 (s, 3H), 3.73 (d, J = 1.8 Hz, 1H), 3.71 (dd, J = 6.0, 2.4 Hz, 1H), 
3.69 (dd, J = 9.6, 4.2 Hz, 1H), 3.66 (dd, J = 7.8, 4.2 Hz, 1H), 3.64 (d, J = 1.8 Hz, 1H), 
3.03 (d, J = 2.4 Hz, 1H), 0.91 (s, 9H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H), 0.08 (s, 
3H), 0.07 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 170.4, 156.0, 136.2, 133.0 (2C), 129.8, 
128.5 (2C), 128.2, 128.1, 126.3, 125.4, 93.8, 91.0, 70.5, 69.9, 67.5, 67.1, 67.0, 66.9, 65.4, 
62.9, 54.1, 52.5, 25.9 (3C), 25.8 (3C), 18.4, 18.2, -5.1, -5.2, -5.4, -5.6; CIHRMS Calcd 
for [C36H59NO11Si2Na+]:  760.3518.  Found 760.3543. 
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1’(2' N-Carbobenzyloxy-L-serine methyl ester -1'-yloxy)- -5’,5-(tert-butyl-dimethyl-
silanyloxymethyl)-bis-1,4-α-L-mannose (III-40b). 
O
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O O
OTBS
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OH
OH
HO
HO
 
A CH2Cl2 (0.7 mL, 1mol) solution of compound of allyl alcohol III-40a (55 mg, 0.07 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
water (0.05 mL).  Crystalline OsO4 (1.0 mg, 5 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column using a small amount of CH2Cl2 (1 mL) in three portions.  The crude 
product was purified using silica gel flash chromatography eluting with 100 % EtOAc to 
give III-40b (50 mg, 0.06 mmol, 86 %) as viscous oil.  Rf (40:10:50  
EtOAc/MeOH/Hexane) = 0.20; [α]26  D   =  -45  (c = 1, CH2Cl2); IR (thin film, cm
-1) 3419, 
2929, 2856, 1720, 1508, 1264, 1094, 1028, 970, 836; 1H NMR (600 MHz, CDCl3) δ 7.33 
(m, 5H), 5.82 (d, 8.4 Hz, 1H), 5.16 (s, 1H), 5.09 (br s, 2H ), 4.72 (d, 1.2 Hz, 1H), 4.55 
(dd, J = 5.4, 2.4 Hz, 1H), 4.09 (ddd, J = 10.2, 2.4, 1.8 Hz, 1H), 3.96 (d, J = 2.4 Hz, 1H), 
3.84 (d, J = 6.0 Hz, 1H), 3.81 (dd, J = 9.6, 4.8 Hz, 1H), 3.79 (d,  J = 4.8 Hz, 1H), 3.75 (br 
s, 1H), 3.74 (d, J = 2.4 Hz, 1H ), 3.72 (s, 3H), 3.67 (d,  J = 6.0 Hz, 1H), 3.64 (dd,  J = 9.0, 
5.4 Hz, 1H), 3.58 (dd, J = 10.2, 2.4 Hz, 1H), 3.43 (d,  J = 3.0 Hz, 1H), 3.38 (dd, J = 15.6, 
7.2 Hz, 1H), 3.13 (d,  J = 2.4 Hz, 1H), 0.88 (s, 9H), 0.87 (s, 9H), 0.08 (s, 3H), 0.07 (s, 
3H), 0.05 (s, 6H);  13C NMR (67.5 MHz, CDCl3) δ  172.0, 158.4, 138.0, 129.4 (2C), 
129.0, 128.8 (2C), 102.5, 100.9, 75.4, 75.3, 73.9, 72.9, 72.5, 72.2, 72.0, 68.4, 67.7, 67.6, 
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64.8, 64.6, 55.4, 52.9, 26.6 (3C), 26.5 (3C), 19.4, 19.2, -4.8 (2C), -4.9, -5.0; CIHRMS 
Calcd for [C36H63NO15Si2Na+]:  828.3628.  Found 828.3646. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[1'-N-Carbobenzyloxy-L-serine methyl ester -5'-(tert-
butyl-dimethyl-silanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy] -5-(tert-butyl-
dimethyl-silanyloxymethyl)-1,4-dihydro-5H-pyran-4-isovalaric ester (III-40). 
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The alcohol compound III-40a (278 mg, 0.371 mmol), isovaleric acid (45.2 mg, 0.445 
mmol) and DCC (91.7 mg, 0.445 mmol) were dissolved in 0.7 mL of CH2Cl2 in a round 
bottom flask and cooled 0 oC then (4.5mg, 0.1 mmol) DMAP was added and the reaction 
mixture was stirred at 0oC for 6 hours and on completion monitored by TLC, reaction 
mixture is diluted with ether and was quenched with 5 mL of satd aq NaHCO3, extracted 
(3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The 
crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexanes to give III-40 (280 mg, 0.34 mmol, 91%) as viscous oil.  Rf (30% 
EtOAc/hexanes) = 0.50; [α]26  D   = -76 (c = 1, CH2Cl2); IR (thin film, cm
-1) 2928, 1738, 
1464, 1510, 1254, 1092, 1005, 836; 1H NMR (600 MHz, CDCl3)  δ 7.34 (m, 5H), 6.03 (d, 
J = 10.2 Hz, 1H), 5.92 (d, J = 10.2 Hz, 1H), 5.74 (dd, J = 10.2, 3.0 Hz, H), 5.71 (dd, J = 
10.8, 2.4 Hz, 1H), 5.39 (dd, J = 9.0, 1.2 Hz, 1H), 5.21 (d, J = 2.4 Hz, 1H), 5.13 (br s, 2H), 
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4.92 (br s, 1H), 4.55 (dd, J = 6.6, 3.0 Hz, 1H), 4.26 (d, J = 9.6 Hz, 1H), 4.20 (dd, J = 9.6, 
3.6 Hz, 1H), 3.88 (d, J = 1.8.0 Hz, 1H), 3.86 (dd, J = 3.0, 1.8 Hz, 1H), 3.84 (ddd, J = 7.2, 
2.4, 2.4 Hz, 1H), 3.75 (d, J = 3.0 Hz, 1H), 3.73 (s, 3H), 3.72 (dd, J = 10.2, 3.6 Hz, 1H), 
3.71 (dd, J = 6.6, 3.6 Hz, 1H), 3.68 (d, J = 1.8 Hz, 1H), 3.67 (dd, J = 6.0, 3.0 Hz, 1H), 
2.21 (d, J = 1.8 Hz, 1H), 2.19 (d, J = 1.8 Hz, 1H), 2.10 (m, 1H), 0.96 (d, J = 7.2 Hz, 6H), 
0.90 (s, 9H), 0.88 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.04 (s, 3H), 0.04 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ  173.7, 172.1, 158.4, 138.1, 130.5, 130.4, 129.4 (2C), 129.0, 128.9 
(2C), 128.8, 127.7, 95.3, 92.3, 72.0, 70.9, 68.4, 68.1, 67.7, 65.9, 64.4, 63.4, 55.6, 52.8, 
44.2, 26.9, 26.6 (3C), 26.4 (5C), 22.7, 22.7, 19.4, 19.2, -4.8, -4.9, -5.0, -5.1; CIHRMS 
Calcd for [C41H67NO12Si2Na+]:  844.4094.  Found 844.4116. 
 
1'-N-Carbobenzyloxy-L-serine methyl ester -5',5-(tert-butyl-dimethyl-
silanyloxymethyl)-bis-1,4-α-L-mannose - isovalaric ester (III-41). 
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A CH2Cl2 (0.3 mL, 1Mol) solution of compound of allyl alcohol III-40 (106 mg, 0.127 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
water (0.10 mL).  Crystalline OsO4 (1.6 mg, 5 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column using a small amount of CH2Cl2 (1 mL) in three portions.  The crude 
product was purified using silica gel flash chromatography eluting with 50:30:20 ( EtOAc 
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: Hexane : Methanol) to give III-41 (140 mg, 0.16 mmol, 94 %) as viscous oil.  Rf (60:40  
EtOAc/Hexane) = 0.20; [α]26  D   = -46 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3448, 2954, 
2928, 1725, 1517, 1463, 1252, 1210, 1097, 834; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 
5H), 5.70 (d, J = 9.0 Hz, 1H), 5.28 (br s, 1H), 5.13 (br s, 2H), 4.98 (dd, J =  9.0, 9.0 Hz, 
1H), 4.76 (d, J = 3.0 Hz, 1H), 4.57 (dd, J = 5.4, 3.0 Hz, 1H), 4.12 (ddd, J = 10.2, 3.6, 3.6 
Hz, 1H), 3.91 (d, J = 4.8 Hz, 1H), 3.88 (dd, J = 9.6, 4.8 Hz, 1H), 3.87 (dd, J = 9.6, 4.2 
Hz, 1H), 3.84 (d, J = 10.2, 3.0 Hz, 1H), 3.82 (d, J = 6.0, 3.0 Hz, 1H), 3.74 (s, 3H), 3.69 
(d, J = 4.2 Hz, 1H), 3.68 (br s, 1H), 3.63 (dd, J = 9.6, 2.4 Hz, 1H), 3.46 (ddd, J = 8.4, 6.0, 
3.0 Hz, 1H), 3.28 (d, J = 3.0 Hz, 1H), 3.15 (d, J = 7.2 Hz, 1H), 2.82 (d, J = 3.0 Hz, 1H), 
2.24 (dd, J = 14.4, 7.2 Hz, 1H), 2.19 (dd, J = 14.4, 7.2 Hz, 1H),  2.11 (m, 1H), 0.96 (d, J 
= 7.2 Hz, 6H), 0.90 (s, 9H), 0.88 (s, 9H), 0.07 (s, 6H), 0.06 (s, 3H), 0.05 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ  173.5, 170.4, 155.9, 136.0, 128.5 (3C), 128.2, 128.1, 98.9, 
98.0, 73.6, 71.7, 71.4, 70.9, 70.8, 70.1, 70.0, 69.8, 67.1, 67.0, 63.1, 62.9, 53.9, 52.6, 43.4, 
25.8 (6C), 25.7, 22.3, 22.3, 18.4, 18.3, -5.2, -5.3, -5.4, -5.5; CIHRMS Calcd for 
[C41H71NO16Si2Na+]:  912.4203.  Found 912.4209. 
             
(1'R,4'R,5'S,1R,4R,5S)-1-[1'-N-Carbobenzyloxy-L-serine methyl ester -5'-(tert-
butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran-4'-yloxy]-5-(tert-butyl-
dimethyl-silanyloxymethyl) -tetrahydro-pyran-4-isovalaric ester (III-43). 
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The allyl alcohol compound III-40 (49 mg, 0.058 mmol), O-NO2ArSO2NHNH2  (71.6 
mg, 0.353 mmol) were dissolved in 0.6 mL of CH2Cl2 in a round bottom flask and cooled 
0 oC under nitrogen condition then triethylamine (47.6 mg, 0.471 mmol)  was added and 
the reaction mixture was stirred at 0 oC for 12 hours and on completion monitored by 
TLC, reaction mixture is three portions.  The crude product was purified using silica gel 
flash chromatography eluting with 20% EtOAc/hexanes to give III-43 (48.3 mg, 0.057 
mmol, 98 %) as viscous oil.  Rf (30% EtOAc/Hexane) = 0.60; [α]26  D   = -69 (c = 1, 
CH2Cl2); IR (thin film, cm-1) 2953, 2928, 1734, 1508, 1462, 1251, 1205, 1122, 993, 833; 
1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 5.61 (d, J = 9.0 Hz, 1H), 5.14 (br s, 2H), 
5.00 (d, J = 2.4 Hz, 1H), 4.74 (d, J = 2.4 Hz, 1H), 4.70 (ddd, J = 10.2, 9.6, 4.8 Hz, 1H), 
4.57 (ddd, J = 6.6, 3.6, 3.0 Hz, 1H), 4.13 (dd, J = 10.2, 3.6 Hz, 1H), 3.92 (dd, J = 10.2, 
1.8 Hz, 1H), 3.75 (s, 3H), 3.72 (dd, J = 10.8, 5.4 Hz, 1H), 3.69 (d, J = 2.4 Hz, 1H), 3.68 
(dd, J = 4.8, 1.8 Hz, 1H), 3.67 (d, J = 2.4 Hz, 1H), 3.64 (m, 1H), 3.60 (dd, J = 10.2, 3.0 
Hz, 1H), 3.55 (ddd, J = 10.8, 10.2, 4.2 Hz, 1H), 3.44 (m, 1H), 2.15 (d, J = 2.4 Hz, 1H), 
2.14 (d, J = 1.2 Hz, 1H), 2.12-2.04 (m, 4H), 1.79-1.42 (m, 4H), 0.95 (d, J = 6.6 Hz, 6H), 
0.91 (s, 9H), 0.87 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.02 (s, 3H), 0.02 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ  172.0, 170.0, 155.9, 136.1, 128.5 (3C), 128.2, 128.1, 95.9, 90.3, 
73.1, 71.6, 67.6, 67.0, 66.4 (2C), 63.4, 62.7, 54.0, 52.3, 43.6 (3C), 28.7, 28.2, 26.0 (3C), 
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25.9 (3C), 25.7, 23.7, 22.4, 22.3, 22.1, 18.4, 18.3, -5.1, -5.3, -5.3, -5.4; CIHRMS Calcd 
for [C41H71NO12Si2Na+]:  848.4407. Found 848.4392. 
 
(1R,5S)-1-N-Carbobenzyloxy-L-threonine methyl ester-5-(tert-butyl-dimethyl-
silanyloxymethyl)-1H-pyran-2-one (III-45a).  
O
O
O OTBS
N
H3COOC
CbzH
 
A CH2Cl2 (1 mL) solution of compound (ent)-III-18 (716 mg, 1.396 mmol) and N-
Carbobenyloxy-L-threonine methyl ester III-44 (447 mg, 1.675 mmol) was cooled to 0 
oC.  A CH2Cl2 (0.4 mL) solution of Pd2(DBA)3.CHCl3 (36 mg, 2.5 mol%) and PPh3 (33 
mg, 10 mol%) was added to the reaction mixture at 0 oC.  The reaction mixture was 
stirred at 0 oC for 3 hours.  The reaction mixture was quenched with 5 mL of satd aq 
NaHCO3, extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under 
reduced pressure.  The crude product was purified using silica gel flash chromatography 
eluting with 16% EtOAc/hexanes to give 914 mg (1.802 mmol, 90%) of III-45a:  Rf 
(20% EtOAc/hexanes) = 0.34; [α]26  D  = - 45 (c = 1.5, CH2Cl2); IR (thin film, cm
-1) 2953, 
1727, 1702, 1514, 1215, 1022, 836; 1H NMR (270 MHz, CDCl3) δ 7.33 (m, 5H), 6.72 
(dd, J = 10.3, 3.5  Hz, 1H), 6.07 (d, J = 10.3 Hz, 1H), 5.47 (d, J = 9.7 Hz, 1H), 5.36 (d, J 
= 3.6 Hz, 1H), 5.14 (br s, 2H), 4.58 (qd, J = 6.3, 2.4 Hz, 1H), 4.44 (dd, J = 9.7, 2.4 Hz, 
1H), 4.22 (dd, J = 4.1, 2.7 Hz, 1H), 4.04 (dd, J = 11.0, 4.3 Hz, 1H), 3.92 (dd, J = 11.0, 
2.5 Hz, 1H), 3.70 (s, 3H), 1.29 (d, J = 6.3, 3H), 0.85 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 
13C NMR (67.5 MHz, CDCl3) δ 194.2, 171.1, 156.6, 143.4, 136.0, 128.5 (2C), 128.3, 
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128.2, 128.1, 89.7, 76.0, 76.1, 72.1, 67.2, 62.5, 58.5, 52.5, 25.8 (3C), 18.3, 15.9, -5.3, -
5.4; CIHRMS Calcd for [C25H37NO8SiNa+]:  530.2186.  Found 530.2195. 
 
3-{4-[6-(tert-Butyl-dimethyl-silanyloxymethyl)-5-hydroxy-5,6-dihydro-2H-pyran-2-
yloxy]-phenyl}-2- N-Carbobenzyloxy-L-threonine methyl ester (III-45b).   
O
OH
O OTBS
N
H3COOC
CbzH
 
A CH2Cl2 (0.3 mL) solution of compound III-45a (120 mg, 0.236 mmol) and MeOH (0.3 
mL) was cooled to -78 oC.  NaBH4 (8.5 mg, 0.236 mmol) was added and the reaction 
mixture was stirred at -78oC for 3 hours. The reaction mixture was diluted with ether (10 
mL) and was quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 20% EtOAc/hexanes to give 
111 mg (0.218 mmol, 91%) of III-45b:  Rf (40% EtOAc/hexanes) = 0.32; [α]26  D  = + 2 (c 
= 1, CH2Cl2); IR (thin film, cm-1) 3437, 2953, 1725, 1517, 1213, 1076, 1009, 838; 1H 
NMR (270 MHz, CDCl3) δ 7.35 (m, 5H), 5.90 (d, J = 10.2  Hz, 1H), 5.58 (dd, J = 10.2, 
2.3 Hz, 1H), 5.50 (d, J = 9.7 Hz, 1H), 5.13 (br s, 2H), 4.96 (s, 1H), 4.46 (qd, J = 6.3, 2.3, 
1H), 4.38 (dd, J = 9.7, 2.3 Hz, 1H), 4.17 (d, J = 9.3, 1H), 3.95 (dd, J = 9.7, 4.5 Hz, 1H), 
3.73 (s, 3H), 3.67 (m, 1H), 3.45 (ddd, J = 12.8, 12.8, 4.5 Hz, 1H), 3.08 (s, 1H), 1.22 (d, J 
=  6.3 Hz, 3H), 0.90 (s, 9H), 0.11 (s, 6H); 13C NMR (67.5 MHz, CDCl3) δ 170.9, 156.6, 
136.2, 132.9, 128.5 (2C), 128.1 (2C), 128.0, 125.2, 90.7, 71.3, 69.4, 67.0 (2C), 65.3, 58.8, 
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52.3, 25.7 (3C), 18.1, 15.9, -5.6, -5.6; CIHRMS Calcd for [C25H39NO8SiNa+]: 532.2343  
Found 532.2356. 
 
(1'R,4'R,5'S,1R,5S)-1-[1'-N-Carbobenzyloxy-L-threonine methyl ester -5-(tert-butyl-
dimethyl-silanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethyl-silanyloxymethyl) -1H-pyran-4-one  (III-45). 
O
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A CH2Cl2 (0.7 mL) solution of compound (ent)-III-18 (574 mg, 1.60 mmol) and alcohol 
III-45b (700 mg, 1.34 mmol) was cooled to 0 oC.  A CH2Cl2 (0.7 mL) solution of 
Pd2(DBA)3.CHCl3 (34.5 mg, 2.5 mol%) and PPh3 (35 mg, 10 mol%) was added to the 
reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 2 hours.  The 
reaction mixture was quenched with 25 mL of satd aq NaHCO3, extracted (3 x 25 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 20% EtOAc/hexanes to 
give 10jα (924 mg, 0.82 mmol, 91%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.50; 
[α]26  D   = +14 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3444, 2930, 2857, 1729, 1701, 1511, 
1254, 1013, 835;  1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 6.81 (dd, J = 10.2, 3.6 Hz, 
1H), 6.12 (d, J = 10.2 Hz, 1H), 6.07 (d, J = 10.2 Hz, 1H), 5.69 (ddd, J = 10.2, 2.4, 2.4 Hz, 
1H), 5.56 (d, J = 3.6 Hz, 1H), 5.54 (d, J = 10.2 Hz, 1H), 5.13 (br s, 2H), 5.01 (d, J = 2.4 
Hz, 1H), 4.50 (dd, J = 9.0, 1.2 Hz, 1H), 4.44 (dddd, J = 9.6, 6.6, 3.0, 3.0 Hz, 1H), 4.39 
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(dd, J = 6.6, 3.0 Hz, 1H), 4.37 (d, J = 3.0 Hz, 1H), 4.10 (dd, J = 11.4, 3.6 Hz, 1H), 3.93 
(dd, J = 11.4, 2.4 Hz, 1H), 3.78 (dd, J = 7.8, 2.4 Hz, 1H), 3.76 (dd, J = 6.6, 2.4 Hz, 1H), 
3.69 (s, 3H), 3.51 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 1.23 (d, J = 6.0 Hz, 3H), 0.88 (s, 9H), 
0.84 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (150 MHz, 
CDCl3) δ  194.8, 170.9, 156.6, 144.0, 136.2, 129.2, 128.6, 128.5 (2C), 128.1, 128.0 (2C), 
127.0, 90.4, 89.6, 76.6, 70.8, 70.1, 67.1, 66.2, 62.9, 62.2, 58.8, 52.3, 25.9 (3C), 25.8 (3C), 
18.4, 18.3, 15.7, -5.1, -5.3 (2C), -5.4; CIHRMS Calcd for [C37H59NO11Si2Na+]: 772.3518. 
Found 772.3543. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[N-Carbobenzyloxy-L-threonine methyl ester -5'-(tert-
butyl-dimethyl-silanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy]-5-(tert-butyl-
dimethyl-silanyloxymethyl)-1,4-dihydro-5H-pyran-4-ol (III-46a). 
O
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The ketone compound III-45 (600 mg, 0.79 mmol), was dissolved in 0.8 mL of CH2Cl2 
and 0.8 mL MeOH were added to a round bottom flask and cooled -78 oC then (44.7 mg,  
1.18 mmol) NaBH4 was added and the reaction mixture was stirred at -78oC for 6 hours 
and on completion monitored by TLC, reaction mixture is diluted with ether and was 
quenched with 10 mL of satd. aq NaHCO3, extracted (3 x 10 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 25% EtOAc/hexanes to give III-46a 
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(529 mg, 0.69 mmol, 88%) as viscous oil.  Rf (30% EtOAc/hexanes) = 0.40;  [α]26  D   = -
16 (c = 1, CH2Cl2); IR (thin film, cm-1) 3445, 2953, 2930, 1729, 1514, 1254, 1036, 837, 
779; 1H NMR (600 MHz, CDCl3) δ 7.36 (m, 5H), 5.99 (dd, J = 10.2, 2.4 Hz, 1H), 5.95 
(dd, J = 10.2, 1.8 Hz, 1H), 5.66 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 5.63 (dd, J = 4.8, 2.4 Hz, 
1H), 5.58 (d, J = 9.6 Hz, 1H), 5.13 (dd, J = 9.0, 1.8 Hz, 1H ), 5.12 (br s, 2H ), 5.00 (d, J = 
2.4 Hz, 1H),  4.45 (dddd, J = 9.0, 3.6, 3.0, 3.0 Hz, 1H), 4.38 (dd, J = 10.2, 3.0 Hz, 1H), 
4.27 (dd, J = 10.2, 1.8 Hz, 1H), 4.23 (dd, J = 10.8, 3.0 Hz, 1H), 3.96 (dd, J = 10.2, 4.2 
Hz, 1H), 3.83 (dd, J = 6.0, 1.8 Hz, 1H), 3.81 (d, J = 1.8 Hz, 1H), 3.75 (dd, J = 10.8, 4.8 
Hz, 1H), 3.71 (s, 3H), 3.54 (ddd, J = 9.0, 5.4, 1.8 Hz, 1H), 3.08 (d, J = 3.6 Hz, 1H), 2.03 
(br s, 1H), 1.25 (d, J = 6.6 Hz, 3H), 0.91 (s, 9H), 0.89 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H), 
0.07 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 170.9, 156.6, 136.2, 132.9, 
129.7, 128.4 (2C), 128.1, 128.0 (2C), 126.5, 125.5, 90.9, 90.0, 70.5, 70.1, 69.8, 67.0, 
66.5, 65.3, 62.5, 60.3, 58.9, 52.3, 25.9 (3C), 25.8 (3C), 18.5, 18.1, 15.5, -5.1, -5.2, -5.4, -
5.6; CIHRMS Calcd for [C37H61NO11Si2Na+]:  774.3675.  Found 774.3655. 
 
1’(2' N-Carbobenzyloxy-L-threonine methyl ester -1'-yloxy)- -5’,5-(tert-butyl-
dimethyl-silanyloxymethyl)-bis-1,4-α-L-mannose (III-46b). 
O
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A CH2Cl2 (0.8 mL, 1mol) solution of compound of allyl alcohol III-46a (60 mg, 0.08 
mmol) at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / 
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water (0.05 mL).  Crystalline OsO4 (1.0 mg, 5 mol %) was added and the reaction was 
stirred for 12 h.  The reaction mixture was concentrated and was pipetted directly on to a 
silica gel column using a small amount of CH2Cl2 (1 mL) in three portions.  The crude 
product was purified using silica gel flash chromatography eluting with 100 % EtOAc to 
give III-46b (54 mg, 0.07 mmol, 83 %) as viscous oil.  Rf (40:10:50  
EtOAc/MeOH/Hexane) = 0.25; [α]26  D   =  -30  (c = 1, CH2Cl2); IR (thin film, cm
-1) 3356, 
2929, 2857, 1719, 1529, 1252, 1046, 968, 838; 1H NMR (600 MHz, CDCl3) δ 7.36 (m, 
5H), 5.68 (d, J = 9.6 Hz, 1H), 5.19 (d, J = 10.2 Hz, 1H), 5.14 (br s, 2H), 4.85 (d, J = 10.8 
Hz, 1H), 4.44 (dd, J = 10.2, 2.4 Hz, 1H), 4.40 (dd, J = 6.0, 2.4 Hz, 1H), 4.06 (d, J = 6.0 
Hz, 1H), 3.97 (br s, 1H), 3.84 (d, J = 5.4 Hz, 1H), 3.81 (br s, 2H), 3.78 (dd,  J = 9.0, 2.4 
Hz, 1H), 3.74 (d, J = 3.6 Hz, 1H ), 3.71 (s, 3H), 3.69 (br s, 1H), 3.68 (br s, 1H), 3.38 (m, 
3H), 3.33 (dd, J = 8.4, 6.0 Hz, 1H), 3.08 (br s, 1H), 1.97 (m, 4H), 1.20 (d, J = 6.0 Hz, 3H 
) 0.90 (s, 9H), 0.89 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 6H);  13C NMR (150 MHz, 
CDCl3) δ  171.3, 156.6, 136.1, 128.5 (2C),128.2, 128.1 (2C), 99.8, 94.6, 74.4, 71.9, 71.8, 
71.4, 71.3, 70.6, 70.4, 69.8, 69.7, 67.2, 64.6, 62.8, 58.2, 52.5, 25.9 (3C), 25.8 (3C), 18.3, 
18.3, 14.3, -5.2, -5.3, -5.4, -5.5; CIHRMS Calcd for [C37H65NO15Si2Na+]:  842.3784.  
Found 842.3751. 
 
(1'R,4'R,5'S,1R,4R,5S)-1-[1'-N-Carbobenzyloxy-L-threonine methyl ester -5'-(tert-
butyl-dimethyl-silanyloxymethyl)-1',4'-dihydro-5'H-pyran-4'-yloxy] -5-(tert-butyl-
dimethyl-silanyloxymethyl)-1,4-dihydro-5H-pyran-4-isovalaric ester (III-46). 
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The alcohol compound III-46a (540 mg, 0.71 mmol), isovaleric acid (86.6 mg, 0.85 
mmol) and DCC (175 mg, 0.85 mmol) were dissolved in 1.5 mL of CH2Cl2 in a round 
bottom flask and cooled 0 oC then (8.6 mg, 0.1 mmol) DMAP was added and the reaction 
mixture was stirred at 0 oC for 6 hours and on completion monitored by TLC, reaction 
mixture is diluted with ether and was quenched with 5 mL of satd aq NaHCO3, extracted 
(3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The 
crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexanes to give III-46 (557 mg, 0.66 mmol, 93%) as viscous oil.  Rf (30% 
EtOAc/hexanes) = 0.60; [α]26  D   = -54 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3448, 2931, 
1736, 1511, 1461, 1254, 1123, 1008, 836; 1H NMR (600 MHz, CDCl3)  δ 7.36 (m, 5H), 
6.04 (d, J = 10.8 Hz, 1H), 5.91 (d, J = 10.2 Hz, 1H), 5.71 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 
5.67 (ddd, J = 10.2, 2.4, 1.8 Hz, 1H), 5.60 (d, J = 10.2 Hz, 1H), 5.42 (dd, J = 9.6, 1.2 Hz, 
1H), 5.22 (d, J = 2.4 Hz, 1H), 5.12 (br s, 2H), 5.01 (d, J = 1.8 Hz, 1H), 4.44 (dd, J = 6.0, 
3.6 Hz, 1H), 4.38 (dd, J = 9.0, 3.6 Hz, 1H), 4.34 (dd, J = 9.0, 1.8 Hz, 1H), 3.84 (dd, J = 
4.2, 1.8 Hz, 1H), 3.81 (dd, J = 11.4, 1.8 Hz, 1H), 3.78 (d, J = 4.8 Hz, 1H), 3.76 (d, J = 4.2 
Hz, 1H), 3.73 (d, J = 7.8 Hz, 1H), 3.71 (s, 3H), 3.58 (dddd, J = 7.2, 5.4, 1.8, 1.8 Hz, 1H), 
2.21 (d, J = 1.2 Hz, 1H), 2.19 (d, J = 1.2 Hz, 1H), 2.11 (m, 1H), 1.20 (d, J = 6.6 Hz, 3H), 
0.96 (d, J = 6.8 Hz, 6H),0.89 (s, 9H), 0.88 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H), 0.03 (s, 3H), 
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0.03 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  172.5, 170.9, 156.7, 136.3, 130.0, 129.6, 
128.4 (2C), 128.0 (2C), 127.4, 126.6, 90.8, 90.2, 70.7, 70.6, 70.2, 69.6, 67.0, 66.3, 64.7, 
62.8, 62.1, 58.9, 52.3, 43.6, 43.4, 26.0, 25.9 (3C), 25.7 (3C), 22.4, 22.3, 18.5, 18.4, 15.6, -
5.1, -5.3 (2C), -5.4; CIHRMS Calcd for [C42H69NO12Si2Na+]:  858.4250.  Found 
858.4267. 
1'-N-Carbobenzyloxy-L-threonine methyl ester -5',5-(tert-butyl-dimethyl-
silanyloxymethyl)-bis-1,4-α-L-mannose - isovalaric ester (III-47). 
O
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A CH2Cl2 (2.5 mL, 0.5 Mol) solution of compound of diene III-46 (430 mg, 0.51 mmol) 
at 0 oC was added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.25 
mL).  Crystalline OsO4 (13 mg, 10 mol %) was added and the reaction was stirred for 12 
h.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using a small amount of CH2Cl2 (3 mL) in three portions.  The crude product was 
purified using silica gel flash chromatography eluting with 50:30:20 ( EtOAc : Hexane : 
Methanol) to give III-47 (394 mg, 0.43 mmol, 85 %) as viscous oil.  Rf (60:40  
EtOAc/Hexane) = 0.20; [α]26  D   = -63 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3443, 2931, 
2857, 1730, 1517, 1462, 1100, 1031, 836; 1H NMR (600 MHz, CDCl3) δ 7.36 (m, 5H), 
5.69 (d, J = 10.2 Hz, 1H), 5.18 (br s, 1H), 5.14 (br s, 2H), 4.85 (d, J =  10.2 Hz, 1H), 4.44 
(d, J = 10.2, 2.4 Hz, 1H), 4.40 (dd, J = 6.0, 2.4 Hz, 1H), 4.06 (d, J = 6.6 Hz, 1H), 3.97 (s, 
1H), 3.84 (d, J = 5.6 Hz, 1H), 3.82 (dd, J = 10.2 Hz, 1H), 3.81-3.73 (m, 6H), 3.74 (d, J = 
 168
3.6 Hz, 1H), 3.71 (s, 3H), 3.68 (d, J = 10.2 Hz, 1H), 3.38 (d, J = 6.0 Hz, 1H), 3.33 (dd, J 
= 9.6, 6.0 Hz, 1H), 3.10 (d, J = 7.8 Hz, 1H), 2.75 (br s, 1H), 2.23 (dd, J = 15.0, 7.8 Hz, 
1H), 2.18 (dd, J = 14.2, 7.2 Hz, 1H), 2.10 (m, 1H), 1.20 (d, J = 6.0 Hz, 3H), 0.94 (d, J = 
7.2 Hz, 6H), 0.91 (s, 9H), 0.88 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 6H); 13C NMR 
(150 MHz, CDCl3) δ  173.5, 171.2, 156.6, 136.0, 128.5 (2C), 128.2, 128.1 (2C), 97.5, 
94.6, 73.5, 71.6, 71.4, 71.3, 71.1, 70.9, 70.1, 69.9, 69.8, 69.3, 67.2, 62.9, 58.5, 52.4, 43.4, 
25.9 (3C), 25.8 (3C), 25.7, 22.4, 22.3, 18.4, 18.3, 14.5, -5.2, -5.3, -5.4, -5.5; CIHRMS 
Calcd for [C42H73NO16Si2Na+]:  926.4360. Found 926.4373. 
            
(1'R,4'R,5'S,1R,4R,5S)-1-[1'-N-Carbobenzyloxy-L-threonine methyl ester -5'-(tert-
butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran-4'-yloxy]-5-(tert-butyl-dimethyl-
silanyloxymethyl) -tetrahydro-pyran-4-isovalaric ester (III-49). 
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The allyl alcohol compound III-46 (85 mg, 0.10 mmol), O-NO2ArSO2NHNH2  (305 mg, 
1.50 mmol) were dissolved in 1.0 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen condition then triethylamine (203 mg, 2.00 mmol)  was added and the 
reaction mixture was stirred at 0 oC for 12 hours and on completion monitored by TLC, 
reaction mixture is three portions.  The crude product was purified using silica gel flash 
chromatography eluting with 20% EtOAc/hexanes to give III-49 (76 mg, 0.09 mmol, 90 
%) as viscous oil.  Rf (30%  EtOAc/Hexane) = 0.60; [α]26  D   = -102 (c = 1, CH2Cl2); IR 
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(thin film, cm-1) 3450, 2955, 2857, 1735, 1510, 1461, 1253, 1124, 995, 836; 1H NMR 
(600 MHz, CDCl3) δ 7.35 (m, 5H), 5.50 (d, J = 9.6 Hz, 1H), 5.14 (br s, 2H), 5.00 (d, J = 
2.4 Hz, 1H), 4.86 (d, J = 3.0 Hz, 1H), 4.72 (dd, J = 10.2, 6.0, 2.4 Hz, 1H), 4.41 (dd, J = 
8.4, 2.4 Hz, 1H), 4.40 (dd, J = 4.2, 2.4 Hz, 1H), 3.84 (dd, J = 10.8, 1.8 Hz, 1H), 3.75 (dd, 
J = 11.4, 4.8 Hz, 1H), 3.72 (s, 3H), 3.70 (dd, J = 10.2, 2.4 Hz, 1H), 3.69 (dd, J = 4.2, 1.8 
Hz, 1H), 3.57 (ddd, J = 10.2, 1.8, 1.8 Hz, 1H), 3.34 (m, 2H), 2.14 (dd, J = 8.4, 3.6 Hz, 
1H), 2.13 (dd, J = 8.4, 3.6 Hz, 1H), 2.08 (m, 1H), 1.21 (d, J = 6.0 Hz, 3H), 1.75 (ddd, J = 
12.6, 4.2, 4.2 Hz, 1H), 1.71 (dd, J = 10.8, 2.4 Hz, 1H), 1.69 (dd, J = 12.6, 3.0 Hz, 1H), 
1.63 (dd, J = 12.0, 6.0 Hz, 1H), 1.59 (m, 2H), 1.46 (dd, J = 10.2, 6.0 Hz, 1H), 1.42 (dd, J 
= 10.8, 6.0 Hz, 1H), 0.90 (d, J = 6.0 Hz, 6H), 0.88 (s, 9H), 0.87 (s, 9H), 0.08 (s, 3H), 0.07 
(s, 3H), 0.04 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  172.0, 171.1, 156.7, 
136.2, 128.5 (2C), 128.2, 128.1, 91.3, 90.2, 72.9, 71.5, 68.8, 67.6, 67.1, 66.1, 63.1, 62.6, 
58.8, 52.1, 43.6, 28.8, 28.4, 26.3, 26.0 (3C), 25.9 (3C), 25.7, 23.7, 22.4, 22.3, 21.9, 18.4, 
18.3, 14.8, -5.1, -5.3, -5.4 (2C); CIHRMS Calcd for [C42H73NO12Si2Na+]:  862.4563. 
Found 862.4522. 
 
1'- N-Carbobenzyloxy-L-threonine methyl ester -5',5-(tert-butyl-dimethyl-
silanyloxymethyl)-2,3,2’,3’-bis acetonide-bis-1,4-α-L-mannose-isovalaric ester (III-
48). 
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To a CH2Cl2 (0.1mL, 1.0M) solution of tris-α-D-manno-tetrol III-46 (70 mg, 0.07 mmol) 
and 2,2 dimethoxy propane (9.5 mg, 0.17 mmol) at 0 oC add CSA (1.8 mg, 10 mol%) and 
the reaction was stirred for 6 h.  The reaction mixture was concentrated and was pipetted 
directly on to a silica gel column using a small amount of CH2Cl2 (2 mL) in three 
portions.  Impurities were eluted with ether and the product was eluted with 
EtOAc/Hexane (40:60).  Pure fractions were combined and concentrated to afford III-48 
(66 mg, 0.06 mmol, 82 %):  Rf (50% EtOAc/Hexane) = 0.50; [α]26  D   =  -38 (c 1, CH2Cl2); 
IR (thin film, cm-1) 2953, 2934, 1735, 1510, 1253, 1090, 1019, 835; 1H NMR (600 MHz, 
CDCl3) δ 7.34 (m, 5H), 6.61 (d, J = 10.2 Hz, 1H), 5.41 (d, J = 10.2, 4.8 Hz, 1H), 5.10 (br 
s, 2H), 4.51 (dd, J = 12.0, 3.6 Hz, 1H), 4.38 (ddd, J = 12.6, 10.2, 3.6 Hz, 1H), 4.12 (dd, J 
= 13.2, 2.4 Hz, 1H), 4.09 (dd, J = 6.6, 2.4 Hz, 1H), 4.06 (d, J = 10.2, 6.0 Hz, 1H), 4.01 (d, 
J = 7.2, 6.0 Hz, 1H), 3.96 (dd, J = 12.6, 6.0 Hz, 1H), 3.90 (dd, J = 10.2, 7.8 Hz, 1H), 3.71 
(dd, J = 8.4, 2.4 Hz, 1H), 3.67 (d, J = 16.2 Hz, 1H), 3.62 (m, 1H), 3.57 (s, 3H), 3.56 (d, J 
= 4.2 Hz, 1H), 3.45 (ddd, J = 10.2, 6.6, 3.6 Hz, 1H), 3.28 (ddd, J = 10.2, 3.6, 3.6 Hz, 1H), 
3.23 (ddd, J = 10.2, 3.0, 2.4 Hz, 1H), 2.21 (dd, J = 10.2, 3.6 Hz, 1H), 2.21 (d, J = 10.2, 
3.6 Hz, 1H), 2.19 (dd, J = 10.8, 3.6 Hz, 1H), 2.05 (m, 1H), 1.49 (d, J = 6.0 Hz, 3H), 1.46 
(d, J = 7.8 Hz, 3H), 1.30 (d, J = 5.4 Hz, 3H), 1.26 (d, J = 8.4 Hz, 3H), 1.20 (d, J = 5.4 Hz, 
3H), 0.98 (d, J = 6.6 Hz, 6H), 0.89 (s, 9H), 0.87 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H), 0.01 
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(s, 3H), -0.00 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  172.7, 170.8,  137.3, 128.5(2C), 
128.2(2C), 128.1(2C), 114.2, 113.4, 109.5, 97.0, 92.9, 78.6, 78.3, 75.8, 70.9, 70.7, 70.0, 
69.7, 69.0, 67.2 (2C), 62.3, 62.0, 58.5, 52.3, 43.5, 27.7(2C), 26.3 (2C), 25.9 (3C), 25.8 
(3C), 22.3, 22.2, 18.4, 18.3, 14.5, -5.1, -5.3, -5.5 (2C); CIHRMS Calcd for 
[C48H81NO16Si2Na+ - C3H62+ ]: 966.4486.  Found 966.4441. 
 
Benzyl (S)-1-(methoxycarbonyl)-2-phenylethylcarbamate (III-64). 
OMeH
N
OCbz
 
To a solution of acid III-58 (8.6 g, 28.7 mmol) in MeOH (56 mL) was added TMSCl 
(9.2 mL, 71.5 mmol) at room temperature. After stirring for 24 hr at room temperature, 
the reaction was quenched by addition of water. The MeOH was removed in vacuo and 
then the mixture was extracted with EtOAc (3 x 25 ml), dried (Na2SO4), concentrated 
under reduced pressure. The crude product was purified using silica gel flash 
chromatography eluting with 20% EtOAc/hexane to give ester III-64 (8.6 g, 27.32 mmol, 
95%) as viscous oil.  Rf (50% EtOAc/hexane) = 0.71; [α]26  D  = + 7 (c = 1, CH2Cl2); IR 
(thin film, cm-1) 3336, 2953, 2880, 1755, 1516, 1212, 1054, 1038, 744; 1H NMR (600 
MHz, CDCl3) δ 7.34 (m, 5H), 7.27 (m, 5H), 5.22 (d, J = 7.8 Hz, 1H), 5.11 (d, J = 12.6 
Hz, 1H), 5.09 (d, J = 12.6 Hz, 1H), 4.66 (dd, J = 12.0, 6.6 Hz, 1H), 3.72 (s, 3H), 3.15 (dd, 
J = 13.8, 5.4 Hz, 1H), 3.09 (dd, J = 13.8, 5.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 
171.9, 155.5, 136.2, 135.6, 129.2 (2C), 128.5 (2C), 128.4 (2C), 128.1 (2C), 128.0, 127.1, 
66.9, 54.7, 52.2, 38.2.; CIHRMS Calcd for [C18H19NO4H+]:  314.1392.  Found 314.1386. 
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(S)-methyl 2-amino-3-phenylpropanoate (III-65). 
OMe
H2N O
 
To a solution of ester III-64 (3.8 g, 12.1 mmol) in dry MeOH (24 mL) was added Pd/C 
(129 mg) and the mixture was stirred under H2 at a 100-psi pressure for 12 h at room 
temperature. The catalyst was filtered off through a short pad of Celite, concentrated 
under reduced pressure. The resulting crude product was pipetted directly on to a silica 
gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and 
the product was eluted with EtOAc/hexanes (40:60).  Pure fractions were combined and 
concentrated to afford amine III-65 (5.14 mg, 28.9 mmol, 97 %) as viscous oil.  Rf (50% 
EtOAc/hexane) = 0.30; [α]26  D  = + 17 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3345, 3028, 
1745, 1662, 1496, 1204, 1016, 700; 1H NMR (600 MHz, CDCl3)  δ 7.31 (m, 5H), 3.73 
(dd, J = 7.8, 5.4 Hz, 1H), 3.70 (s, 3H), 3.07 (dd, J =13.2, 5.4 Hz, 1H), 2.86 (dd, J = 13.8, 
7.8 Hz, 1H), 1.45 (s, 2H); 13C NMR (150 MHz, CDCl3) δ 175.3, 137.2, 129.2 (2C), 128.5 
(2C), 126.7, 55.8, 51.8, 41.0; CIHRMS Calcd for [C10H13NO2H+]: 180.1024.  Found 
180.1019.  
 
(S)-benzyl (methylcarbamoyl)-methyl-2-amino-3-phenylpropanoate (III-66). 
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To a solution of amine III-65 (1.28 g, 7.15 mmol), Cbz-glycin acid III-57 (1.65 g, 7.86 
mmol) in CH3CN (15 ml) was added HBTU (2.98 g, 7.86 mmol) at 0 °C, and after 5 min, 
triethylamine (2.0 mL, 15.3 mmol) was added and stirring was continued for 8 h at rt.  
The mixture was taken up in EtOAc (50 mL) and washed with 5% aqueous KHSO4 
solution, 5% aqueous NaHCO3 solution, and saturated aqueous NaCl solution. Then the 
reaction mixture was dried (Na2SO4) and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography eluting with 
MeOH/EtOAc/hexane (2:48:50) to give dipeptide III-66 (2.3 g, 6.10 mmol, 85%) as a 
colorless oil, Rf = 0.41 (50% EtOAc/Hexane); [α]26  D  = + 49 (c = 1, CH2Cl2); IR (thin 
film, cm-1) 3311, 2953, 1718, 1664, 1516, 1213, 1047, 732; 1H NMR (600 MHz, 
CD3OD) δ 7.36 (m, 5H), 7.25-7.06 (m, 5H), 6.38 (br s, 1H), 5.33 (br s, 1H), 5.12 (br s, 
2H), 4.88 (dd, J = 13.2, 5.4 Hz, 1H), 3.88 (dd, J = 10.2, 5.4 Hz, 1H), 3.81 (dd, J = 10.2, 
5.4 Hz, 1H), 3.71 (s, 3H), 3.12 (d, J = 5.4 Hz, 1H), 3.10 (d, J = 5.4 Hz, 1H)d; 13C NMR 
(150 MHz, CDCl3) δ  171.6, 168.5, 136.1, 135.5, 129.2, 128.6 (2C), 128.5 (2C), 128.2 
(2C), 128.0 (2C), 127.1 (2C), 67.1, 53.0, 52.3, 44.3, 37.8; CIHRMS Calcd for 
[C20H22N2O5H+]:  371.1607.  Found 371.1601. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-  
(III-67).    
 174
OHH
N
NH
O
O
Cbz
 
To a solution of methyl ester III-66 (3.7 g, 9.60 mmol) in CH3OH (18 mL) was added 
LiOH (0.46 g, 19.26 mmol) at 0 °C, and the reaction mixture was stirred at rt for 2 hours 
and on completion, as monitored by TLC, the reaction mixture was diluted with ether and 
was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 25 mL) with AcOEt. The 
combined aqueous phases were taken to pH 3 by addition of 2M aqueous KHSO4 and 
extracted with AcOEt (3 x 25 mL). The combined organic phases were washed with 
saturated aqueous NaCl solution (3 x 10 mL), dried, and dried (Na2SO4), and 
concentrated under reduced pressure.  The crude product was purified using silica gel 
flash chromatography eluting with 100% EtOAc to give acid III-67 (2.84 g, 7.68 mmol, 
80%) as viscous oil.  Rf (10:40:50% MeOH/EtOAc/hexanes) = 0.20; [α]26  D  = + 24 (c = 1, 
CH2Cl2); IR (thin film, cm-1) 3312, 2982, 2935, 1737, 1655, 1556, 1259, 1048, 940, 743; 
1H NMR (600 MHz, CDCl3) δ 7.30 (m, 5H), 7.16 (m, 5H), 5.05 (br s, 2H), 5.64 (dd, J = 
7.8, 5.4 Hz, 1H), 3.74 (d, J = 17.4 Hz, 1H), 3.70 (d, J = 17.4 Hz, 1H), 3.14 (dd, J = 14.4, 
4.8 Hz, 1H), 2.96 (dd, J = 13.8, 8.4 Hz, 1H); 13C NMR (150 MHz, CDCl3) 173.1, 170.6, 
157.7, 136.9, 129.1 (2C), 128.27 (2C), 128.29, 127.8 (2C), 127.6 (2C), 126.4, 66.6, 53.7, 
53.6, 43.5, 37.1; CIHRMS Calcd for [C19H20N2O5H+]: 357.1444. Found 357.1450. 
 
Benzyl (S)-1-(methoxycarbonyl)-2-(4-tert-butyl-dimethylsilanyloxy phenyl) 
ethylcarbamate (III-53). 
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D-tyrosine III-68 was first protected as its methyl ester. Thionyl chloride (2.3 mL) 
was added drop wise to dry methanol (30 mL) at -15 °C, following by addition of D -
tyrosine (2.8 g, 16.2 mmol). The resulting mixture was warmed to room temperature for 
15 hrs. The solvent was removed under reduced pressure, and the residue was further 
dried under high vacuum to provide the methyl ester as a white solid. The above methyl 
ester and Na2CO3 (2.2 g, 15.7 mmol) was dissolved in 1:1 mixture 60 mL of 
acetone/H2O.  Benzyl chloroformate (CbzCl) (4.7 mL, 34.7 mmol) was added drop wise. 
After 2 hrs at room temperature, the reaction solution was diluted with EtOAc (250 mL). 
The layers were separated, and the organic layer was washed with H2O, brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography (silica, 3:1 to 1:1 hexane/EtOAc) to give N-Cbz protected tyrosine 
methyl ester III-68a (5.0 g, 95%).  Phenol III-68a  (2.47 g, 7.50 mmol), 15 mL of 
CH2Cl2, and 4.2 mL of Et3N were added to a round bottom flask and cooled to 0 oC.  A 
catalytic amount (92 mg, 0.75 mmol) of DMAP was added followed by addition of tert-
butyldimethylsilyl chloride (1.35 g, 9.00 mmol) and the solution was stirred at 0 oC for 6 
h.  The reaction was quenched with 1 M NaHSO4 and extracted (3 x 50 mL) with Et2O, 
washed with satd aq NaHCO3 (2 x 50 mL), and dried (Na2SO4). The reaction mixture was 
concentrated and was pipetted directly on to a silica gel column using CH2Cl2 (1 mL) in 
three portions.  Impurities were eluted with ether and the product was eluted with 
EtOAc/Hexane (15:85).  Pure fractions were combined and concentrated to afford 
protected tyrosine III-53 (2.89 g, 6.52 mmol, 87 %) as viscous oil.  Rf (50% 
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EtOAc/Hexane) = 0.80; [α]26  D   = -75 (c 1, CH2Cl2); IR (thin film, cm
-1) 3337, 2954, 
2930, 1720, 1508, 1438, 1225, 1055, 837; 1H NMR (600 MHz, CDCl3) δ 7.34 (m, 5H), 
6.95 (d, J = 7.8 Hz, 1H), 6.75 (d, J = 8.4 Hz, 2H), 5.21 (br s, 1H), 5.12 (d, J = 12.0 Hz, 
1H), 5.09 (d, J = 12.0 Hz, 1H), 4.62 (dd, J = 13.2, 6.0 Hz, 1H), 3.69 (s, 3H), 3.04 (m, 
2H), 1.63 (m, 1H), 0.98 (s, 9H), 0.18 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 172.2, 
155.8, 155.0, 136.5, 130.4 (2C), 128.7 (2C), 128.4, 128.3 (2C), 128.2 (2C), 120.3, 67.1, 
55.1, 52.4, 37.7, 25.8 (3C), 18.3, -4.1, -4.2; CIHRMS Calcd for [C24H33NO5H+]: 
444.2206.  Found 444.2201. 
 
(S)-methyl 2-amino-3-(4-tert-butyl-dimethylsilanyloxyphenyl)propanoate (III-69). 
OTBS
N
CO2CH3
H
H
 
To a solution of Cbz-ester III-53 (3.3 g, 7.45 mmol) in dry MeOH (15 mL) was added 
Pd/C (79 mg) and the mixture was stirred under H2 at a 100-psi pressure for 12 h at room 
temperature. The catalyst was filtered off through a short pad of Celite, concentrated 
under reduced pressure. The resulting crude product was pipetted directly on to a silica 
gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and 
the product was eluted with EtOAc/hexanes (40:60).  Pure fractions were combined and 
concentrated to afford amine III-69 (2.50 g, 6.63 mmol, 89 %) as viscous oil.  Rf (50% 
EtOAc/Hexane) = 0.33; [α]26  D   = + 8 (c 1, CH2Cl2); IR (thin film, cm
-1) 3365, 2953, 
2930, 1738, 1509, 1211, 1217, 1015, 914, 839; 1H NMR (600 MHz, CDCl3) δ 7.95 (s, 
1H), 7.01 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 3.68 (s, 3H), 3.66 (m, 2H), 2.97 
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(dd, J = 13.8, 5.4 Hz, 1H), 2.78 (dd, J = 13.2, 7.8 Hz, 1H), 0.95 (s, 9H), 0.16 (s, 6H); 13C 
NMR (150 MHz, CDCl3) δ  175.4, 154.5, 130.3, 130.1 (2C), 120.1 (2C), 115.5, 55.8, 
51.8, 40.3, 25.6 (3C), 18.1, -4.4; CIHRMS Calcd for [C16H27NO3H+]:  310.1838.  Found 
310.1833. 
 
1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(tert-butyl-
dimethylsilanyloxymethyl)-di-1,4-α-D-mannose -N-4 isovalaric amide (III-52a). 
MeO
HNH
N
Cbz
NH
O
O
O OTBS
 
To a solution of amine III-69 (83.5 mg, 0.27 mmol), acid III-67 (100 mg, 0.27 mmol) in 
CH3CN (0.5 mL) was added HBTU (112.5 mg, 0.29 mmol) at 0 °C, and after 5 min, 
triethylamine (76 µL, 0.54 mmol) was added and stirring was continued for 5 h at rt.  The 
mixture was taken up in EtOAc (10 mL) and washed with 5% aqueous KHSO4 solution, 
5% aqueous NaHCO3 solution, and saturated aqueous NaCl solution. Then the reaction 
mixture was dried (Na2SO4) and concentrated under reduced pressure. The crude product 
was purified using silica gel flash chromatography eluting with EtOAc/hexane (60:40) to 
give tripeptide III-52a (140 mg, 0.22 mmol, 80%) as a colorless oil, Rf = 0.60 (100% 
EtOAc); [α]26  D  = + 35 (c = 1, CH2Cl2); IR (thin film, cm
-1) 3275, 2954, 1739, 1696, 
1508, 1241, 1218, 915, 838; 1H NMR (600 MHz, CDCl3) δ 7.33 (m, 5H), 7.23 (m, 4H), 
7.10 (d, J = 7.2 Hz, 2H), 6.76 (d, J = 7.2 Hz, 2H), 6.69 (m, 3H), 6.50 (br s, 1H), 5.45 (br 
s, 1H), 5.08 (br s, 2H), 4.70 (m, 2H), 3.80 (d, J = 5.4 Hz, 1H), 3.79 (d, J = 5.4 Hz, 1H), 
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3.59 (s, 3H), 2.98 (m, 1H), 2.88 (dd, J = 13.8, 6.6 Hz, 1H), 2.79 (dd, J = 13.8, 6.0 Hz, 
1H), 0.94 (s, 9H), 0.14 (s, 6H); 13C NMR (150 MHz, CDCl3) δ  171.6, 170.1, 168.8, 
156.5, 154.78, 154.73, 136.2, 136.0, 130.1 (2C), 129.3 (2C), 128.6 (2C), 128.5 (2C), 
128.2 (2C), 128.1 (2C), 127.0, 120.1, 67.2, 54.2, 53.3, 52.2, 44.4, 38.3, 37.0, 25.6 (3C), 
18.1, -4.4 (2C); CIHRMS Calcd for [C35H45N3O7SiH+]:  648.3105.  Found 648.3102. 
 
1'- N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5',5-(hydroxy methyl)-di-1,4--
D-mannose –N-4 isovaleric amide  (III-70). 
MeO
HNH
N
Cbz
NH
O
O
O O O
OO
O
O
OO
O
OTBS
OTBS
O
 
To a solution of tyrosine ester III-3b (600 mg, 0.62 mmol) in dry MeOH (3.0 mL) was 
added Pd/C (6.5 mg) and the mixture was stirred under H2 at a 100-psi pressure for 6 h at 
room temperature and checked against the completion of the reaction with TLC analysis. 
The catalyst was filtered off through a short pad of Celite, concentrated under reduced 
pressure as amine III-70, Rf = 0.35 (70% EtOAc). To a solution of crude amine III-70 
(100 mg, 0.11 mmol), acid III-67 (58.6 mg, 0.17 mmol) in CH3CN (0.2 mL) was added 
HBTU (45.7 mg, 0.12 mmol) at 0 °C, and after 5 min, iPr2NEt (31 µL, 0.22 mmol) was 
added and stirring was continued for 4 h at rt.  The mixture was taken up in EtOAc (10 
mL) and washed with 5% aqueous KHSO4 solution, 5% aqueous NaHCO3 solution, and 
saturated aqueous NaCl solution. Then the reaction mixture was dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified using silica gel 
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flash chromatography eluting with EtOAc/hexane (40:60) to give tripeptide III-52b (96 
mg, 0.07 mmol, 70%) as a colorless oil, Rf = 0.47 (70% EtOAc); [α]26  D  = + 35 (c = 1, 
CH2Cl2); IR (thin film, cm-1) 3296, 2930, 2857, 1741, 1649, 1510, 1372, 1225, 1140, 
986, 835; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 7.22 (m, 5H), 7.13 (m, 1H), 6.91 
(m, 1H), 6.63 (d, J = 7.2 Hz, 1H), 6.29 (m, 1H), 5.75 (s, 1H), 5.69 (s, 1H), 5.48 (br s, 
1H), 5.10 (m, 2H), 4.97 (dd, J = 10.2, 7.2 Hz, 1H), 4.70 (dd, J = 13.2, 7.8 Hz, 1H), 4.60 
(d, J = 7.8 Hz, 1H), 4.40 (dd, J = 6.6, 6.0 Hz, 1H), 4.30 (d, J = 5.4 Hz, 1H), 4.13 (m, 2H), 
4.01 (dd, J = 10.2, 7.2 Hz, 1H), 3.83 (d, J = 6.0 Hz, 1H), 3.76 (s, 3H), 3.66 (br s, 1H), 
3.65 (d, J = 1.2 Hz, 1H), 3.65 (br s, 1H), 3.62 (m, 3H), 3.05 (dd, J = 13.8, 5.4 Hz, 1H), 
2.98 (m, 2H), 2.64 (m, 1H), 2.25 (dd, J = 15.0, 6.6 Hz, 1H), 2.16 (dd, J = 14.4, 7.8 Hz, 
1H), 2.09 (m, 1H), 1.16 (s, 3H), 1.54 (s, 3H), 1.35 (s, 3H), 1.34 (s, 3H), 1.24 (m, 1H), 
0.95 (d, J = 1.8 Hz, 3H), 0.94 (d, J = 1.8 Hz, 3H), 0.86 (s, 18H), 0.04 (s, 6H) 0.03 (s, 6H); 
13C NMR (150 MHz, CDCl3) δ  171.8, 171.2, 169.9, 169.0, 154.6, 136.2, 130.3 (2C), 
129.8, 129.1, 129.2 (2C), 128.69, 128.65 (2C), 128.5 (2C), 128.2 (2C), 128.1 (2C), 127.0, 
116.8, 110.0, 109.7, 95.6, 95.4, 78.7, 76.0, 75.87, 75.80, 71.1, 70.0, 69.4, 69.3, 67.2, 62.8, 
61.4, 54.1, 53.3, 52.3, 44.4, 43.3, 37.6, 37.0, 37.1, 29.6, 27.8, 27.5, 26.4, 26.3, 25.9 (3C), 
25.7 (3C), 27.3, 18.5 (2C), -5.3 (4C); CIHRMS Calcd for [C64H95N3O18Si2Na+]:  
1272.6227.  Found 1272.6400. 
 
Benzyl (R)-1-(methoxycarbonyl)-2-(4-tert-butyl-dimethylsilanyloxyl) ethylcarbamate 
(III-60). 
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Alcohol III-59  (5.0 g, 19.76 mmol), 40 mL of CH2Cl2, and 7.9 mL of Et3N were 
added to a round bottom flask and cooled to 0 oC.  A catalytic amount (241 mg, 1.97 
mmol) of DMAP was added followed by addition of tert-butyldimethylsilyl chloride 
(3.57 g, 23.71 mmol) and the solution was stirred at 0 oC for 10 h.  The reaction was 
quenched with 1 M NaHSO4 and extracted (3 x 50 mL) with Et2O, washed with satd aq 
NaHCO3 (2 x 50 mL), and dried (Na2SO4). The reaction mixture was concentrated and 
was pipetted directly on to a silica gel column using CH2Cl2 (1 mL) in three portions.  
Impurities were eluted with ether and the product was eluted with EtOAc/Hexane 
(15:85).  Pure fractions were combined and concentrated to afford protected tyrosine III-
60 (6.1 g, 16.9 mmol, 90 %) as viscous oil.  Rf (40% EtOAc/Hexane) = 0.75; [α]26  D   = -
43 (c 1, CH2Cl2); IR (thin film, cm-1) 3443, 2953, 2857, 1721, 1504, 1203, 1063, 870, 
775; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 5.57 (d, J = 8.4 Hz, 1H), 5.14 (d, J = 
12.0 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 4.41 (d, J = 8.4 Hz, 1H), 4.04 (dd, J = 10.2, 1.8 
Hz, 1H), 3.83 (dd, J = 10.2, 2.4 Hz, 1H), 3.73 (s, 3H), 0.83 (s, 9H), 0.002 (s, 3H), -0.006 
(s, 3H); 13C NMR (150 MHz, CDCl3) δ 170.8, 155.9, 136.2, 128.4 (2C), 128.1 (2C), 
128.0, 69.9, 63.6, 55.9, 52.3, 25.6 (3C), 18.1, -5.5, -5.7; CIHRMS Calcd for 
[C18H29NO5SiH+]: 368.1893.  Found 368.1884. 
 
Benzyl (R)-1-((R)-1,2-di-tert-butoxyethylcarbamoyl)-2-(4-tert-butyl-dimethyl 
silanyloxy) ethylcarbamate (III-61). 
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To a solution of amine III-56 (1.68 g, 7.71 mmol), acid III-55 (2.88 g, 8.84 mmol) in 
CH3CN (15 ml) was added HBTU (3.20 g, 8.84 mmol) at 0 °C, and after 5 min, 
triethylamine (2.1 mL, 15.4 mmol) was added and stirring was continued for 12 h at rt.  
The mixture was taken up in EtOAc (50 mL) and washed with 5% aqueous KHSO4 
solution, 5% aqueous NaHCO3 solution, and saturated aqueous NaCl solution. Then the 
reaction mixture was dried (Na2SO4) and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography eluting with EtOAc/hexane 
(20:80) to give dipeptide III-61 (3.45 g, 6.39 mmol, 83%) as a colorless oil, Rf = 0.65 
(50% EtOAc/Hexane); [α]26  D  = + 6 (c = 4, CH2Cl2); IR (thin film, cm
-1) 3348, 2930, 
2857, 1732, 1670, 1497, 1249, 1099, 875, 732; 1H NMR (600 MHz, CD3OD) δ 7.33 (m, 
5H), 7.15 (d, J = 7.8 Hz, 1H), 5.69 (br s, 1H), 5.10 (br s, 2H), 4.58 (ddd, J = 5.4, 3.0, 3.0 
Hz, 1H), 4.24 (br s, 1H), 4.04 (d, J = 6.6 Hz, 1H), 3.75 (dd, J = 8.4, 3.0 Hz, 1H), 3.69 
(dd, J = 10.2, 6.0 Hz, 1H), 3.48 (m, 1H), 1.43 (s, 9H), 1.10 (s, 9H), 0.87 (s, 9H), 0.06 (s, 
6H); 13C NMR (150 MHz, CDCl3) δ  169.6, 169.4, 168.8, 136.0, 128.3 (2C), 128.0, 127.9 
(2C), 81.5, 72.8, 66.8, 63.1, 62.0, 56.1, 53.2, 27.8 (3C), 27.1 (3C), 25.7 (3C), 18.1, -5.5, -
5.6; CIHRMS Calcd for [C28H48N2O7H+]:  553.3309.  Found 555.3305. 
 
(2R)-N-((R)-1,2-di-tert-butoxyethyl)-2-amino-3-(4-tert-butyl-dimethylsilanyloxy) 
propanamide (III-62). 
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To a solution of Cbz-ester III-61 (1.89 g, 3.50 mmol) in dry MeOH (7.0 mL) was added 
Pd/C (37 mg) and the mixture was stirred under H2 at a 100-psi pressure for 8 h at room 
temperature. The catalyst was filtered off through a short pad of Celite, concentrated 
under reduced pressure. The resulting crude product was pipetted directly on to a silica 
gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and 
the product was eluted with EtOAc/hexanes (50:50).  Pure fractions were combined and 
concentrated to afford amine III-62 (1.27 g, 3.15 mmol, 90 %) as viscous oil.  Rf (50% 
EtOAc/Hexane) = 0.21; [α]26  D   = + 7 (c 1, CH2Cl2); IR (thin film, cm
-1) 3392, 2971, 
2930, 1729, 1672, 1509, 1365, 1230, 837; 1H NMR (600 MHz, CDCl3) δ 7.93 (d, J = 8.4 
Hz, 1H), 4.45 (ddd, J = 8.4, 3.6, 3.0 Hz, 1H), 3.86 (dd, J = 9.6, 4.8 Hz, 1H), 3.77 (dd, J = 
9.0, 3.0 Hz, 1H), 3.71 (dd, J = 9.6, 7.2 Hz, 1H), 3.51 (dd, J = 8.4, 3.6 Hz, 1H), 3.46 (dd, J 
= 6.6, 4.8 Hz, 1H), 1.65 (br s, 2H), 1.44 (s, 9H), 1.33 (s, 9H), 0.87 (s, 9H), 0.59 (s, 3H), 
0.53 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  172.5, 169.3, 81.5, 72.9, 65.3, 62.3, 56.9, 
52.9, 27.9 (3C), 27.3 (3C), 25.8 (3C), 18.2, -5.40, -5.44; CIHRMS Calcd for 
[C20H42NO5SiH+]:  419.2941.  Found 419.2936. 
 
(2R)-N-((R)-1,2-di-tert-butoxyethyl)-2-amido-3-(4-tert-butyl-dimethylsilanyloxy)5-
amino-fluorenylmethoxycarbonyl-6-(benzyloxy)hexamide (III-63). 
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To a solution of dipeptide amine III-62 (860 mg, 2.13 mmol), acid III-54 (976 mg, 2.34 
mmol) in CH3CN (4.5 mL) was added HBTU (887 mg, 2.34 mmol) at 0 °C, and after 5 
min, triethylamine (0.6 mL, 15.3 mmol) was added and stirring was continued for 4 h at 
rt.  The mixture was taken up in EtOAc (50 mL) and washed with 5% aqueous KHSO4 
solution, 5% aqueous NaHCO3 solution, and saturated aqueous NaCl solution. Then the 
reaction mixture was dried (Na2SO4) and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography eluting with EtOAc/hexane 
(35:65) to give tripeptide III-63 (1.48 g, 1.81 mmol, 85%) as a colorless oil, Rf = 0.65 
(50% EtOAc/Hexane); [α]26  D  = + 8 (c = 3, CH2Cl2); IR (thin film, cm
-1) 3296, 2954, 
2929, 1731, 1645, 1520, 1249, 1152, 1102, 838, 737; 1H NMR (600 MHz, CD3OD) δ 
7.67 (m, 2H), 7.58 (m, 2H), 7.39 (m, 4H), 7.33 (m, 5H), 7.19 (d, J = 8.4 Hz, 1H), 5.71 (br 
s, 1H), 4.65 (d, J = 6.6 Hz, 1H), 4.61 (m, 2H), 4.51 (br s, 1H), 4.90 (dd, J = 10.2, 4.8 Hz, 
1H), 4.41 (d, J = 7.8 Hz, 1H), 4.39 (d, J = 7.8 Hz, 1H), 4.36 (d, J = 7.2 Hz, 1H), 4.21 (dd, 
J = 7.2, 6.6 Hz, 1H), 4.06 (dd, J = 8.4, 3.0 Hz, 1H), 3.90 (br s, 1H), 3.77 (dd, J = 9.0, 3.0 
Hz, 1H), 3.62 (m, 2H), 3.52 (d, J = 8.4, 3.6 Hz, 1H), 1.45 (s, 9H), 1.12 (s, 9H), 0.90 (s, 
9H), 0.11 (s, 3H), 0.10 (s, 3H); 13C NMR (150 MHz, CDCl3) δ  169.7, 169.3, 168.9, 
143.8, 143.6 (2C), 141.25, 141.23 (2C), 137.3, 128.4 (2C), 127.9 (2C), 127.8 (2C), 128.6 
(2C), 127.0, 125.1, 119.9 (2C), 81.7, 73.3, 70.0, 69.3, 67.3, 62.9, 62.1, 54.6, 53.4, 47.0, 
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27.9 (3C), 27.2 (3C), 25.86, 25.81 (3C), 18.1, -5.4, -5.5; CIHRMS Calcd for 
[C45H63N3O9SiH+]:  818.4399.   Found 818.4419. 
 
(1'S,4'S,5'R,1S,4S,5R)-1-[1'-N-carbobenzyloxy-D-tyrosine methoxycarbonyl -5'-(tert- 
dimethylsilanyloxymethyl) -tetrahydro-pyran-N-4-isovaleric amide (IV-7). 
O
O
O
OH
 
The enone compound IV-2 (100 mg, 0.34 mmol) and o-NO2C6H4SO2NHNH2 (414 mg, 
2.04 mmol) were dissolved in 3.4 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen atmosphere then triethylamine (393 µL, 2.72 mmol) was added and the 
reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with EtOAc/hexanes (15:85) to give deoxy ketone 
IV-7 (96 mg, 0.32 mmol, 95 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.70; [α]26  D   
= -19.4 (c 1, CH2Cl2); IR (thin film, cm-1) 3481, 2965, 2934, 1726, 1703, 1458, 1170, 
992, 898; 1H NMR (600 MHz, CDCl3) δ 4.69 (ddd, J = 7.8, 5.4, 2.4 Hz, 1H), 3.50 (dd, J 
= 10.2, 5.4 Hz, 1H), 3.10 (ddd, J = 18.6, 12.6, 1.2 Hz, 1H), 2.70 (m, 1H), 2.54 (m, 1H), 
2.12 (ddd, J = 19.2, 5.4, 2.4 Hz, 1H), 1.87 (m, 3H), 1.55 (d, J = 5.4 Hz, 1H), 1.53 (m, 
2H), 1.44 (m, 1H), 1.36 (dd, J = 12.6, 3.6 Hz, 1H), 1.26 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 
7.2 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 7.2 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H); 
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13C NMR (150 MHz, CDCl3) δ 214.2, 174.5, 80.9, 79.0, 45.9, 43.8, 33.97, 33.94, 33.5, 
32.2, 24.2, 20.6, 19.4, 17.9, 16.9, 15.3, 10.8; CIHRMS Calcd for [C17H30O4Na+]:  
321.2041.  Found 321.2037. 
 
(S)-1-(2-Furyl)-ethanol (IV-6a). 
O
OH
 
To a 25 ml flask was added furan ketone II-24 (800 mg, 7.27 mmol), CH2Cl2 (3.7 ml), 
formic acid/triethylamine (1:1, 9.71 ml) and Noyori asymmetric transfer hydrogenation 
catalyst (R)-Ru(η6-mesitylene)-(S, S)-TsDPEN (22.2 mg, 0.5 mol%). The resulting 
solution was stirred at room temperature for 24 h. The reaction mixture was diluted with 
water (10 ml) and extracted with EtOAc (3 x 25 ml). The combined organic layers were 
washed with saturated NaHCO3, dried over Na2SO4, and concentrated under reduced 
pressure. The crude product was purified by silica gel flash chromatography eluting with 
30% EtOAc/hexane to give furan alcohol IV-6a (745 mg, 6.76 mmol, 93%): colorless oil; 
Rf (30% EtOAc/hexane) = 0.41; [α]25D = + 21 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 
3360, 2980, 2935, 1668, 1505, 1467, 1370, 1229, 1149, 1007, 877, 734; 1H NMR (600 
MHz CDCl3)  δ 7.30 (d, J = 1.8, 1H), 6.26 (dd, J = 3.0, 1.8 Hz, 1H),  6.15 (d, J = 3.0, 
1H), 4.78 (dq, J =6.6, 6.6 Hz, 1H), 3.11 (s, 1H), 1.46 (d, J =  6.6 Hz, 3H); 13C NMR (150 
MHz, CDCl3) δ 157.7, 141.6, 109.9, 104.9, 63.3, 21.1. 
 
(2S)-6-Hydroxy-2- methyl-2H-Pyran-3 (6H)-one (II-26). 
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Compound furan alcohol IV-6a (8.30 g, 74.1 mmol), 184.5 mL of THF, and 61.5 mL of 
H2O were added to a round bottom flask and cooled to 0 oC.  Solid NaHCO3 (12.4 g, 
148.2 mmol), NaOAc•3H2O (10.1 g, 74.1 mmol), and NBS (13.1 g, 74.1 mmol) were 
added to the solution and the mixture was stirred for 1 h at 0 oC.  The reaction was 
quenched with saturated NaHCO3 (200 mL), extracted (3 x 200 mL) with Et2O, dried 
(Na2SO4), concentrated under reduced pressure and purified by silica gel chromatography 
eluting with 25% EtOAc/hexane to give pyranone II-26 (8.56 g, 67.4 mmol, 91%): Rf 
(60% EtOAc/hexane) = 0.29; [α]25D = + 44 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 3381, 
2988, 2942, 1692, 1447, 1373, 1232, 1021, 937; 1H NMR (600 MHz, CDCl3) major 
isomer δ 6.82 (dd, J = 10.2, 3.0 Hz, 1H), 5.96 (d, J = 10.2, 1H), 5.48 (d, J = 3.0 Hz, 1H), 
3.99 (q, J = 7.2 Hz, 1H), 1.23 (d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) major 
isomer δ 197.6, 145.3, 126.6, 87.2, 74.8, 15.1.  
 
(2S, 6S)-tert-butyl -5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl carbonate (IV-6α). 
OBocO
O
 
Pyronone alcohol II-26 (5.5 g, 42.9 mmol) was dissolved in CH2Cl2 (42 mL) and the 
solution was cooled to -78 oC.  A CH2Cl2 (2 mL) solution of (Boc)2O (13.46 g, 51.6 
mmol) and a catalytic amount of DMAP (524.2 mg, 4.76 µmol) was added to the reaction 
mixture. The reaction was stirred for 1 h at -78 oC, and quenched with 200 mL of 
saturated NaHCO3, extracted with Et2O (3 x 200 mL), dried (Na2SO4), and concentrated 
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under reduced pressure. The crude product was purified using silica gel flash 
chromatography eluting with 6% EtOAc/hexane to give 7.62 g (33.5 mmol, 78%) of two 
diastereomers of Boc-protected pyranone IV-6α and IV-6β in 3:1:  Rf (20% Et2O/hexane) 
= 0.58; [α]25D = + 98 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 2984, 2942, 1752, 1703, 
1371, 1273, 1254, 1153, 938, 838; 1H NMR (600 MHz, CDCl3) δ 6.78 (dd, J = 10.2, 3.6 
Hz, 1H), 6.22 (d, J = 3.6 Hz, 1H), 6.09 (d, J = 10.2 Hz, 1H), 4.53 (q, J = 6.6 Hz, 1H), 
1.40 (s, 9H), 1.28 (d, J = 6.6 Hz, 3H); 13C NMR (150.8 MHz, CDCl3) δ 195.5, 151.7, 
140.9, 128.2, 89.1, 83.3, 72.0, 27.5 (3C), 15.1; ClHRMS Calculated for [C11H16O5Na+]: 
251.0890, Found: 251.0883. 
 
(2S, 6S)-tert-butyl -5,6-dihydro-6-methyl-5-oxo-2H-pyran-2-yl carbonate (IV-6β). 
OBocO
O
 
To a 1000 ml flask was added furan ketone II-26 (40 g, 363.5 mmol), CH2Cl2 (240 ml), 
formic acid/triethylamine (5:3, 480 ml) and Noyori asymmetric transfer hydrogenation 
catalyst (R)-Ru(η6-mesitylene)-(R, R)-TsDPEN (222 mg, 0.1 mol%). The resulting 
solution was stirred at room temperature for 24 h. The reaction mixture was diluted with 
water (500 ml) and extracted with EtOAc (3 x 700 ml). The combined organic layers 
were washed with saturated NaHCO3, dried over Na2SO4, and concentrated under 
reduced pressure. The resulted crude compound furan alcohol was dissolve in 603 mL of 
THF/H2O (3:1) and cooled down to 0 oC.  Solid NaHCO3 (60.9 g, 727.8 mmol), 
NaOAc•3H2O (49.6 g, 363.9 mmol), and NBS (64.3 g, 363.7 mmol) were added to the 
solution and the mixture was stirred for 1 h at 0 oC.  The reaction was quenched with 
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saturated NaHCO3 (600 mL), extracted (3 x 800 mL) with Et2O, dried (Na2SO4), 
concentrated under reduced pressure.  The crude mixture was dissolved in CH2Cl2 (500 
mL) and the solution was cooled to -78 oC.  (Boc)2O (93 g, 400 mmol) and a catalytic 
amount of DMAP ( 4.0 g) was added to the reaction mixture. The reaction was stirred for 
12 h at -78 to -30 oC, and quenched with saturated NaHCO3, extracted with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure. The crude product was purified 
using silica gel flash chromatography eluting with 6% EtOAc/hexane to give 61.4 g 
(269.2 mmol, 80%) of two diastereomers of Boc-protected pyranone II-26β in 3:1:  Rf 
(20% Et2O/hexane) = 0.58; [α]25D = - 98 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 2984, 
2942, 1752, 1703, 1371, 1273, 1254, 1153, 938, 838; 1H NMR (600 MHz, CDCl3) δ 6.78 
(dd, J = 10.2, 3.6 Hz, 1H), 6.22 (d, J = 3.6 Hz, 1H), 6.09 (d, J = 10.2 Hz, 1H), 4.53 (q, J 
= 6.6 Hz, 1H), 1.40 (s, 9H), 1.28 (d, J = 6.6 Hz, 3H); 13C NMR (150.8 MHz, CDCl3) δ 
195.5, 151.7, 140.9, 128.2, 89.1, 83.3, 72.0, 27.5 (3C), 15.1; ClHRMS Calculated for 
[C11H16O5Na+]: 251.0890, Found: 251.0883. 
 
6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-2-methyl-6H-pyran-3-one 
(IV-8). 
O
O
O
O
O
O
 
A CH2Cl2 (0.6 mL) solution of Boc-enone IV-6 (93 mg, 0.40 mmol) and 10-
deoxymethynolide alcohol 5 (60 mg, 0.20 mmol) was cooled to 0 oC.  A CH2Cl2 (0.2 mL) 
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solution of Pd2(dba)3.CHCl3 (21 mg, 2.5 mol%) and PPh3 (22 mg, 10 mol%) was added to 
the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 5 hours.  The 
reaction mixture was quenched with 5 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 20% EtOAc/hexanes to 
give enone IV-8 (75 mg, 0.18 mmol, 90%) as viscous oil.  Rf (50% EtOAc/hexanes) = 
0.50; [α]26  D  = -65 (c = 0.3, MeOH); IR (thin film, cm
-1) 2965, 2930, 1724, 1701, 1459, 
1171, 1019, 974; 1H NMR (600 MHz, CDCl3) δ 6.85 (dd, J = 10.8, 3.0 Hz, 1H), 6.07 (d, 
J = 10.2 Hz, 1H), 5.24 (d, J = 3.6 Hz, 1H), 4.70 (ddd, J = 7.8, 5.4, 2.4 Hz, 1H), 4.60 (dd, 
J = 13.8, 6.6 Hz, 1H), 3.65 (dd, J = 10.2, 1.2 Hz, 1H), 3.09 (ddd, J = 19.6, 11.4, 2.4 Hz, 
1H), 2.87 (ddd, J = 16.8, 7.2, 6.6 Hz, 1H), 2.56 (m, 1H), 2.13 (ddd, J = 18.6, 5.4, 3.0 Hz, 
1H), 1.88 (d, J = 13.2 Hz, 1H), 1.83 (m, 1H), 1.51 (m, 3H), 1.47 (m, 1H), 1.36 (dd, J = 
7.2, 2.4 Hz, 1H), 1.42 (m, 1H), 1.36 (d, J = 6.6 Hz, 3H), 1.24 (d, J = 7.2 Hz, 3H), 1.14 (d, 
J = 7.2 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 214.1, 196.8, 174.1, 142.5, 126.9, 109.9, 95.8, 88.5, 
81.1, 70.6, 45.8, 44.1, 34.7, 34.3, 33.8, 32.3, 24.2, 20.6, 17.9, 17.1, 15.3, 14.9, 10.8; 
CIHRMS Calcd for [C23H36O6Na+]:  431.2409.  Found 431.2405. 
 
6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-2-methyl-3, 6-dihydro-
2H-pyran-3-ol (IV-9). 
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The enone compound IV-8 (60 mg, 0.15 mmol) was dissolved in 0.2 mL of CH2Cl2 and 
0.2 mL MeOH in round bottom flask and cooled -78 oC then  NaBH4 (6.1 mg, 0.15 
mmol) was added and the reaction mixture was stirred at -78 oC for 3 hours and on 
completion, monitored by TLC, reaction mixture was diluted with ether and was 
quenched with 2 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 25% EtOAc/hexanes to give allylic 
alcohol IV-9 (56 mg, 0.14 mmol, 92%) as viscous oil.  Rf (50% EtOAc/hexanes) = 0.35; 
[α]26  D   = - 14 (c = 0.25, MeOH); IR (thin film, cm
-1) 3444, 2968, 2934, 1726, 1704, 
1460, 1171, 1039, 899; 1H NMR (600 MHz, CDCl3) δ 5.94 (d, J = 10.2 Hz, 1H), 5.78 (td, 
J = 10.2, 2.4 Hz, 1H), 4.98 (br s, 1H), 4.68 (ddd, J = 7.2, 4.8, 2.4 Hz, 1H), 3.81 (d, J = 8.4 
Hz, 1H), 3.67 (ddd, J = 12.6, 9.0, 6.0 Hz, 1H), 3.57 (d, J = 10.2 Hz, 1H), 3.10 (ddd, J = 
18.6, 12.6, 2.4 Hz, 1H), 2.83 (m, 1H), 2.55(m, 1H), 2.14 (ddd, J = 18.6, 5.4, 2.4 Hz, 1H), 
2.06 (m, 1H), 1.88 (m, 2H), 1.83 (m, 2H), 1.66 (br s, 1H), 1.51 (td, J = 14.4, 7.2 Hz, 1H), 
1.29 (d, J = 6.0 Hz, 3H), 1.24 (br s, 2H), 1.21 (d, J = 7.2 Hz, 3H), 1.14 (d, J = 7.2 Hz, 
3H), 1.07 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR 
(150 MHz, CDCl3) δ 214.4, 174.4, 133.4, 126.0, 96.4, 86.8, 80.9, 69.2, 68.0, 45.9, 44.3, 
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34.8, 34.0, 33.8, 32.2, 29.6, 24.2, 20.5, 17.9, 17.6, 17.1, 15.3, 10.8; CIHRMS Calcd for 
[C23H38O6Na+]:  433.2566.  Found 433.2560. 
 
(2S,3R,6R)-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-tetrahydro-2-
methyl-2H-pyran-3-ol (IV-10).  
O OH
O
O
O
O
H
 
The enol compound IV-9 (40 mg, 0.10 mmol) and o-NO2C6H4SO2NHNH2 (120 mg, 0.60 
mmol) were dissolved in 1.0 mL of CH2Cl2 in a round bottom flask and cooled 0 oC 
under nitrogen atmosphere then triethylamine (114 µL, 0.80 mmol) was added and the 
reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with EtOAc/hexanes (30:70) to give deoxy 
alcohol IV-10 (40 mg, 0.09 mmol, 96 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.26; 
[α]26  D   = - 34 (c 0.25, CH2Cl2); IR (thin film, cm
-1) 3449, 2963, 2928, 1726, 1703, 1459, 
1170, 1019, 940, 898; 1H NMR (600 MHz, CDCl3) δ 4.74 (d, J = 2.4 Hz, 1H), 4.67 (ddd, 
J = 8.4, 5.4, 1.8 Hz, 1H), 3.70 (ddd, J = 12.6, 9.0, 6.0 Hz, 1H), 3.48 (d, J = 10.2 Hz, 1H), 
3.28 (ddd, J = 10.2, 9.0, 4.2 Hz, 1H), 3.10 (ddd, J = 18.6, 12.6, 2.4 Hz, 1H), 2.79 (ddd, J 
= 13.2, 10.2, 7.2 Hz, 1H), 2.55 (m, 1H), 2.13 (m, 1H), 1.93 (m, 1H), 1.91 (m, 1H), 1.89 
 192
(d, J = 2.4 Hz, 1H), 1.87 (d, J = 1.8 Hz, 1H), 1.84 (m, 1H), 1.82 (dd, J = 4.2, 2.4 Hz, 1H), 
1.75 (ddd, J = 10.2, 7.2, 3.6 Hz, 1H), 1.73 (m, 1H), 1.69 (dd, J = 10.2, 3.6 Hz, 1H), 1.43 
(m, 3H), 1.37 (d, J =  4.8 Hz, 1H), 1.21 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 7.2 Hz, 3H), 1.15 
(d, J = 7.2 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 7.2 Hz, 3H), 0.87 (t, J = 7.2 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 214.3, 174.5, 99.2, 80.8, 72.0, 70.2, 45.9, 44.3, 34.7, 
34.3, 33.8, 32.2, 29.9, 29.6, 27.6, 24.2, 20.6, 19.2, 18.0, 17.5, 17.0, 15.5, 10.7; CIHRMS 
Calcd for [C23H40O6Na+]:  435.2722.  Found 435.2717. 
 
(2R,5R,6R)-2-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-tetrahydro-6-
methyl-2H-pyran-3,4,5-triol (IV-11). 
O
OH
OH
OH
O
O
O
O
H
 
To a CH2Cl2 (0.2 mL) solution of allylic alcohol IV-9 (10 mg, 0.02 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (10 µL).  
Crystalline OsO4 (2.0 mg, 10 mol %) was added and the reaction was stirred for 12 h.  
The reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with MeOH/EtOAc/hexanes (10:40:50).  Pure fractions were combined and 
concentrated to afford triol IV-11 (9.7 mg, 0.02 mmol, 91 %) as viscous oil.  Rf (90% 
EtOAc/MeOH) = 0.30; [α]26  D   =  - 39 (c = 0.3, MeOH); IR (thin film, cm
-1) 3390, 2965, 
 193
2929, 1723, 1702, 1458, 1173, 1062, 899, 735; 1H NMR (600 MHz, CDCl3) δ 4.80 (d, J 
= 1.2 Hz, 1H), 4.67 (ddd, J = 8.4, 4.8, 1.8 Hz, 1H), 4.02 (br s, 1H), 3.78 (ddd, J = 12.6, 
9.6, 6.0 Hz, 1H), 3.71 (m, 1H), 3.51 (d, J = 10.2 Hz, 1H), 3.47 (dd, J = 10.2, 9.0 Hz, 1H), 
3.09 (ddd, J = 12.0, 9.2, 2.4 Hz, 1H), 2.81 (ddd, J = 13.8, 10.2, 6.6 Hz, 1H), 2.54 (m, 
1H), 2.42 (m, 1H), 2.23 (m, 1H), 2.15 (dd, J = 5.4, 3.0 Hz, 1H), 1.85 (m, 2H), 1.52 (dd, J 
= 12.6, 7.2 Hz, 1H), 1.55 (m, 3H), 1.44 (m, 2H), 1.29 (d, J = 6.0 Hz, 3H), 1.25 (d, J = 1.2 
Hz, 1H), 1.22 (d, J = 6.6 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 1.06 (d, J = 6.6 Hz, 3H), 0.93 
(d, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.1, 174.2, 
102.6, 81.1, 73.4, 71.8, 71.2, 68.4, 45.8, 44.1, 34.6, 34.2, 33.8, 32.3, 29.6, 24.2, 20.6, 
19.2, 18.0, 17.1, 16.9, 15.5, 10.7; CIHRMS Calcd for [C23H40O8Na+]:  467.2620.  Found 
467.2616. 
 
(2R,3R,6R)-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-3,6-dihydro-
2-methyl-2H-pyran-3-yl methyl carbonate (IV-12). 
O O
O
O
O
O O O
 
To a solution of allylic alcohol IV-9 (60 mg, 0.15 mmol) in dry CH2Cl2 (1.0 mL) at 0 oC, 
was added pyridine (59 µL, 0.73 mmol), DMAP (3.6 mg), and methyl chloroformate (57 
mg, 0.73 mmol). After stirring 24 h at room temperature, water (1 mL) was added and 
then the mixture was extracted with EtOAc (3 x 5 mL), dried (Na2SO4), concentrated 
under reduced pressure. The crude product was purified using silica gel flash 
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chromatography eluting with EtOAc/hexane (20:80) to give carbonate IV-12 (60.2 mg, 
0.13 mmol, 88%) as viscous oil.  Rf (50% EtOAc/hexane) = 0.50; [α]26  D  = - 12 (c = 0.5, 
CH2Cl2); IR (thin film, cm-1) 2962, 2924, 1752, 1701, 1459, 1261, 1045, 970; 1H NMR 
(600 MHz, CDCl3) δ 5.94 (d, J = 10.2 Hz, 1H), 5.85 (ddd, J = 7.8, 4.8, 2.4 Hz, 1H), 5.01 
(br s, 1H), 4.85 (dd, J = 9.0, 1.8 Hz, 1H), 4.69 (ddd, J = 8.4, 5.4, 1.8 Hz, 1H), 3.95 (ddd, 
J = 12.0, 9.6, 6.0 Hz, 1H), 3.81 (s, 3H), 3.65 (dd, J = 10.2, 1.2 Hz, 1H), 3.10 (ddd, J = 
18.6, 12.6, 2.4 Hz, 1H), 2.84 (ddd, J = 13.8, 10.2, 6.6 Hz, 1H), 2.54 (ddd, J = 13.2, 7.2, 
1.8 Hz, 1H), 2.12 (ddd, J = 18.6, 6.0, 2.4 Hz, 1H), 1.89 (dd, J = 6.0, 1.2 Hz, 1H), 1.85 (br 
s, 1H), 1.83 (m, 2H), 1.52 (dd, J = 7.2, 6.0 Hz, 1H), 1.50 (dd, J = 7.2, 6.6 Hz, 1H), 1.43 
(m, 1H), 1.36 (ddd, J = 16.8, 9.6, 4.2 Hz, 1H), 1.24 (d, J = 6.0 Hz, 3H), 1.21 (d, J = 7.2 
Hz, 3H), 1.15 (d, J = 7.2 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 7.2 Hz, 3H), 0.88 
(t, J = 7.8 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.5, 174.5, 155.5, 129.3, 127.8, 
96.5, 87.2, 81.1, 74.5, 64.9, 55.2, 46.1, 44.4, 34.9, 34.2, 34.0, 32.4, 24.4, 20.8, 19.5, 18.1, 
17.8, 17.3, 15.4, 11.0; CIHRMS Calcd for [C25H40O8Na+]:  491.2620.  Found 491.2615. 
 
(2R,3R,6R)-3-azido-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-3,6-
dihydro-2-methyl-2H-pyran (IV-13). 
O N3
O
O
O
O
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To a mixture of carbonate IV-12 (55 mg, 0.12 mmol), allylpalladium chloride dimer (6.4 
mg, 0.02 mmol) and 1,4-bis(diphenylphosphino)butane (30 mg, 0.08 mmol) in anhydrous 
THF (0.20 mL) was added TMSN3 (77 µg, 0.59 mmol) under argon atmosphere. The 
solution was stirred at room temperature for 3 h.  Then the mixture was evaporated under 
reduced pressure, purified using silica gel flash chromatography eluting with 
EtOAc/hexane (15:85) to give allylic azide IV-13 (43 mg, 0.10mmol, 85%) as viscous 
oil.  Rf (30% EtOAc/hexane) = 0.60; [α]26  D  = - 45 (c = 1, CH2Cl2); IR (thin film, cm
-1) 
2968, 2934, 2103, 1725, 1703, 1459, 1170, 1041, 984; 1H NMR (600 MHz, CDCl3) δ 
5.96 (d, J = 10.8 Hz, 1H), 5.93 (ddd, J = 9.6, 2.4, 2.4 Hz, 1H), 5.00 (br s, 1H), 4.69 (ddd, 
J = 8.4, 6.0, 2.4 Hz, 1H), 3.74 (ddd, J = 12.6, 9.0, 6.6 Hz, 1H), 3.51 (d, J = 10.2 Hz, 1H), 
3.55 (d, J = 9.6 Hz, 1H), 3.10 (ddd, J = 18.6, 12.6, 2.4 Hz, 1H), 2.84 (ddd, J = 13.2, 10.2, 
7.2 Hz, 1H), 2.55 (m, 1H), 2.13 (ddd, J = 18.6, 6.0, 1.8 Hz, 1H), 1.88 (m, 2H), 1.83 (m, 
1H), 1.51 (m, 2H), 1.43 (m, 1H), 1.35 (m, 2H), 1.30 (d, J = 6.6 Hz, 3H), 1.21 (d, J = 7.2 
Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H), 0.88 
(t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.5, 174.5, 128.6, 128.2, 94.4, 87.3, 
81.1, 66.3, 60.2, 46.1, 44.4, 34.9, 34.2, 34.0, 32.4, 24.4, 20.8, 19.5, 18.3, 18.1, 17.4, 15.5, 
11.0; CIHRMS Calcd for [C23H37N3O5Na+]:  458.2630.  Found 458.2625. 
 
(2R,3R,6R)-3-azido-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-
tetrahydro-2-methyl-2H-pyran (IV-14).  
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The allylic azide compound IV-13 (20 mg, 0.04 mmol) and o-NO2C6H4SO2NHNH2 (56 
mg, 0.27 mmol) were dissolved in 0.4 mL of CH2Cl2 in a round bottom flask and cooled 
0 oC under nitrogen atmosphere then triethylamine (60 µL, 0.36 mmol) was added and 
the reaction mixture was stirred at 0
 
oC for 12 hours and on completion, as monitored by 
TLC.  The reaction mixture was concentrated and was pipetted directly on to a silica gel 
column using CH2Cl2 (1 mL) in three portions.  The crude product was purified using 
silica gel flash chromatography eluting with EtOAc/hexanes (15:85) to give deoxy azide 
IV-14 (18 mg, 0.04 mmol, 90 %) as viscous oil.  Rf (50% EtOAc/Hexane) = 0.65; [α]26  D   
=  - 13 ( c = 0.5,  CH2Cl2); IR (thin film, cm-1) 2965, 2930, 1724, 1701, 1459, 1171, 
1019, 974; 1H NMR (600 MHz, CDCl3) δ 4.78 (d, J = 3.0 Hz, 1H), 4.68 (ddd, J = 8.4, 
4.2, 2.4 Hz, 1H), 3.73 (ddd, J = 12.6, 9.6, 6.6 Hz, 1H), 3.48 (d, J = 10.8 Hz, 1H), 3.10 (m, 
1H), 3.04 (m, 1H), 2.80 (ddd, J = 13.2, 10.2, 7.2 Hz, 1H), 2.56 (ddd, J = 11.4, 7.8, 4.2 
Hz, 1H), 2.14 (m, 1H), 1.97 (m, 1H), 1.95 (dd, J = 4.2, 1.8 Hz, 1H), 1.88 (br s, 1H), 1.86 
(m, 2H), 1.84 (m, 1H), 1.80 (d, J = 2.4 Hz, 1H), 1.78 (dd, J = 9.0, 2.4 Hz, 1H), 1.75 (d, J 
= 3.6 Hz, 1H), 1.51 (d, J = 7.2 Hz, 3H), 1.44 (m, 1H), 1.35 (m, 1H), 1.21 (d, J = 6.6 Hz, 
3H), 1.17 (t, J = 6.0 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H), 0.88 (t, J 
= 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.3, 174.4, 99.1, 88.3, 80.9, 68.2, 62.6, 
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45.9, 44.3, 34.7, 34.5, 33.8, 32.2, 29.5, 24.5, 23.9, 20.6, 19.2, 18.3, 18.0, 17.0, 15.5, 10.7; 
CIHRMS Calcd for [C23H39 N3O5Na+]:  460.2787.  Found 460.2783. 
 
(2R,5R,6R)-5-azido-2-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-
tetrahydro-6-methyl-2H-pyran-3,4-diol (IV-15). 
O
OH
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To a CH2Cl2 (0.3 mL) solution of allylic azide IV-13 (15 mg, 0.3 mmol) at 0 oC was 
added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (17 µL).  
Crystalline OsO4 (1.0 mg, 10 mol %) was added and the reaction was stirred for 12 h.  
The reaction mixture was concentrated and was pipetted directly on to a silica gel column 
using CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product 
was eluted with MeOH/EtOAc/hexanes (2:48:50).  Pure fractions were combined and 
concentrated to afford diol IV-15 (15 mg, 0.03 mmol, 90 %) as viscous oil.  Rf (50% 
EtOAc/hexanes) = 0.20; [α]26  D   =  - 62 (c = 0.5, MeOH); IR (thin film, cm
-1) 3411, 2968, 
2933, 2108, 1725, 1703, 1459, 1174, 1051, 997, 900; 1H NMR (600 MHz, CDCl3) δ 4.81 
(d, J = 1.2 Hz, 1H), 4.67 (ddd, J = 7.8, 5.4, 2.4 Hz, 1H), 4.11 (dd, J = 14.4, 7.2 Hz, 1H), 
4.00 (ddd, J = 4.8, 3.0, 1.8 Hz, 1H), 3.78 (ddd, J = 10.2, 7.2, 3.0 Hz, 1H), 3.69 (m, 1H), 
3.51 (d, J = 10.2 Hz, 1H), 3.31 (d, J = 10.2 Hz, 1H), 3.07 (ddd, J = 17.4, 6.6, 2.4 Hz, 1H), 
2.80 (ddd, J = 13.2, 10.2, 6.6 Hz, 1H), 2.55 (m, 2H), 2.35 (br s, 1H), 1.16 (br s, 1H), 2.13 
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(m, 1H), 1.84 (m, 3H), 1.60 (d, J = 3.0 Hz, 1H), 1.51 (dd, J = 14.4, 7.8 Hz, 1H), 1.44 (m, 
1H), 1.32 (d, J = 6.0 Hz, 3H), 1.20 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.0 Hz, 3H), 1.03 (d, 
J = 6.6 Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 214.1, 174.1, 102.4, 89.6, 81.1, 70.5, 67.4, 65.8, 60.3, 45.8, 44.1, 34.6, 34.2, 
33.7, 32.3, 24.2, 20.5, 19.2, 18.0, 17.0, 15.6, 14.1, 10.7; CIHRMS Calcd for 
[C23H39N3O7Na+]:  492.2685.  Found 492.2684. 
 
(2S,3R,6R)-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-tetrahydro-2-
methyl-2H-pyran-3-amine (IV-17). 
O NH2
O
O
O
O
H
 
To a solution of allylic azide IV-13 (15 mg, 0.04 mmol) in dry MeOH (0.3 mL) was 
added Pd/C (10 mg) and the mixture was stirred under H2 at an 100 psi pressure for 8 h at 
room temperature. The catalyst was filtered off through a short pad of Celite, 
concentrated under reduced pressure. The resulting crude product was pipetted directly 
on to a silica gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted 
with ether and the product was eluted with MeOH/EtOAc/hexanes (200:40:40).  Pure 
fractions were combined and concentrated to afford deoxy amine IV-17 (13.2 mg, 0.03 
mmol, 92 %) as viscous oil.  Rf (90% EtOAc/MeOH) = 0.30; [α]26  D   =  - 38 (c = 0.5, 
MeOH); IR (thin film, cm-1) 3345, 2964, 2929, 1728, 1705, 1457, 1167, 1016, 983, 897; 
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1H NMR (600 MHz, CDCl3) δ 4.71 (d, J = 3.0 Hz, 1H), 4.61 (ddd, J = 9.0, 4.2, 1.8 Hz, 
1H), 3.92 (ddd, J = 12.6, 9.6, 6.6 Hz, 1H), 3.40 (d, J = 10.2 Hz, 1H), 3.12 (m, 1H), 2.79 
(ddd, J = 13.2, 10.2, 7.2 Hz, 1H), 2.48 (m, 1H), 1.95 (d, J = 10.2 Hz, 1H), 1.91 (d, J = 
10.2 Hz, 1H), 1.79 (m, 2H), 1.76 (br s, 1H), 1.68 (m, 3H), 1.53 (m, 3H), 1.50 (m, 1H), 
1.48 (dd, J = 6.0, 2.4 Hz, 1H), 1.36 (ddd, J = 15.6, 10.2, 4.2 Hz, 1H), 1.25 (br s, 2H), 1.15 
(d, J = 7.2 Hz, 3H), 1.14 (d, J = 6.0 Hz, 3H), 1.12 (d, J = 7.2 Hz, 3H), 1.03 (d, J = 6.0 Hz, 
3H), 0.90 (d, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ 217.1, 176.6, 101.2, 82.6, 68.9, 66.8, 49.7, 47.4, 41.0, 36.3, 35.9, 35.2, 33.7, 31.5, 25.4, 
21.7, 19.5, 19.2, 18.5, 17.8, 16.2, 16.1, 11.3; CIHRMS Calcd for [C23H41NO5H+]:  
412.3063.  Found 412.3061. 
 
(2R,3R,4R,5R,6S)-5-amino-2-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-
dione)-tetrahydro-6-methyl-2H-pyran-3,4-diol (IV-16). 
O
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To a solution of dihydroxy azide IV-15 (10 mg, 0.02 mmol) in dry MeOH (0.2 mL) was 
added Pd/C (2 mg) and the mixture was stirred under H2 at an 100 psi pressure for 6 h at 
room temperature. The catalyst was filtered off through a short pad of Celite, 
concentrated under reduced pressure. The resulting crude product was pipetted directly 
on to a silica gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted 
with ether and the product was eluted with MeOH/EtOAc/hexanes (20:40:40).  Pure 
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fractions were combined and concentrated to afford dihydroxy amine IV-16 (8.5 mg, 
0.02 mmol, 90 %) as viscous oil.  Rf (90% EtOAc/MeOH) = 0.20; [α]26  D   =  - 130 (c = 
0.5, MeOH); IR (thin film, cm-1) 3373, 2967, 2933, 1721, 1702, 1458, 1366, 1173, 1032, 
984; 1H NMR (600 MHz, CDCl3) δ 4.71 (d, J = 2.4 Hz, 1H), 4.63 (ddd, J = 8.4, 4.8, 1.8 
Hz, 1H), 3.85 (dd, J = 3.0, 1.8 Hz, 1H), 3.69 (ddd, J = 12.6, 9.6, 5.4 Hz, 1H), 3.48 (dd, J 
= 10.2, 3.0 Hz, 1H), 3.42 (d, J = 10.8 Hz, 1H), 3.13 (ddd, J = 19.2, 12.0, 2.4 Hz, 1H), 
2.83 (ddd, J = 13.8, 10.2, 6.6 Hz, 1H), 2.76 (t, J = 10.2 Hz, 1H), 2.49 (m, 1H), 2.21 (m, 
2H), 1.88 (ddd, J = 12.6, 7.8, 4.8 Hz, 1H), 1.81 (dd, J = 14.4, 2.4 Hz, 1H), 1.57 (m, 1H), 
1.55 (m, 3H), 1.45 (d, J = 4.2 Hz, 1H), 1.43 (dd, J = 4.2, 1.8 Hz, 1H), 1.40 (d, J = 4.2 Hz, 
1H), 1.27 (br s, 1H), 1.24 (m, 1H), 1.20 (d, J = 7.2 Hz, 3H), 1.19 (d, J = 6.0 Hz, 3H), 1.16 
(d, J = 7.2 Hz, 3H), 1.04 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.88 (t, J = 7.2 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 217.1, 176.3, 105.5, 82.7, 72.1, 71.5, 71.1, 55.3, 
47.4, 45.8, 35.9, 35.8, 35.1, 33.6, 31.4, 25.4, 21.7, 19.5, 18.3, 18.1, 17.6, 16.0, 11.3; 
CIHRMS Calcd for [C23H41NO7H+]:  444.2961.  Found 444.2955. 
 
(2R,3S,6R)-3-azido-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione))-3,6-
dihydro-2-methyl-2H-pyran (IV-19). 
O
N3
O
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O
O
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To a solution of allylic alcohol IV-9 (15 mg, 0.03 mmol) and methanesulphonyl chloride 
(4 µL, 0.05 mmol)  in dry CH2Cl2 (0.3 mL) at 0 oC, was added triethylamine (6 µL, 0.04 
mmol). After stirring 8 h at room temperature, water (1 mL) was added and then the 
mixture was extracted with EtOAc (3 x 5 mL), dried (Na2SO4), concentrated under 
reduced pressure. The crude product was purified using silica gel flash chromatography 
eluting with EtOAc/hexane (15:85) to give mesylate IV-18. To a solution mesylate IV-18 
(15 mg, 0.12 mmol) in THF (0.3 mL) was added NaN3 (3.0 mg, 0.05 mmol) under argon 
atmosphere. The solution was stirred at room temperature for 2 h.  Then the mixture was 
evaporated under reduced pressure, purified using silica gel flash chromatography eluting 
with EtOAc/hexane (20:80) to give allylic azide IV-19 (10 mg, 0.02 mmol, 80%) as 
viscous oil.  Rf (30% EtOAc/hexane) = 0.55; [α]26  D  = + 73 (c = 0.3, CH2Cl2); IR (thin 
film, cm-1) 2967, 2932, 2100, 1725, 1702, 1460, 1170, 1041, 972; 1H NMR (600 MHz, 
CDCl3) δ 6.16 (dd, J = 10.2, 3.0 Hz, 1H), 6.10 (dd, J = 10.2, 6.0 Hz, 1H), 5.06 (d, J = 2.4 
Hz, 1H), 4.69 (ddd, J = 7.8, 5.4, 2.4 Hz, 1H), 4.22 (ddd, J = 13.2, 6.0, 2.4 Hz, 1H), 3.62 
(d, J = 10.2 Hz, 1H), 3.13 (dd, J = 5.4, 2.4 Hz, 1H), 3.09 (ddd, J = 12.6, 6.0, 2.4 Hz, 1H), 
2.84 (m, 1H), 2.54 (m, 1H), 2.13 (m, 1H), 1.91 (d, J = 13.2 Hz, 1H), 1.87 (d, J = 13.2 Hz, 
1H), 1.83 (m, 1H), 1.53 (dd, J = 8.6, 6.0 Hz, 1H), 1.50 (d, J = 7.2, 6.6 Hz, 1H), 1.43 (m, 
2H), 1.32 (d, J = 6.0 Hz, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.17 (m, 1H ), 1.14 (d, J = 7.2 Hz, 
3H), 1.07 (d, J = 6.6 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H), 0.89 (t, J = 7.8 Hz, 3H); 13C NMR 
(150 MHz, CDCl3) δ 214.2, 174.2, 129.8, 124.9, 96.3, 86.7, 80.9, 66.4, 55.1, 45.9, 44.2, 
34.7, 34.1, 33.8, 32.2, 24.2, 20.6, 19.3, 17.9, 17.2, 16.9, 15.3, 10.8; CIHRMS Calcd for 
[C23H37N3O5Na+]:  458.2630.  Found 458.2631. 
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(2R,3S,6R)-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-tetrahydro-2-
methyl-2H-pyran-3-amine (IV-20). 
O
NH2
O
O
O
O
 
To a solution of allylic azide IV-19 (10 mg, 0.02 mmol) in dry MeOH (0.2 mL) was 
added Pd/C (5 mg) and the mixture was stirred under H2 at an 100 psi pressure for 7 h at 
room temperature. The catalyst was filtered off through a short pad of Celite, 
concentrated under reduced pressure. The resulting crude product was pipetted directly 
on to a silica gel column using CH2Cl2 (1 mL) in three portions.  Impurities were eluted 
with ether and the product was eluted with MeOH/EtOAc/hexanes (20:60:20).  Pure 
fractions were combined and concentrated to afford deoxy amine IV-20 (7.1 mg, 0.02 
mmol, 87 %) as viscous oil.  Rf (90% EtOAc/MeOH) = 0.35; [α]26  D   =  + 39 (c = 0.3, 
CH2Cl2); IR (thin film, cm-1) 3329, 2942, 2832, 1728, 1705, 1449, 1112, 1021, 856; 1H 
NMR (600 MHz, CDCl3) δ 4.62 (dd, J = 6.0, 2.4 Hz, 1H), 4.60 (br s, 1H), 4.30 (m, 1H), 
4.18 (dd, J = 6.0, 2.4 Hz, 1H), 4.12 (d, J = 9.6 Hz, 1H), 3.41 (d, J = 10.8 Hz, 1H), 3.38 
(m, 1H), 3.15 (dd, J = 3.6, 1.8 Hz, 1H), 3.13 (dd, J = 6.0, 1.8 Hz, 1H), 3.10 (d, J = 2.4 
Hz, 1H), 2.84 (dd, J = 9.0, 3.6 Hz, 1H), 2.80 (dd, J = 10.2, 6.6 Hz, 1H), 2.61 (br s, 1H), 
2.47 (m, 1H), 2.46 (dd, J = 6.0, 5.4 Hz, 1H), 2.39 (s, 1H), 2.24 (s, 1H), 2.22 (dd, J = 8.4, 
3.0 Hz, 1H), 2.19 (dd, J = 5.4, 3.0 Hz, 1H), 1.74 (m, 1H), 1.53 (m, 1H), 1.24 (br s, 1H), 
1.15(d, J = 6.6 Hz, 3H),  1.14 (d, J = 6.6 Hz, 3H), 1.12 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 
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6.0 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 216.0, 175.4, 100.3, 81.5, 56.5, 84.5, 48.5, 46.3, 34.9, 34.7, 34.5, 34.0, 32.5, 
29.8, 27.5, 24.3, 20.8, 20.6, 18.4, 17.2, 16.5, 14.9, 10.1; CIHRMS Calcd for 
[C23H41NO5H+]:  412.3063.  Found 412.3061. 
 
6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione )-2-methyl-2H-pyran-
3(6H)-one (IV-22). 
O
O
O
O O
O
 
A CH2Cl2 (1.5 mL) solution of Boc-enone IV-21 (366 mg, 1.60 mmol) and 10-
deoxymethynolide alcohol IV-7 (120 mg, 0.41 mmol) was cooled to 0 oC.  A CH2Cl2 (1.5 
mL) solution of Pd2(dba)3.CHCl3 (41 mg, 2.5 mol%) and PPh3 (42 mg, 10 mol%) was 
added to the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 2 
hours.  The reaction mixture was quenched with 10 mL of satd. aq. NaHCO3, extracted (3 
x 10 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The 
crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexanes to give enone IV-22 (131 mg, 0.32 mmol, 80%) as viscous oil.  Rf (50% 
EtOAc/hexanes) = 0.45; [α]26  D  = -12 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 2967, 2934, 
1725, 1703, 1459, 1171, 1018, 899; 1H NMR (600 MHz, CDCl3) δ 6.92 (dd, J = 10.2, 1.2 
Hz, 1H), 6.12 (dd, J = 10.2, 1.8 Hz, 1H), 5.34 (d, J = 1.2 Hz, 1H), 4.70 (ddd, J = 9.0, 4.8, 
1.8 Hz, 1H), 4.11 (m, 1H), 3.68 (dd, J = 10.2, 1.2 Hz, 1H), 3.11 (ddd, J = 18.6, 6.6, 2.4 
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Hz, 1H), 2.92 (ddd, J = 13.2, 10.2, 7.2 Hz, 1H), 2.56 (m, 1H), 2.14 (m, 1H), 1.89 (dd, J = 
6.0, 3.0 Hz, 1H), 1.86 (br s, 1H), 1.84 (dd, J = 3.0, 2.4 Hz, 1H), 1.53 (dd, J = 13.8, 7.2 
Hz, 1H), 1.45 (m, 2H), 1.42 (d, J = 6.6 Hz, 3H), 1.39 (d, J = 4.2 Hz, 1H), 1.26 (d, J = 6.6 
Hz, 3H), 1.17 (m, 1H), 1.13 (d, J = 6.6 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 7.2 
Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.5, 196.6, 174.4, 
147.5, 129.2, 98.6, 88.2, 81.3, 75.3, 46.0, 44.1, 34.6, 34.3, 34.0, 32.4, 24.4, 20.8, 19.4, 
18.1, 17.1, 15.9, 15.8, 11.0; CIHRMS Calcd for [C23H36O6Na+]:  431.2409.  Found 
431.2403. 
 
6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-3,6-dihydro-2-methyl-2H-
pyran-3-ol (IV-23).  
O
O
O
O O
OH
 
The enone compound 8 IV-22 (90 mg, 0.22 mmol) was dissolved in 0.3 mL of CH2Cl2 
and 0.3 mL MeOH in round bottom flask and cooled -78 oC then  NaBH4 (9.2 mg, 0.24 
mmol) was added and the reaction mixture was stirred at -78 oC for 3 hours and on 
completion, monitored by TLC, reaction mixture was diluted with ether and was 
quenched with 2 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried 
(Na2SO4), and concentrated under reduced pressure.  The crude product was purified 
using silica gel flash chromatography eluting with 25% EtOAc/hexanes to give allylic 
alcohol IV-23 (77 mg, 0.19 mmol, 85%) as viscous oil.  Rf (50% EtOAc/hexanes) = 0.35; 
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[α]26  D   =  + 7 (c = 1.0, CH2Cl2); IR (thin film, cm
-1) 3329, 2939, 22834, 1721, 1697, 
1456, 1172, 1032, 900; 1H NMR (600 MHz, CDCl3) δ 5.92 (td, J = 12.0, 2.4 Hz, 1H), 
5.82 (td, J = 11.4, 1.2 Hz, 1H), 5.06 (br s, 1H), 4.70 (dd, J = 10.8, 2.4 Hz, 1H), 3.93 (ddd, 
J = 10.2, 6.0, 1.8 Hz, 1H), 3.60 (d, J = 7.2 Hz, 1H), 3.50 (m, 1H), 3.10 (ddd, J = 15.6, 
12.6, 2.4 Hz, 1H), 2.85 (m, 1H), 2.55(m, 1H), 2.10 (m, 1H), 2.04 (s, 1H), 1.86 (br s, 1H), 
1.84 (m, 2H), 1.54 (dd, J = 8.4, 5.4 Hz, 1H), 1.50 (dd, J = 5.4, 1.2 Hz, 1H), 1.43 (m, 2H), 
1.33 (d, J = 6.0 Hz, 3H), 1.26 (dd, J = 7.2, 2.4 Hz, 1H), 1.23 (d, J = 6.6 Hz, 3H), 1.13 (d, 
J = 7.2 Hz, 3H), 1.09 (d, J = 6.0 Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H), 0.90 (t, J = 7.2 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 214.5, 174.5, 132.8, 128.9, 99.4, 87.5, 80.9, 74.5, 
69.0, 64.5, 45.9, 44.0, 34.5, 34.2, 33.8, 32.2, 24.2, 20.6, 19.2, 18.1, 16.9, 15.5, 10.7; 
CIHRMS Calcd for [C23H38O6Na+]:  433.2566.  Found 433.2559. 
 
2-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-3,6-dihydro-6-methyl-2H-
pyran (IV-24). 
O
O
O
O O
 
A flask was charged with dry N-methyl morpholine (NMM) 0.8 mL, triphenyl phosphine 
(126 mg, 0.48 mmol) and was cooled to -30 oC under Ar atmosphere. 
Diethylazodicarboxylate (69 µL, 0.44 mmol) was added and the reaction was stirred for 
25 min, Allylic alcohol IV-23 (60 mg, 0.15 mmol) was added in a 1M solution of NMM 
and the reaction mixture was stirred for 10 min, followed by addition of o-
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nitrobenzenesulfonyl hydrazide (NBSH) (89 mg, 0.44 mmol). The reaction was stirred at 
-30 oC for 2h and was monitored by TLC, upon consumption of starting material, warm 
up to room temperature and stirred for another 4h. The reaction mixture was diluted with 
ether (10 mL) and was quenched with 5 mL of satd aq NaHCO3, extracted (3 x 5 mL) 
with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product 
was purified using silica gel flash chromatography eluting with 30% EtOAc/hexanes to 
give IV-24 (29 mg, 0.07 mmol, 40%) of viscous product:  Rf (50% EtOAc/hexanes) = 
0.60; [α]26  D   =  + 20 (c = 0.5, CH2Cl2); IR (thin film, cm
-1) 2959, 2932, 1756, 1700, 
1429, 1131, 1017, 985; 1H NMR (600 MHz, CDCl3) δ 5.64 (m, 1H), 5.57 (td, J = 11.4, 
1.8 Hz, 1H), 4.69 (ddd, J = 7.8, 5.4, 2.4 Hz, 1H), 4.60 (dd, J = 8.4, 3.6 Hz, 1H), 4.27 (m, 
1H), 3.54 (d, J = 10.2 Hz, 1H), 3.12 (ddd, J = 19.2, 12.0, 2.4 Hz, 1H), 2.85 (m, 1H), 2.57 
(m, 1H), 2.18 (dd, J = 5.4, 3.6 Hz, 1H), 2.13 (dd, J = 5.4, 3.0 Hz, 1H), 2.10 (dd, J = 5.4, 
3.0 Hz, 1H), 1.86 (br s, 1H), 1.84 (m, 1H), 1.53 (d, J = 1.8 Hz, 1H), 1.52 (d, J = 2.4 Hz, 
1H), 1.51 (br s, 1H), 1.49 (dd, J = 4.2, 2.4 Hz, 1H), 1.44 (m, 2H), 1.24 (d, J = 7.2 Hz, 
3H), 1.22 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H), 1.10 (br s, 3H), 0.94 (d, J = 7.2 
Hz, 3H), 0.89 (d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.6, 174.6, 131.3, 
122.7, 100.9, 86.4, 80.8, 71.1, 45.9, 44.1, 34.5, 34.1, 33.8, 32.1, 31.0, 24.2, 20.7, 20.6, 
19.2, 18.0, 16.9, 15.4, 10.7; CIHRMS Calcd for [C23H38O5Na+]:  417.2617.  Found 
417.2613. 
 
(3S,4R,6R)-6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-tetrahydro-2-
methyl-2H-pyran-3,4-diol (IV-25). 
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O
O
O
O O OH
OH
 
To a CH2Cl2 (0.5 mL) solution of ene IV-24 (10 mg, 0.03 mmol) at 0 oC was added a 
solution of (50% w/v) of N-methyl morpholine N-oxide / water (10 µL).  Crystalline 
OsO4 (0.3 mg, 10 mol %) was added and the reaction was stirred for 12 h.  The reaction 
mixture was concentrated and was pipetted directly on to a silica gel column using 
CH2Cl2 (1 mL) in three portions.  Impurities were eluted with ether and the product was 
eluted with MeOH/EtOAc/hexanes (10:40:50).  Pure fractions were combined and 
concentrated to afford diol IV-25 (8 mg, 0.02 mmol, 70 %) as viscous oil.  Rf (90% 
EtOAc/MeOH) = 0.20; [α]26  D   =  - 12 (c = 0.5, CH2Cl2); IR (thin film, cm
-1) 3442, 2928, 
2919, 1741, 1711, 1459, 1167, 1080, 989, 734; 1H NMR (600 MHz, CDCl3) δ 4.78 (dd, J 
= 10.2, 1.8 Hz, 1H), 4.69 (ddd, J = 12.0, 7.8, 1.8 Hz, 1H), 4.10 (dd, J = 6.6, 3.0 Hz, 1H), 
3.68 (m, 1H), 3.52 (d, J = 10.8 Hz, 1H), 3.31 (dd, J = 10.2, 3.0 Hz, 1H), 3.11 (ddd, J = 
16.8, 12.6, 1.8 Hz, 1H), 2.81 (m, 1H), 2.56 (m, 1H), 2.25 (m, 1H), 2.12 (m, 2H), 1.96 (m, 
1H), 1.88 (d, J = 2.4 Hz, 1H), 1.84 (m, 2H), 1.69 (ddd, J = 13.8, 10.2, 2.4 Hz, 1H), 1.55 
(br s, 2H), 1.46 (d, J = 6.0 Hz, 1H), 1.26 (d, J = 6.0 Hz, 3H), 1.21 (d, J = 6.6 Hz, 3H), 
1.12 (d, J = 7.2 Hz, 3H), 1.06 (d, J = 6.0 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 
7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 214.6, 174.6, 99.4, 86.9, 80.8, 73.0, 69.2, 
68.3, 45.9, 44.0, 37.8, 34.5, 34.1, 33.8, 32.1, 29.6, 24.2, 20.6, 19.2, 17.9, 16.9, 15.4, 10.7; 
CIHRMS Calcd for [C23H40O7Na+]:  451.2671.  Found 451.2665. 
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6-(11-hydroxy-12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-2,8-dione)-2-methyl-6H-
pyran-3-one (IV-28). 
O
O
O
O
O
O
HO
 
A CH2Cl2 (0.1 mL) solution of Boc-enone IV-27 (17 mg, 0.07 mmol) and 11-hydroxy-
10-deoxymethynolide alcohol IV-26 (20 mg, 0.06 mmol) was cooled to 0 oC.  A CH2Cl2 
(0.1 mL) solution of Pd2(dba)3.CHCl3 (2 mg, 2.5 mol%) and PPh3 (2 mg, 10 mol%) was 
added to the reaction mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 2 
hours.  The reaction mixture was quenched with 3 mL of satd. aq. NaHCO3, extracted (3 
x 3 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude 
product was purified using silica gel flash chromatography eluting with 35% 
EtOAc/hexanes to give enone IV-28 (21 mg, 0.05 mmol, 80%) as viscous oil.  Rf (50% 
EtOAc/hexanes) = 0.30; [α]26  D  = +44 (c = 0.5, CH2Cl2); IR (thin film, cm
-1) 3401, 2970, 
2936, 1725, 1686, 1458, 1280, 1153, 1082, 977; 1H NMR (600 MHz, CDCl3) δ 6.85 (dd, 
J = 10.2, 3.6 Hz, 1H), 5.59 (d, J = 16.2 Hz, 1H), 6.32 (d, J = 16.2 Hz, 1H), 6.07 (d, J = 
10.2 Hz, 1H), 5.26 (d, J = 3.0 Hz, 1H), 4.79 (dd, J = 10.8, 1.8 Hz, 1H), 4.58 (dd, J = 13.2, 
7.2 Hz, 1H), 3.78 (d, J = 10.2 Hz, 1H), 2.74 (m, 1H), 2.57 (m, 1H), 1.95 (ddd, J = 16.2, 
5.4, 1.8 Hz, 1H), 1.66 (m, 1H), 1.51 (m, 2H), 1.38 (d, J = 6.6 Hz, 3H), 1.37 (s, 3H), 1.35 
(d, J = 7.2 Hz, 3H), 1.25 (m, 2H), 1.21 (d, J = 7.2 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 0.92 
(t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 203.6, 196.6, 174.7, 148.8, 142.5, 
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126.9, 125.4, 95.8, 87.4, 76.5, 74.4, 70.7, 44.9, 42.8, 34.2, 33.8, 21.2, 19.4, 18.1, 17.5, 
16.5, 14.9, 10.6; CIHRMS Calcd for [C23H34O7Na+]:  445.2202.  Found 445.2201. 
 
6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-9-ene-2,8-dione)-2-methyl-6H-
pyran-3-one. 
O
O
O
O
O
O
 
A CH2Cl2 (0.2 mL) solution of Boc-enone  (31 mg, 0.14 mmol) and 10-methynolide 
alcohol  (20 mg, 0.07 mmol) was cooled to 0 oC.  A CH2Cl2 (0.2 mL) solution of 
Pd2(dba)3.CHCl3 (7 mg, 2.5 mol%) and PPh3 (7 mg, 10 mol%) was added to the reaction 
mixture at 0 oC.  The reaction mixture was stirred at 0 oC for 5 hours.  The reaction 
mixture was quenched with 3 mL of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography eluting with 15% EtOAc/hexanes to give 
enone  (24 mg, 0.06 mmol, 88%) as viscous oil.  Rf (50% EtOAc/hexanes) = 0.60; [α]26  D  
= -32 (c = 0.5, MeOH); IR (thin film, cm-1) 2979, 2949, 1718, 1705, 1458, 1171, 1018, 
969; 1H NMR (600 MHz, CDCl3) δ 6.83 (dd, J = 10.2, 3.6 Hz, 1H), 6.75 (dd, J = 16.2, 
5.4 Hz, 1H), 6.42 (dd, J = 16.2, 1.2 Hz, 1H), 6.06 (d, J = 10.2 Hz, 1H), 5.19 (d, J = 2.4 
Hz, 1H), 4.79 (ddd, J = 8.4, 5.4, 2.4 Hz, 1H), 4.60 (dd, J = 13.8, 6.6 Hz, 1H), 3.68 (d, J = 
10.8 Hz, 1H), 2.77 (m, 1H), 2.63 (m, 1H), 2.54 (m, 1H), 1.71 (m, 3H), 1.57 (m, 2H), 1.36 
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(d, J = 6.6 Hz, 3H), 1.27 (d, J = 7.2 Hz, 3H), 1.20 (d, J = 7.2 Hz, 3H), 1.11 (d, J = 6.6 Hz, 
3H), 1.05 (d, J = 6.0 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ 204.5, 196.8, 174.3, 147.0, 142.0, 126.9, 125.7, 95.8, 88.1, 74.0, 70.6, 45.0, 43.7, 37.8, 
34.1, 33.5, 25.1, 17.6, 17.5, 16.1, 14.9, 10.2, 9.5; CIHRMS Calcd for [C23H34O6Na+]:  
429.2253.  Found 429.2249. 
 
6-(12-ethyl-3,5,7,11-tetramethyl-oxacyclododec-9-ene-2,8-dione)-2-methyl-3, 6-
dihydro-2H-pyran-3-ol. 
O OH
O
O
O
O
 
The enone compound (20 mg, 0.05 mmol) was dissolved in 0.2 mL of CH2Cl2 and 0.2 
mL MeOH in round bottom flask and cooled -78 oC then  NaBH4 (2.0 mg, 0.05 mmol) 
was added and the reaction mixture was stirred at -78 oC for 3 hours and on completion, 
monitored by TLC, reaction mixture was diluted with ether and was quenched with 2 mL 
of satd. aq. NaHCO3, extracted (3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated 
under reduced pressure.  The crude product was purified using silica gel flash 
chromatography eluting with 25% EtOAc/hexanes to give allylic alcohol (18 mg, 0.04 
mmol, 90%) as viscous oil.  Rf (50% EtOAc/hexanes) = 0.40; [α]26  D   = - 62 (c = 0.33, 
MeOH); IR (thin film, cm-1) 3470, 2951, 2923, 1725, 1711, 1478, 1179, 1045, 890; 1H 
NMR (600 MHz, CDCl3) δ 6.74 (dd, J = 15.6, 6.0 Hz, 1H), 6.42 (d, J = 15.6 Hz, 1H), 
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5.94 (d, J = 10.2 Hz, 1H), 5.79 (dd, J = 10.2, 2.4 Hz, 1H), 4.97 (m, 1H), 4.12 (dd, J = 
14.4, 7.2 Hz, 1H), 3.82 (m, 1H), 3.69 (m, 1H), 3.62 (d, J = 10.8 Hz, 1H), 2.75 (ddd, J = 
14.4, 10.8, 7.2 Hz, 1H), 2.63 (dd, J = 6.6, 6.6 Hz, 1H), 2.55 (m, 1H), 1.90 (m, 1H), 1.73 
(dd, J = 14.4, 6.6 Hz, 1H), 1.68 (m, 1H), 1.55 (br s, 2H), 1.33 (dd, J = 13.8, 4.2 Hz, 1H), 
1.30 (d, J = 6.0 Hz, 3H), 1.25 (d, J = 6.0 Hz, 3H), 1.20 (d, J = 6.6 Hz, 3H), 1.10 (d, J = 
6.6 Hz, 3H), 1.04 (d, J = 6.6 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 204.8, 174.6, 146.9, 133.3, 126.1, 125.9, 96.4, 86.4, 73.8, 69.5, 68.4, 68.0, 60.3, 
45.0, 43.9, 37.8, 34.2, 33.3, 25.1, 17.6, 16.2, 10.2, 9.5; CIHRMS Calcd for 
[C23H36O6Na+]:  431.2409.  Found 431.2405. 
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